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Chikungunya virus: from neglected pathogen to global public health concern 
In 2005 a mysterious virus suddenly surfaced on several islands in the Indian Ocean. It 
caused high fever and severe joint pains, and infected a large proportion of the islands’ 
populations. The unidentified virus spread rapidly and attracted the attention of the 
scientific community as well as the media. Soon it was discovered that the chikungunya 
virus (CHIKV) was responsible for this outbreak, causing the non-lethal but debilitating and 
untreatable chikungunya fever (CHIKF). CHIKV is a mosquito-borne virus belonging to the 
alphavirus genus of the Togaviridae family. CHIKF is characterized by the abrupt onset of 
high fever, headache, nausea, skin rash, myalgia and a characteristic arthralgia that can 
persist for weeks or even months (1, 2). Its name is a descriptive Kimakonde term and can 
loosely be translated as ‘disease that bends up the joints’, referring to the contorted posture 
of many of patients. The disease is usually self-limiting and rarely fatal, but the arthralgia 
can be extremely painful and debilitating. Severe complications are rare, but can include 
myocarditis, retinitis, hepatitis, acute renal disease, and neurological complications, such 
as meningoencephalitis, Guillain-Barré syndrome, paresis or palsies (brain damage resulting 
in muscle weakness or paralysis) (reviewed in (3)). Especially newborns and patients with 
underlying conditions are at risk for these severe complications, which can occasionally 
result in death. Maternal-fetal (vertical) transmission has been reported and often leads to 
neurological birth defects (4, 5). CHIKV likely originates from Africa, where it was first isolated 
at the Makonde plateau in Tanzania in 1952 (6). The virus subsequently spread to Asia (7) and 
in the next three decades caused several localized and limited outbreaks, as well as larger 
outbreaks in urban areas in India and other parts of Asia (reviewed in (8)). However, CHIKV 
remained a rather neglected pathogen and did not receive much attention from the media, 
medical, or scientific community. This changed when in 2004 a major outbreak started in 
Kenya (9), which spread to numerous islands in the Indian Ocean, India and other countries 
in southern Asia (1). By January 2005, CHIKV had reached the Comoros, and subsequently 
the French territory island of La Reunion, where it infected roughly a third of the island’s 
population (at least 270.000 cases) and gained global attention (10, 11). Aided by trade-
related traffic and infected (air) travelers, CHIKV continued to spread globally, and infected 
millions of people, mostly in India, Africa and South-East Asia (12, 13). 
By the end of 2013, CHIKV had also crossed the Atlantic Ocean and reached the Caribbean, 
yet another area with an immunologically naïve population. CHIKV rapidly spread over many 
islands and territories in the region and caused over a million suspected and confirmed cases 
in the Americas in about a year’s time, resulting in severe human suffering and economic 
damage (13, 14). Many islands in the Caribbean and the Indian Ocean region, such as the 
Seychelles and Maldives, are popular holiday destinations. Therefore, returning travelers 
brought home CHIKV to countries all over the world, including Japan, Canada, Australia, the 
USA and many European countries (15, 16). Also the Netherlands is receiving CHIKV-infected 
travelers, especially due to the ties with the Dutch Antilles and Suriname. Because CHIKV is 




unclear. However, the amount of returning travelers is thought to be substantial, since 
already 181 CHIKV cases were laboratory-confirmed in the Netherlands from September 
to November 2014 (19). CHIKV infections are probably still underdiagnosed due to limited 
awareness clinicians (20). If an infected traveler arrives in a country where a competent 
mosquito vector is present, local (autochthonous) transmission can occur, potentially starting 
a new outbreak. Indeed, in 2007 a local outbreak was reported in the Emilia-Romagna region 
of Italy, involving over 200 cases (21, 22). This outbreak was caused by a returning traveler 
Figure 1. Chikungunya virus is an arthropod-borne virus belonging to the New World alphaviruses. (A) 
CHIKV is transmitted mostly by infected Aedes mosquitoes, especially Aedes aegypti and Aedes albopictus 
(depicted here). During the 2004 Indian Ocean outbreak CHIKV acquired a mutation in its glycoprotein 
(E1-A226V) that facilitated spread via Aedes albopictus (CDC/James Gathany). (B) Infection with CHIKV 
results in chikungunya fever, which is characterized by fever, headache, skin rash, joint swelling and 
arthralgia. Reprinted with permission from (17). (C) Phylogenetic tree of New and Old World alphaviruses. 
In addition, alphaviruses can be divided in different serological complexes based on antigenicity. CHIKV 
belongs to the Old World alphaviruses that are associated with arthralgia, whereas the New World 
alphaviruses are associated with encephalitis. Adapted from (18). 
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from India and supported by a local population of Aedes (Ae.) albopictus mosquitoes (22, 23). 
Local transmission in Europe was reported again in the summer of 2010 in France, when two 
young girls were found to be infected with CHIKV while they had not been out of the country 
recently (24, 25). Some years later, locally-acquired CHIKV infections were again reported 
from France (Montpellier, 2014) when 12 people living in the vicinity of a CHIKV patient that 
had returned from Cameroon (26, 27) became infected. The outbreak in the Caribbean (late 
2013-present) greatly increased the number of CHIKV-infected travelers returning to the USA. 
Especially the southern USA hosts competent mosquito vectors, and it was therefore not 
surprising that local CHIKV transmission in the continental USA was reported from Florida 
in July 2014 (28). Since the start of the CHIKV epidemic in the Caribbean a relatively low 
number of local transmissions have been reported (11 cases), and it is not expected that 
this number will increase enormously. It is expected that CHIKV transmission in the USA will 
be similar to that of dengue virus (DENV), which causes sporadic local transmission but no 
large outbreaks (29) (although increasing numbers of CHIKV-infected travelers increase the 
likelihood). However, the risk of CHIKV becoming endemic in Latin America is very real (8). 
These countries host several competent mosquito vectors, together with a human population 
that is largely immunologically naïve and spends a lot of time outdoors or in rooms without 
window screens or air-conditioning, thus increasing their exposure to mosquitoes. In 
addition, the surveillance and diagnostic capacity in these countries is limited, paving the 
way for unhindered, initially unnoticed, outbreaks. 
Based on phylogenetic analysis, three major CHIKV genotypes can be distinguished: West 
African, East/Central/South African (ECSA), and Asian (7). These names reflect their original 
geographic distribution, but the distribution of these CHIKV genotypes is no longer restricted 
to the areas they were originally named after. The genome sequences of these three 
genotypes differ about 3-5% from each other. The recent Indian Ocean and Indian strains 
form a monophyletic group within the ECSA lineage, dubbed IOL (Indian Ocean Lineage), of 
which some members acquired the E1-A226V mutation, and others did not (10, 30, 31).
CHIKV is the causative agent of the largest outbreaks caused by any alphavirus, resulting in 
an estimated 4-7 million cases in over 40 countries worldwide since 2004 (Figure 2). Other 
alphavirus family members include Sindbis virus (SINV), Semliki Forest virus (SFV), Ross 
River virus (RRV), Barmah Forest virus, o’nyong-nyong and Mayaro virus. These viruses are 
considered the ‘Old World’ alphaviruses, and are generally associated with arthralgia and 
myalgia (reviewed in (32)). In contrast, the ‘New World’ alphaviruses: Eastern, Western 
and Venezuelan equine encephalitis (EEEV, WEEV and VEEV) are mostly associated with 
encephalitis (33). SINV and SFV are well-studied model viruses within the alphavirus genus, 
but especially SINV is quite distantly related to CHIKV (Figure 1C). O’nyong-nyong is the 
alphavirus most closely related to CHIKV, and for a period was even thought to be a strain 
of CHIKV, but it was later shown to be genetically distinct and to have diverged probably 




In total the alphavirus genus comprises ~30 virus species, which are able to infect a range 
of vertebrates (mammals, fish, birds etc.) as well as invertebrates. Most alphaviruses are 
arthropod-born, although the particular vector may differ from virus to virus. CHIKV is 
typically transferred by infected Aedes species, such as Ae. aegypti and Ae. albopictus (35, 36). 
However, during the 2005 outbreak CHIKV acquired a mutation in its envelope protein (E1-
A226V) that enabled a more efficient transmission by Ae. albopictus (37, 38). This mutation 
was acquired independently by different CHIKV lineages through convergent evolution 
(10, 39-42). Ae. albopictus is better known as the Asian tiger mosquito, and is an aggressive 
daytime biter that prefers urban areas (Figure 1B). In recent years, it has quickly spread 
throughout large parts of the world, including parts of Europe and the Americas (43). This - in 
combination with the acquisition of the A226V mutation by CHIKV – dramatically increased 
the epidemic potential of CHIKV in the early 2000s. Therefore it is worrisome that licensed 
vaccines or specific antiviral drugs to prevent or treat CHIKV infection are currently not 
available. CHIKF can only be treated symptomatically using analgesics, and protection from 
mosquito bites is the only way to prevent CHIKV infection. Research on this quickly spreading 
pathogen is hampered because CHIKV is a biosafety level 3 pathogen in most countries, 
including the Netherlands. In addition, it is considered a potential ‘dual-use agent’ by the 
Dutch government and is listed as a category C priority pathogen by the US National Institute 
of Allergy and Infectious Diseases (NIAID). This means that CHIKV is considered a pathogen 
Countries and territories where chikungunya cases have been reported* 
(as of March 10, 2015)  
 
*Does not include countries or territories where only imported cases have been documented. This map is updated weekly if 
there are new countries or territories that report local chikungunya virus transmission. 
 
Data table: Countries and territories where chikungunya cases have been reported 
AFRICA ASIA AMERICAS  
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Burundi Bhutan Antigua and Barbuda Paraguay 
Cameroon Cambodia Aruba Puerto Rico 
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Figure 2. Geographic distribution of CHIKV. Prior to 2004, CHIKV was geographically restricted to Africa, 
India and South-East Asia. Adaptation to the tiger mosquito (Ae. Albopictus) and wide-spread distribution 
of th t vector facilitated the dispe sion of CHIKV across the globe. At pr sent, cases have been reported 
in 101 countries and territories, divided over all inhabited continents. Local CHIKV transmission was 
reported in 44 countries or territories (indicated in dark green). Reprinted with permission from (34). 
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that could potentially be engineered for mass dissemination, and has the potential for high 
morbidity and mortality rates, resulting in a major health impact.
The CHIKV replicative cycle
Alphaviruses share a common genome organization and replication strategy (44, 45). SINV 
and SFV are well-studied members of the alphavirus genus, in part because they do not 
cause serious disease in humans. Studies on these viruses have yielded many important 
insights into the molecular details of alphavirus replication. The insights into the alphaviral 
replication cycle obtained using the SINV and SFV models often form the fundament on 
which hypotheses and further studies on CHIKV replication are based. 
Alphavirus particles are spherical, enveloped and ~70 nm in diameter. The envelope is 
comprised of a host-derived lipid bilayer and trimeric spikes consisting of E2-E1 glycoprotein 
heterodimers. The envelope surrounds a ~40 nm capsid core containing the viral RNA 
genome (Figure 3). The replicative cycle starts when the virion attaches to a host cell using 
E2 and one or more cellular receptors (Figure 5) (44, 45). For many alphaviruses, including 
CHIKV, these receptors have not been (convincingly) identified. Laminin was proposed to 
be a receptor during SINV entry, as well as heparin sulphate (46, 47). The cellular receptor 
needed for SFV remains unidentified thus far. After internalization of the viral particle, 
glycoprotein E1 mediates low-pH induced fusion, resulting in the release of the nucleocapsid 
into the cytoplasm (48, 49). Replication takes places in invaginations of the plasma 
membrane or modified endosomal/lysosomal membranes, termed cytopathic vacuoles 
CPV) (50-52). Alphaviruses possess a ~12 kb positive-strand RNA genome, that is capped and 
polyadenylated, and contains two open reading frames (ORFs) encoding two polyproteins 
(Figure 4). The first polyprotein can be directly translated from the incoming genome and 







Figure 3. Schematic overview of a CHIKV particle. The ~12 kb single stranded, positive-sense RNA genome 
is encapsidated and enveloped by a host-derived lipid bilayer. This lipid bilayer contains 80 glycoprotein 
spikes composed of E1 and E2 heterotrimers. The spikes facilitate attachment and entry via low pH-
dependent endocytosis. The viral genome is capped and polyadenylated and can be directly translated 




have an opal stop codon at the end of the nsP3-coding region and occasional translational 
read-through results in production of nsP4 (53, 54). A portion of the four nsPs assemble into 
the replication complex (RTC), presumably together with host factors, whereas another 
subset of the nsPs is associated with other compartments of the cell, performing additional 
functions (44). Alphavirus nsP1 anchors the RTC to the plasma membrane and contains the 
methyl- and guanylyltransferase activities that are needed to cap the (sub)genomic RNA (55, 
56).
Alphavirus nsP2 has protease and helicase activity, and nsP2 of the Old World alphaviruses 
induces transcriptional and translational host shut off (58). The exact function of nsP3 has not 
been elucidated yet, but it contains a macro domain that can bind ADP-ribose, DNA and RNA 
(59), a zinc-binding domain (60), and an unstructured region that binds to cellular factors, 
such as G3BP (61-63). NsP4 is the RNA-dependent RNA-polymerase (RdRp). Proteolytic 
cleavage by nsP2 releases the individual nsPs from the polyprotein. The extent to which the 
non-structural polyprotein is proteolytically processed determines the polarity of the newly 
synthesized RNA. RTCs that contain uncleaved nsP123 produce only negative strand RNA. 
Proteolytic cleavage of the nsP1-2 site results in complexes that produce both + and – RNA, 
whereas RTCs containing completely processed nsPs exclusively produce +RNA (64). 
The structural polyprotein (C-E3-E2-6K-E1) is produced from a subgenomic RNA that is 
transcribed under control of the 26S subgenomic promoter in the minus strand (45, 65). The 
subgenomic RNA of most alphaviruses includes a translational enhancer sequence, which 
allows the continued translation of structural proteins when cellular translation is blocked 
(induced by nsP2 and/or stress granule formation) (66-68). This translational enhancer 
sequence has not been identified for CHIKV. The virus may contain one, as it is able to produce 
structural proteins after host shut-off has been induced (69). However, the characteristic 
stemloop structure has not been found in the 5’ region of the subgenomic RNA. Assembly 
of alphavirus particles begins when capsid proteins bind genomic RNA, thus forming the 
nucleocapsid in the cytoplasm (44). The viral RNA is encapsidated by 240 copies of the capsid 
protein, which contains a putative coiled-coil α-helix, needed for core assembly (70). The 
completely assembled nucleocapsid binds to the cytoplasmic tails of the viral glycoprotein 
spikes embedded in the plasma membrane and buds through that membrane to acquire 
a lipid envelope containing E1-E2 trimers (71, 72). Glycoprotein E3 is not associated with 
mature virions, but likely prevents premature fusion activity and E1 trimerization by binding 




Figure 4. Genome organization of chikungunya virus. The CHIKV genome is ~12 kb in length, capped and 
polyadenylated. It contains two open reading frames, which encode the non-structural and the structural 
proteins, respectively. The first open reading frame can directly be translated from the incoming genome 
and proteolytic processing produces the individual non-structural proteins that subsequently assemble 
into the viral replication complex. Transcription of the genomic RNA results in a double-stranded 
replication intermediate. This replication intermediate contains a subgenomic promoter that directs the 
synthesis of the subgenomic mRNA from which the second open reading frame, encoding the structural 
proteins, is translated. The structural polyprotein is processed by a combination of viral and host 




Figure 5. Replicative cycle of chikungunya virus. The CHIKV replicative cycle starts when the virus particle 
attaches to the host cell using its E2 glycoprotein and a thus far unidentified cellular receptor. The virion 
is internalized using receptor-mediated endocytosis, the local low pH triggers a conformational change, 
which results in fusion with the cellular membrane, and the viral genome is released in the cytosol. The 
5’-proximal ORF of the incoming genome can directly be translated into the non-structural polyprotein, 
and proteolytic processing yields the four individual nsPs, which assemble into the viral replication 
complex. This replication complex initially produces negative-sense RNA which can be used as a template 
to produce more genomic RNA. It also contains a subgenomic promoter to generate a subgenomic mRNA 
for expression of the structural proteins. The structural polyprotein is proteolytically processed by 
both viral and host proteases. The glycoprotein precursors are further processed in the endoplasmatic 
reticulum (ER) and Golgi system. The mature glycoproteins form E2-E1 heterodimers which gather at the 
cell surface as trimeric spikes. The viral RNA is encapsidated by capsid proteins to form nucleocapsids, 
which interact with the cytoplasmic tails of the glycoprotein spikes to trigger budding. Adapted from (76). 
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The host (immune) response to CHIKV – pathogenesis and chronic disease 
CHIKV is able to infect a wide range of cell lines, including hamster, human, monkey, and insect 
cells. Permissive cells include epithelial cells, endothelial cells, fibroblasts, and monocyte-
derived macrophages (in vitro) (77). During a natural infection, CHIKV is transmitted via the 
bite of an infected mosquito. It replicates initially in the skin, and subsequently spreads to the 
joints, muscles and organs via the blood stream (Figure 6) (78-80). CHIKV infection results in a 
brief viraemia, usually lasting 5-7 days, which is controlled primarily by interferon (IFN) α and 
antibodies (Figure 7) (81-84). The innate immune response to CHIKV typically includes elevated 
levels of IFN-α, INF-β, IFN-γ, monocyte chemoattractant protein 1 (MCP-1), interleukin (IL)-
1β, and IL-6 (85, 86). Like other alphaviruses, CHIKV induces a strong, protective IFN response, 
and mice lacking the IFNα receptor are highly susceptible to CHIKV infection (79). CHIKV has 
been described to counteract the type I IFN response through various mechanisms, including 
transcriptional and translational host shut off, which renders the host cell unable to respond 
to IFN (69, 87-89). In addition, nsP2 interferes with the JAK-STAT signaling pathway and 
blocks STAT phosphorylation (90). Besides induction (and suppression) of innate immune 
responses, CHIKV infection also induces an adaptive immune response, although the role of 
T cells in controlling CHIKV infection is less well characterized. In the sera of acutely infected 
patients elevated levels of activated CD4+ and CD8+ T cells were detected, as well as NK 
and dendritic cells (91-93). Acute lymphopenia (abnormally low levels of lymphocytes in the 
blood) is often observed in CHIKV-infected patients (94). Since CHIKV does not infect T and 
B cells, this most likely is an indirect effect caused by the IFN response, which results in both 
cell death and migration of lymphocytes from the blood stream into tissue (95).
Generally, chikungunya fever is regarded as a self-limiting disease, typically lasting from a few 
days to a couple of weeks. However, many patients report persisting joint pain (polyarthralgia 
and/or polyarthritis) that can last up to months or even years. The chronic joint pain often 
presents as relapses, which can be extremely painful and debilitating. Especially elderly 
people are at risk for developing such long-term symptoms (86, 91, 96-99). These persisting 
pathologies illustrate that - despite low mortality rates – CHIKV is a serious pathogen that 
causes severe morbidity. The persistent arthralgia can seriously affect the quality of life of a 
large group of patients. 
Besides CHIKV there are several other alphaviruses that can cause chronic joint pain, although 
often less severe than CHIKV. For example, also SINV, RRV, Barmah Forest virus, o’nyong-
nyong and Mayaro virus were described to cause rheumatic symptoms (reviewed in (32, 
100)). Chronic alphaviral rheumatic disease is thought to arise from inflammatory responses 
to virus in joint tissues, which persists despite robust antiviral immune responses. The exact 
mechanism behind this prolonged arthralgia has not been elucidated, yet several possible 
mechanisms have been proposed, including (I) an autoimmune response, (II) tissue damage 
caused by inflammation, and (III) low levels of persistent replication. It has been suggested 
repeatedly that auto-immune responses are responsible for the CHIKV-induced arthralgia, 





























Stem cells that are localized 
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surrounding each myofibre 
and that give rise to 
regenerated muscle and 
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Myotube
A developing skeletal muscle 
fibre, formed by the fusion 
of myoblasts.
Myositic syndrome
A poorly understood clinical 
musculoskeletal and/or nerve 
disease that may be of 
psychosomatic origin.
rare, being observed in around 15% of infected individu-
als21. Strikingly, during the acute phase, the viral load 
can reach 108 viral particles per ml of blood, and the 
plasma concentration of type I interferons (IFNs) is in 
the range of 0.5–2 ng per ml, accompanied by a robust 
induction of other pro-inflammatory cytokines and 
chemokines42–44 (FIG. 3).
The acute phase of CHIKV infection typically lasts 
from a few days to a couple of weeks. In contrast to the 
acute phase, the chronic phase of disease has not been 
extensively investigated. Recurrent joint pain, which can 
last for years in some cases, is experienced by 30–40% 
of those infected, although this is not thought to be a 
result of chronic infection, as infectious virus cannot 
be isolated from these patients. Radiographic studies are 
typically normal or show mild swelling, which is consist-
ent with joint pain. It has been suggested that this joint 
pain, similarly to the pain caused by the related alphavi-
rus Ross River virus (RRV)45, is immune mediated. This 
has not been formally shown, although the presence of 
autoantibodies has been reported in one case of CHIKV 
infection with severe musculoskeletal complications46.
Cellular and tissue tropism
A large effort has been made recently to describe viral 
tropism and replication in cell culture systems and in 
animal models to better understand CHIKV pathogen-
esis (for details on the Alphavirus life cycle in mamma-
lian cells, see BOX 2). Studies in the 1960–1980s showed 
that CHIKV grows in a panel of non-human cell lines, 
including Vero cells, chick embryo cells, BHK21 and 
L929 fibroblast-like cells, and HEp-2 hepatic cells47–50. 
The cellular tropism of CHIKV in humans was char-
acterized recently. In tissue culture experiments, the 
virus replicates in various human adherent cells, such 
as epithelial and endothelial primary cells and cell lines, 
fibroblasts and, to a lesser extent, monocyte-derived 
macrophages51. CHIKV also replicates in human muscle 
satellite cells, but not in differentiated myotubes52 (FIG. 2). 
In contrast to adherent cells, B cells and T cells are not 
susceptible to CHIKV infection in vitro51,53. Like other 
alphaviruses, CHIKV is highly cytopathic in human 
cell cultures, and infected cells rapidly undergo apop-
totic cell death33,51. This pattern of replication probably 
governs the pathological properties of the virus.
In a highly pathogenic mouse model in which ani-
mals lack the type I IFN receptor (Ifnar–/– mice) and are 
much more susceptible to severe disease, the CHIKV 
tissue tropism seems to match the tropism reported 
using in vitro systems. CHIKV was found to primarily 
target muscle, joint and skin fibroblasts, but it was also 
identified in the epithelial and endothelial layers of many 
organs, including the liver, spleen and brain38 (FIG. 2). 
Notably, newborn and young mice are highly sensitive 
to CHIKV infection and represent a valuable model for 
studying CHIKV pathogenesis38,54.
Non-human primates have also been used as mod-
els for CHIKV-associated pathology and vaccine test-
ing55–57. In two recent studies, intravenous or intradermal 
CHIKV inoculation of macaques resulted in high virae-
mia, peaking 24–48 hours after infection. Although 
infection was not lethal, it was associated with a tran-
sient acute lymphopenia and neutropenia (that is, loss of 
lymphocytes and neutrophils, respectively), an increase 
in monocytes and a pro-inflammatory response56,57. 
Infection recapitulated the viral, clinical and patho-
logical features observed in humans57. CHIKV targeted 
lymphoid tissue, the liver, the central nervous system, 
joints and muscle during the acute phase57. Persistent 
infection (measured 44 days post-infection) occurred 
in splenic macrophages and in endothelial cells lining 
the liver sinusoids. Tissue derived from these animals 
carried low levels of replication-competent virus57. It 
will be important to establish whether this is reflective 
of the situation during human infection and what role 
viral persistence has in the chronic sequellae associated 
with chikungunya fever. One recent study has indicated 
that elderly patients are at high risk of chronic disease, 
but clearly more work is necessary58.
The human tissue culture systems and the simian 
and mouse models have provided clues about the tissue 
and cellular localization of CHIKV in infected humans. 
Samples from CHIKV-infected patients with myositic 
syndrome showed CHIKV antigen expression in skeletal 
Figure 2 | Dissemination of chikungunya virus in vertebrates. Transmission 
of chikungunya virus (CHIKV) occurs following a mosquito (Aedes aegypti or Aedes 
albopictus) bite. CHIKV then replicates in the skin, in fibroblasts, and disseminates to the 
liver, muscle, joints, lymphoid tissue (lymph nodes and spleen) and brain. The target cells 
are indicated for each tissue.
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Figure 6. Dissemination of chikungunya virus. The viral replicative cycle starts when a CHIKV-infected 
mosquito bites a susceptible host. Virus particles are released with the mosquito’s saliva and infect 
fibroblasts in the skin. The virus replicates locally and newly formed particles are released into the 
bloodstream, enabling their spread to various organs, muscle and joint tissue. In rare cases the virus can 
cross the blood-brain barrier and cause encephalitis, which happens mostly in new-borns. Reproduced 
with permission from (76). 
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number of research groups have attempted but failed to detect autoimmune or rheumatoid 
markers in chronic patients (99, 101, 102), with the exception of one study on La Reunion 
(103). However, multiple arthritogenic viruses have been shown to cause inflammation by 
replicating within joint tissues, which is mediated primarily by infiltrating macrophages and 
the complement system (100, 104, 105). Several studies have suggested that CHIKV is able 
to establish a chronic infection in joint cells. For example, viral antigen was found in satellite 
cells in a muscle biopsy three months after initial infection, and it was confirmed that CHIKV 
could replicate in cultured primary human satellite cells (80). In another patient, viral RNA 
and proteins were found in perivascular synovial macrophages 18 months after onset of the 
disease (91). This suggests that CHIKV may invade and persistently infect joint tissues.
Macrophages likely are the main cellular reservoir during persistent infection, and 
macrophage infiltrates were found in affected joints, suggesting they are involved in 
pathogenesis (104, 106). Clodronate is a macrophage-specific inhibitor that can specifically 
deplete macrophages from organs and tissues. Treatment of CHIKV-infected mice with 
clodronate reduced foot swelling (83). However, clodronate treatment prolonged CHIKV 
viraemia, indicating that macrophages also play a role in clearance of the virus (83). In 
conclusion, these studies indicate that macrophages are a target of infection, promote viral 
clearance and are involved in the development of rheumatic disease. 
Strikingly, joint inflammation does not occur simultaneously with the peak of viraemia, but 
the maximum joint swelling occurs after the virus has already been cleared from circulation, 
around 4 d.p.i. in animal experiments (83, 107). Knockout mice lacking T and B lymphocytes 
needed for adaptive immunity (RAG2-/-) developed persistent viraemia, but no signs of 
inflammation, suggesting a key role for humoral responses during CHIKV infection. CD4-/- 
and CD8-/- mice experienced normal viraemia, but the peak of joint swelling, infiltrates and 
tissue damage was reduced in the CD4-/- but not CD8-/- mice, indicating that CD4+ T cells are 
involved in CHIKV-induced joint pathology (93). 
Taken together, the experimental field of CHIKV-induced rheumatic disease is still immature 
and various controversial findings and conflicting results have been reported. Our current 
knowledge is by far not sufficient to understand, let alone prevent or treat this CHIKV-
induced pathology. However, increasing numbers of studies are performed to identify the 
mechanism(s) behind rheumatic disease caused by alphaviruses, and slowly more light is 
shed on this interesting and important clinical disease sign. 
CHIKV diagnosis and misdiagnosis
CHIKV can be diagnosed using several laboratory tests, including virus isolation, real time 
(RT-)PCR and serological testing. These tests detect either virus, viral RNA, virus-specific IgM 
and IgG or neutralizing antibodies. Virus isolation from patient material is the most definitive 
diagnostic method. However, infectious virus can usually be isolated only within the first 
three days after the onset of symptoms, requires a BSL-3 laboratory and may take up to one 




suitable during the first 7 days after onset of symptoms and requires reagents and equipment 
that may not be available in diagnostic laboratories throughout the world. After 7 days, CHIKV 
infection can be detected using IgM and IgG serology, however, these tests are often unable 
to differentiate between a recent past infection and an acute infection. In addition, cross-
reactivity with other alphaviruses can occur. 
A laboratory-confirmed CHIKV diagnosis is important, as there are many other diseases 
causing symptoms like fever, headache, skin rash and myalgia, with or without arthralgia. 
For example, CHIKV infections often occur in areas where DENV is also endemic, and both 
viruses initially cause very similar symptoms. Unfortunately, both viruses occur in regions 
where the capacity to perform differential diagnoses is often limited. In retrospect, many 
cases that were attributed to DENV infections, may very well have been CHIKV infections, 
making it likely that the incidence of CHIKV disease is much higher than reported (108). In 
addition to cases of mistaken identity, CHIKV-DENV co-infections have been reported (109-
113), although it remains unclear how this impacts the replication and pathogenesis of both 
viruses. Malaria is another infectious agent that often occurs in areas where people are at risk 
of contracting CHIK fever, and generally can give rise to similar symptoms.
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CHIKV transmission
Clinical presentation; 
acute disease Displaying disease symptoms 
muscle satellite cells but not in muscle fibres52. Infected 
fibroblasts have also been reported in biopsy material 
taken from acutely infected patients38. There is a debate 
about the sensitivity of primary blood monocytes 
to CHIKV infection51,59. Sourisseau et al.51 reported 
that the high viral load in blood plasma (ranging from 
105 to 108 RNA copies per ml) during acute infection 
does not correspond to detectable levels of viral RNA 
in blood cells. They also found that, in vitro, peripheral 
blood mononuclear cells (including B cells, T cells and 
monocytes) are not susceptible to CHIKV infection51. 
By contrast, Her et al.59 observed that CHIKV antigens 
are detected in vitro in monocytes exposed to high viral 
inocula (multiplicity of infection = 10–50). CHIKV 
antigen-positive monocytes were also isolated from 
acutely infected patients59, but definitive evidence of 
productive infection was not established. As monocytes 
are phagocytic, and as viral titres are high in acutely 
infected patients, the presence of negative-strand viral 
RNA must be assessed to determine whether produc-
tive infection of monocytes does occur and whether 
monocytes are true targets of CHIKV. There are nota-
ble cell tropism variations among alphaviruses, which 
probably influences the pathogenesis of disease30. For 
example, human monocyte-derived dendritic cells 
(DCs) and plasmacytoid DCs (pDCs) are not sensi-
tive to CHIKV51,60; Venezuelan equine encephalitis 
virus (VEEV) can infect DCs and macrophages in 
lymphoid tissues and cultures, whereas this is not the 
case for Eastern equine encephalitis virus (EEEV)61,62. 
Interestingly, EEEV infection of myeloid-lineage cells 
is restricted after virus binding and entry, by inhibiting 
translation of incoming EEEV genomes61. Of note, RRV 
infects mouse macrophages31,63–65, which are implicated 
in the pathogenesis of disease. During RRV infection, 
infiltrates of inflammatory macrophages are observed in 
muscles and joints45, and treatment of mice with agents 
that are toxic to macrophages abrogated the symptoms 
of infection66.
The cellular tropism of alphaviruses is regulated 
by many parameters. For example, RRV envelope 
glyco proteins allow the infection of mouse DCs but 
not human DCs67, and the ability of Sindbis virus 
(SINV)68 and VEEV69 to infect DCs is determined by 
a single amino acid substitution in the E2 envelope 
protein. Further work should examine the sensitivity 
of Langerhans cells to CHIKV and other alphaviruses. 
The use of rhabdoviruses and lentiviruses pseudotyped 
with CHIKV envelope glycoproteins may facilitate the 
study of early entry or post-entry events70.
Type I IFNs (IFNα and IFNβ) are also major regula-
tors of tissue tropism and virulence71. For example, they 
prevent the widespread dissemination of Semliki Forrest 
virus (SFV) in mouse extraneural tissues, and this is 
associated with reduced sensitivity to type I IFNs and 
enhanced virus pathogenicity72. More generally, type I 
IFN induction in vivo, as well sensitivity to type I IFN 
treatment in cell culture, differs markedly between dif-
ferent alphaviruses73. The interplay between CHIKV and 
the innate immune system is discussed below.
Jumping species — an atypical vector for CHIKV
CHIKV is endemic to Africa, India and Southeast Asia 
and is transmitted to humans by several species of mos-
quito, with geographical variations33,74–76. Although 
A. aegypti is the classical vector for CHIKV, the 2005 
outbreak in La Réunion was associated with an atypical 
vector, A. albopictus6,14,75–78. Other Aedes species are sen-
sitive to experimental CHIKV infection, but their role in 
field transmission has not been shown79.
why did CHIKV adopt A. albopictus as its host? The 
transmission success of arboviral diseases depends on 
many factors, including the geographical and temporal 
distribution of the insect vectors, their growth rate and 
the viral incubation period inside them80–84. A. albopictus 
is a competent vector for dengue virus and numerous 
arboviruses, and its distribution has expanded recently, 
even replacing A. aegypti in some places14,83–85. It is native 
to Southeast Asia and has colonized both tropical and 
temperate regions. It was identified in Europe (first in 
Albania) and in North America in the early 1980s, prob-
ably having been introduced through shipments of used 
car tyres from Asia86. Currently, A. albopictus is present 
in at least 12 European countries and in around 25% of 
the United States.
There are several features of A. albopictus that make 
it a good viral vector: it survives in both rural and urban 
environments; it was probably first zoophilic and then 
progressively became anthropophilic87; it is long lived 
(4–8 weeks); it has a flight radius of 400–600 metres; and 
it can successfully infect humans and animals because it is 
aggressive, quiet and diurnal. Furthermore, the mosquito’s 
eggs are highly resistant and can remain viable through-
out the dry season, giving rise to larvae and adults the 
Figure 3 | chikungunya virus pathogenesis. Following transmission by mosquito 
bite, infected individuals experience an acute onset of disease 2–4 days after infect n. 
Symptoms include high fever, rigors, headache and a petechial or maculopapular rash. 
In addition, most infected individuals complain of severe joint pain that is often 
incapacitating. Disease onset coincides with rising viral titre, which triggers the activation 
of an innate immune response, the hallmark of which is the production of type I 
interferons (IFNs). Patients successfully clear the virus approximately 1 week after 
infection, and only at this time is there evidence of CHIKV-specific adaptive immunity 
(that is, T cell and antibody-mediated responses). Importantly, ~30% of individuals 
experience long-term sequellae that include arthralgia and, in some cases, arthritis.
R E V I E W S
494 | JULy 2010 | VOLUME 8  www.nature.com/reviews/micro
© 20  Macmillan Publishers Limited. All rights reserved10
Figure 7. Host imm ne response to chikungunya virus infecti n. CHIKV i fection typically induces a strong, 
pro ctive IFN response, which cont ols th viral load t gether with the humoral (antibody) response. The 
role of T ly phocytes during CHIKV replication is less well characterized. CHIKV-infected patients display 
an increased T cell activation, but lymphopenia (depletion of lymphocytes) is also commonly observed. 
CHIKV infection results in CHIKV-specific IgG and IgM, which can typically be detected from 7 after onset of 
symptoms. The acute phase of CHIKV infection usually resolves after ~7-10 days, but relapses (arthralgia) 




CHIKV research tools are indispensable in order to increase our understanding of this 
important human pathogen. The virus was regarded as rather obscure for quite a while, so 
many research tools have only been developed in the last decade, when the impact of CHIKV 
on health and society became clear. Obviously, the development of CHIKV-specific tools 
greatly benefited from the knowledge and tools created for the well-studied SINV and SFV 
alphaviruses. Research tools include antibodies, in vitro assays, animal models, virus-like 
particles, replicons and infectious cDNA clones. 
Full-length cDNA clones from which infectious viral RNA can be transcribed are invaluable 
tools to study many aspects of the viral life cycle, including virus-host interactions, 
attenuation/virulence markers and immunogenicity. Such clones enable manipulation of 
the viral genome through reverse genetics, allowing for example the construction of a mutant 
virus expressing a reporter gene to facilitate the quantification of virus replication. Replicons 
are self-replicating RNA molecules that encode the CHIKV replication machinery (nsPs) but 
lack the structural protein gene, and therefore infectious particles cannot be produced. 
CHIKV RNA replicons can be handled at the more convenient biosafety level 2 to study certain 
aspects of CHIKV replication, such as translation, polyprotein processing and RNA synthesis. 
Replicon-based assays are also useful to exclude the involvement of antiviral compounds 
or host factors in entry or assembly/release. Several replicons and full-length clones have 
been created for CHIKV, including some based on the sequence of the La Reunion outbreak 
strain (LR2006 OPY1) (62, 69, 114-117). These CHIKV cDNA clones often contain a reporter 
gene under control of a subgenomic promoter. However, most of these infectious clones are 
based on the sequence of a single genome of a clinical isolate, which may have adapted to 
the specific patient or to cell culture passaging during isolation procedures. Therefore it is 
possible that different infectious cDNA clones yield viruses with different properties. It would 
be prudent to repeat key experiments with several different virus isolates.
Host factors in CHIKV replication
RNA viruses are highly dependent on the exploitation and subversion of host proteins, 
structures and pathways to facilitate their replication. For example, viruses depend on 
cellular receptors and (clathrin-mediated) endocytosis for entry, the translational machinery 
of the host cell to produce viral proteins, and the cellular plasma membrane to acquire the 
viral envelope during budding. Furthermore the anabolic capacity of the host cell is used as 
a source of NTPs, amino acids and lipids, and cellular factors are part of the RNA replication 
machinery. To facilitate their replication, viruses manipulate many cellular pathways, 
including stress and antiviral responses, to create a cellular environment that is optimally 
suited to their specific needs. Therefore it is of great importance to understand the interplay 
between viral proteins and host factors, as this will help us to understand how the virus 
can influence the host cell and vice versa. In recent years, many efforts have been made to 




involved genes have been discovered. However, only a handful of the host factors involved 
in CHIKV replication have been identified (118-122). Their specific role, and the specific 
step(s) of the viral replication cycle in which they are involved, also remains largely unclear. 
Identification and characterization of the cellular factors needed for CHIKV replication is a 
crucial step to improve our understanding of this important human pathogen. In addition, 
knowledge of host factors co-opted by the virus can potentially be used to counter emerging 
antiviral resistance. Most +RNA viruses lack proofreading capability and can therefore rapidly 
acquire mutations that provide resistance against specific antiviral treatment. Traditional 
approaches to develop antiviral drugs have mostly focused on viral proteins, but antiviral 
strategies that target cellular factors required for virus replication could reduce the risk of 
the development of viral drug resistance, as host factors are far less likely to change/mutate. 
An additional advantage of targeting cellular factors instead of a viral protein is that the 
antiviral agent is more likely to be effective against a wide(r) range of pathogens/viruses. 
Cellular factors involved in CHIKV replication can thus provide interesting starting points for 
novel antiviral strategies, besides the fact that their identification sheds more light on the 
replication cycle of this virus. 
There is a range of techniques available to identify host factors involved in viral replication. 
The first host factors were identified by studying physical interactions between viral and host 
proteins using co-immunoprecipitation and antisera specific to viral and host proteins. At 
present, roughly the same technique is still being used, often aided by viral proteins equipped 
with affinity tags and the analysis of pull-down samples by mass spectrometry, which greatly 
increases the number of interaction partners that can be identified. Other techniques to 
study molecular interactions between viral and host proteins include yeast two-hybrid 
(Y2H) screening, virus overlay protein binding assay (VOPBA), tandem affinity purification, 
and glutathione S-transferase (GST) protein purification. However, interactions identified in 
in vitro assays do not necessarily reflect functional in vivo interactions. In addition, weak or 
transient interactions may be missed. Most of the above-mentioned assays are limited to 
direct protein-protein interactions, meaning that host proteins that are part of a virus/host-
protein complex but lacking a direct physical interaction with viral proteins will be missed, 
as well as proteins that exert their function during viral replication in an indirect manner. 
The discovery of RNA interference (RNAi) by Fire and Mello in 1998 and the adaptation of 
its application to high-throughput screening formats started a revolution in the genomics 
field, as it allowed genes to be specifically silenced at a large scale (123). The advantage of 
RNAi is that it can be used to identify functional interactions between proteins that directly 
physically interact with viral proteins, as well as host proteins that affect replication indirectly, 
e.g. because they are part of viral replication complexes, bind to viral RNA, or are involved 
in signaling pathways that affect viral replication. RNAi screens enable large-scale loss-of-
function studies in cell culture, and have been performed in recent years to identify cellular 
factors involved in the replication of a variety of +RNA viruses, including hepatitis C virus 
(HCV) (124-127), West Nile virus (WNV) (128), yellow fever virus (YFV) (129) and DENV (130, 
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131). These studies have provided valuable insights into the replicative cycle of these viruses, 
and the cellular proteins and pathways involved.
Previous efforts to identify host factors involved in alphavirus replication included two 
genome-wide RNAi screens aimed at identifying factors involved in SINV entry (132, 133), 
a SINV in vivo RNAi screen (134), a study of cellular components of the SFV replication 
complex (119), as well as a genome-wide RNAi screen aimed at the identification of host 
factors involved in SFV replication (135). Other studies have sought to identify interaction 
partners of SINV nsP2, -3 and -4 by applying tagged nsPs, expressed by plasmids or 
recombinant viruses (136-138). For CHIKV mainly differential proteome analyses (121, 139-
144) have been performed, in addition to a Y2H screen (122). However, differential proteome 
analysis is not a very suitable technique to identify host factors, since it mostly aims to detect 
cellular changes upon infection by monitoring changes in cellular protein abundance. Such 
changes are often linked to antiviral responses or host shut-off. Targets identified in CHIKV 
proteomic studies generally cluster in distinct functional pathways/groups, including energy 
metabolism, transcription, translation, stress response and apoptosis (summarized in (142, 
145)). However, the sets of potential host factors identified in the above-mentioned studies 
share only a very limited overlap. This might be due to the use of different viruses, expression 
systems, cell lines, experimental conditions, and/or differences in data interpretation. Some 
hits were found in more than one screen, for example, nsP2 of both SINV and CHIKV was 
found to bind hnRNP K and vimentin (122, 136, 146). A serious drawback of many of the 
studies summarized above is that the importance of most of the (potential) host factors 
identified has not been validated using an alternative technical approach. Consequently the 
presence of false-positive hits cannot be excluded, which may for example be caused by off-
target effects, aspecific binding of host proteins to the tagged viral protein, or general effects 
on the cell’s ability to support viral replication. 
In summary, although in recent years many efforts have been made to identify host factors 
that play a role during CHIKV replication, the involvement of only a relatively small number of 
proteins was confirmed and systematic large-scale RNAi screens have not been reported for 
CHIKV. The number of host factors whose precise function is known is even smaller. Further 
elucidating the replicative cycle of this increasingly important human pathogen will aid 
us in developing antiviral strategies, thus providing means to combat the extensive socio-




Outline of this thesis
In this thesis the interplay of CHIKV with cellular (host) factors involved in its replication 
is addressed. An in-depth understanding of the interactions between the viral proteins 
and those of their host within the infected cell is required for the elucidation of molecular 
mechanisms underlying viral replication. A variety of proteins and pathways involved 
in CHIKV replication were identified in this thesis, and the role of a selection of those is 
described. First, the construction and characterization of a novel synthetic CHIKV full-length 
cDNA clone is described in chapter 2. The CHIKV genome sequence of this construct was 
based on the consensus sequence of CHIKV strains containing the A226V mutation, rather 
than on the genome of a single isolate. The virus derived from this clone is a valuable tool to 
study many aspects of the viral replicative cycle, including virus-host interactions. In chapter 
3 the synthetic reporter gene-expressing virus described in chapter 2 was used to screen a 
siRNA library targeting the human kinome, aiming to identify cellular kinases involved in 
CHIKV replication. We identified dozens of cellular factors and pathways that are potentially 
involved in CHIKV replication and validated a selection of these hits using a secondary siRNA 
screen. Chapter 4 describes the response of the p38 MAPK and MEK/ERK signaling pathways 
in CHIKV-infected human cells. In contrast to the distantly related alphavirus VEEV, CHIKV 
does not induce MEK/ERK signaling, nor is its replication affected by either inhibition or 
stimulation of this signaling cascade. Chapter 5 describes the unexpected proviral role of 
stress granule components G3BP1 and G3BP2 early during CHIKV infection. Stress granules 
are cellular protein-mRNA aggregates formed in response to stress, such as viral infection. 
Generally, their formation is considered to be part of an antiviral response, inhibiting viral 
replication. This chapter describes G3BP1- and G3BP2-containing granules that are formed 
in response to CHIKV infection, but differ from bona fide stress granules in composition, 
morphology and behavior. We demonstrate that the G3BPs are likely needed for the switch 
from translation to amplification of the CHIKV genome. In chapter 6 the inhibitory effect 
of a RIG-I agonist (5’pppRNA) on CHIKV and DENV replication is described. A low, non-
cytotoxic dose of 5’pppRNA stimulates RIG-I and leads to a robust antiviral response, which 
is dependent on an intact RIG-I/MAVS/TBK1/IRF3 signaling axis but not on the type 1 IFN 
response. This might open up therapeutic options against these two important human 
pathogens. Finally, Chapter 7 discusses the findings described in this thesis, and places them 
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Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that re-emerged in 2004 and 
has caused massive outbreaks in recent years. The lack of a licensed vaccine or treatment 
options emphasize the need to obtain more insight into the viral life cycle and CHIKV-host 
interactions. Infectious cDNA clones are important tools for such studies, and for mechanism 
of action studies on antiviral compounds. Existing CHIKV cDNA clones are based on a single 
genome from an individual clinical isolate, which is expected to have evolved specific 
characteristics in response to the host environment, and possibly also during subsequent 
cell culture passaging. To obtain a virus expected to have the general characteristics of the 
recent E1-226V CHIKV isolates, we have constructed a new CHIKV full-length cDNA clone, 
CHIKV LS3, based on the consensus sequence of their aligned genomes. Here we report the 
characterization of this synthetic virus and a green fluorescent protein-expressing variant 
(CHIKV LS3-GFP). Their characteristics were compared to those of natural strain ITA07-RA1, 
which was isolated during the 2007 outbreak in Italy. In cell culture the synthetic viruses 
displayed phenotypes comparable to the natural isolate, and in a mouse model they caused 
lethal infections that were indistinguishable from infections with a natural strain. Compared 
to ITA07-RA1 and clinical isolate NL10/152, the synthetic viruses displayed similar sensitivities 
to several antiviral compounds. 3-deaza-adenosine was identified as a new inhibitor of CHIKV 
replication. Cyclosporin A had no effect on CHIKV replication, suggesting that cyclophilins 
-opposite to what was found for other +RNA viruses- do not play an essential role in CHIKV 
replication. The characterization of the consensus sequence-based synthetic viruses and 
their comparison to natural isolates demonstrated that CHIKV LS3 and LS3-GFP are suitable 
and representative tools to study CHIKV-host interactions, screen for antiviral compounds 
and unravel their mode of action. 




Chikungunya virus (CHIKV) re-emerged in 2004 and has caused unprecedented outbreaks 
in Asia and Africa since 2005. The estimated number of cases exceeds 2 million and over 
a thousand infected travelers have returned to Europe and the USA since 2006 (15, 147). 
CHIKV generally causes a fever that resolves within several days, a maculopapular rash, 
and a characteristic arthralgia that can be extremely painful and may persist for months. 
During the recent outbreaks also more severe clinical manifestations have been reported 
occasionally, such as neurological complications and even deaths, usually in the elderly, 
patients with underlying conditions, and newborns (148, 149). A licensed vaccine or specific 
antiviral therapy are currently not available. 
CHIKV is an alphavirus with an 11.7 kb positive-stranded RNA genome that contains two 
open reading frames (ORFs). The 5’ ORF encodes the nonstructural polyproteins P123 and 
P1234. The latter results from translational read-through of an opal termination codon that 
is present at the end of the nonstructural protein (nsP) 3 coding sequence of most CHIKV 
isolates. Assuming that CHIKV follows the typical alphavirus life cycle, proteolytic processing 
of the nonstructural polyproteins by the protease domain in nsP2 will ultimately lead to the 
release of nsP1, nsP2, nsP3, and nsP4. These nsPs and their precursors possess a variety of 
functions and the enzymatic activities, including protease, helicase, methyltransferase, and 
RNA-dependent RNA polymerase (RdRp) activity that drive CHIKV replication (44). In addition 
to replication of its genomic RNA, CHIKV also transcribes a subgenomic (sg) RNA encoding 
a precursor polyprotein that is processed by viral and cellular proteases into the structural 
proteins C, E3, E2, 6K and E1. CHIKV nsPs will - presumably together with host factors - 
assemble into replication and transcription complexes (RTCs) that associate with membrane 
structures derived from the plasma membrane and/or endosomes, as observed for other 
alphaviruses (44, 51, 52). 
The CHIKV strains that emerged during the 2005-2006 outbreaks had acquired a mutation 
(A226V) in the E1 envelope glycoprotein, which facilitated transmission of the virus via a new 
vector, the Asian tiger mosquito Aedes albopictus, and consequently dramatically increased 
the epidemic potential of CHIKV (10, 37). Later studies suggested that recent Indian and 
Indian Ocean epidemics have emerged separately as the result of at least three independent 
events, and that convergent evolution of East-Central-South African lineage strains in 
different geographical regions ultimately led to the emergence of strains with the A226V 
substitution in E1 (39, 40, 42, 150). More recently, other amino acid positions and epistatic 
interactions were also shown to play an important role in the emergence of these new CHIKV 
variants, which are now even replacing endemic strains that have been circulating in Asia for 
decades (151). Aedes albopictus also thrives in more temperate climates and its geographical 
distribution has rapidly expanded. Over the past decades, parts of southern Europe and large 
areas of the USA have been invaded by this mosquito, providing imported cases of CHIKV with 
a competent mosquito vector, thus paving the road for outbreaks in non-endemic-areas such 
as the USA and Europe. Indeed, autochthonous infections have been reported from Italy in 
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2007 and France in 2010 (22, 25). The recent and ongoing CHIKV outbreaks are characterized 
by their rapid geographical spread, high numbers of infected people and high morbidity, 
emphasizing the need to gain more insight into the replicative cycle of this important human 
pathogen. 
Infectious cDNA clones of viruses have become invaluable tools that allow reverse genetics 
studies to elucidate the contribution of specific amino acids or RNA structures to viraemia, 
virulence, antigenicity, replication kinetics, interactions with host factors, adaptation 
to new vectors, and many other aspects of the viral life cycle. The use of cDNA clones is 
also instrumental in mechanism of action studies to pinpoint the viral target of antiviral 
compounds by selecting for and genotyping compound-resistant viruses, followed by reverse 
engineering of the identified mutations to assess their individual phenotypic contribution to 
resistance. Finally, the generation of cDNA clones of reporter viruses, like those expressing 
green fluorescent protein (GFP), greatly facilitates high throughput screening, e.g. for antiviral 
compounds or host factors that affect replication. 
Several CHIKV cDNA clones have been constructed in the past, which - except for the West 
African lineage strain 37997 strain that was isolated from a mosquito - were all based on 
clinical isolates from infected humans (93, 114-116, 152-154). Each natural isolate is expected 
to have evolved its own specific characteristics in terms of sequence, virulence and virus-
host interactions as a result of specific selective pressures within the infected host (tissue) 
and possibly also during subsequent passaging in cell culture. Intrahost evolution and 
quasispecies diversity is expected to be substantial, especially compared to the relatively low 
level of interhost variation when the consensus sequences of CHIKV genomes isolated from 
different hosts are aligned. The low level of interhost variation is a typical trait of arboviruses, 
due to evolutionary constraints imposed by the alternating replication in vertebrate and 
arthropod hosts. A recent study on the distantly related Ross River virus indeed reported a 
high level of intrahost diversity (155). The existing CHIKV molecular clones can be considered 
to represent a single individual genome (or fragments of several individual genomes) out 
of the whole spectrum of viruses present in the CHIKV quasispecies population that has 
been shaped by intrahost evolution and probably a complex set of environmental factors. 
In contrast, most deposited CHIKV genome sequences represent the consensus (or master 
sequence) of a viral quasispecies population. 
To obtain a virus that - in terms of virulence, sensitivity to antiviral compounds, and CHIKV-
host interactions - is expected to have the general characteristics of the E1-226V CHIKV strains 
that were circulating during the 2005-2009 outbreaks, we have constructed a completely 
synthetic CHIKV cDNA clone based on the consensus sequence of the aligned genomes of 
these recent isolates. This new infectious clone, CHIKV LS3 (Leiden Synthetic 3), and a variant 
that expresses the eGFP reporter gene under control of a duplicated subgenomic promoter 
(CHIKV LS3-GFP), were created by custom DNA synthesis. 
The properties and replicative cycle of the new synthetic viruses were characterized in 
detail, and comparison with a field isolate (ITA07-RA1) from the 2007 CHIKV outbreak in Italy 
Characterization of synthetic chikungunya viruses
31
2
demonstrated that they have similar characteristics. The sensitivity of LS3 to a number of 
antiviral compounds was compared to those of ITA07-RA1 and clinical isolate NL10/152. All 
compounds tested had a similar antiviral activity against LS3 and the natural isolates. These 
experiments also identified 3-deaza-adenosine as a novel inhibitor of CHIKV replication. This 
study describes a detailed characterization of the CHIKV replication cycle at the molecular 
level and demonstrates that a new synthetic infectious clone-derived virus is a useful and 
representative tool to gain more insight into the replicative cycle of CHIKV, its interactions 
with the host, and the mode of action of antiviral compounds, which should aid in the 
development of antiviral strategies against this important human pathogen. 
MATERIALS AND METHODS
Cells and viruses. Vero E6, Ae. albopictus C6/36 (156) and 293/ACE2 cells (157) were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM; Lonza), supplemented with 
8% fetal calf serum (FCS; PAA), 2 mM L-glutamine, 100 IU/ml of penicillin and 100 μg/ml of 
streptomycin. 293/ACE2 cells were grown in the presence of 12 µg/ml blasticidin (PAA) and 
C6/36 medium was supplemented with non-essential amino acids (Lonza). BHK-21 cells were 
cultured in Glasgow’s Modified Eagles Medium (Gibco) supplemented with 7.5% FCS, 10 mM 
HEPES pH 7.4, 8% tryptose phosphate broth (Gibco), and antibiotics. The mammalian cell 
lines were grown at 37°C and C6/36 cells at 30°C in 5% CO2. CHIKV strain ITA07-RA1 (GenBank 
accession number EU244823) was isolated from Ae. albopictus during the 2007 outbreak 
in Ravenna, Italy, and was passaged twice on BHK-21 cells. CHIKV NL10/152 (GenBank 
KC862329) was isolated at the Erasmus Medical Center in Rotterdam from the serum of an 
infected traveler that returned from Indonesia and was passaged twice on Vero cells. Working 
stocks of CHIKV were routinely produced in Vero E6 cells at 37°C, typically yielding titers of 
~107 PFU/ml. Infections were performed in Eagle’s minimal essential medium (EMEM; Lonza) 
with 25 mM HEPES (Lonza) supplemented with 2% FCS, L-glutamine, and antibiotics. After 1 
h, the inoculum was replaced with fresh culture medium. All procedures with live CHIKV were 
performed in a biosafety level 3 facility at the Leiden University Medical Center. 
Construction of synthetic CHIKV full-length cDNA clones. A cDNA clone of the synthetic 
CHIKV strain LS3-GFP, which contains a duplicated subgenomic promoter and expresses the 
eGFP reporter gene, was designed in silico as described in the results section. Three DNA 
fragments together forming a cDNA copy of CHIKV LS3-GFP were chemically synthesized 
(GeneArt, Germany). Using standard cloning techniques, these fragments were assembled 
and cloned into the AscI-NotI sites of vector pUC19AN, a pUC19-derived plasmid in which 
the original polylinker was replaced by one with AscI-NcoI-EcoRV-XhoI-NotI sites. The 
resulting plasmid (pCHIKV-LS3-GFP) contains the genomic cDNA of CHIKV LS3-GFP directly 
downstream of a phi2.5 promoter and followed by a unique SpeI linearization site for DNA 
linearization prior to in vitro transcription. The ‘wild type’ synthetic pCHIKV-LS3 construct was 
made by deleting the 920 bp eGFP-containing SacI fragment from pCHIKV-LS3-GFP (Fig. 1). 
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A third variant with a duplicated subgenomic promoter and a multiple cloning site behind 
subgenomic promoter 1 (pCHIKV-LS3-MCS), which allows the introduction of e.g. a reporter 
gene, was generated by removing the 737 bp AsiSI-PacI fragment from pCHIKV-LS3-GFP. The 
constructs were verified by sequencing. 
 
In vitro transcription and RNA transfection. RNA was transcribed from plasmids with 
the phi2.5 promoter (158) using the AmpliScribe T7 high yield transcription kit (Epicenter), 
the m7GpppA RNA cap structure analog (NEB) and 0.7 µg of template DNA that had been 
linearized with SpeI. After a 3-h reaction at 37°C, template DNA was digested with DnaseI 
and RNA was purified by precipitation with 7.5 M LiCl (Ambion). The concentration of in vitro 
transcribed RNA was determined with a NanoDrop spectrophotometer (Thermo Scientific) 
and its integrity was checked by agarose gel electrophoresis. BHK-21 cells (2 x 106) were 
electroporated with 1 µg of RNA using program T-20 of the Amaxa Nucleofector and Kit T 
(Lonza) according to the manufacturer’s instructions. Electroporated cells were plated 
in 6-well clusters and incubated at 37°C in the same medium used for CHIKV infection 
experiments.
Sequencing of CHIKV genomes. CHIKV RNA was isolated from virions using the QIAamp 
Viral RNA mini kit. Four overlapping amplicons were generated by a two-step reverse 
transcriptase (RT) PCR. In the first step cDNA was synthesized using RevertAid H Minus 
Reverse transcriptase (Fermentas) and primers AT-39 (GACTGCAGATGCCCGCCATT), 
AT-41 (CGCTCGGTCCAGGCAACTCT), AT-43 (CGTGGTGTTTGCCAACAGGC), or AT-52 
(CGCCGTTTTTTTTTTTTTTTTTTTTTTTTT). In the second step 4 PCR products were generated 
using combinations of primers AT-38 (ATGGCTGCGTGAGACACACG) and AT-39, AT-40 
(TGCACCCAAGTGTACCACAA) and AT-41, AT-42 (CAGGAGAGTGCATCCATGGC) and AT-43, or 
AT-44 (GAATGCGCGCAGATACCCGT) and AT-52. The resulting RT-PCR products were purified 
and directly sequenced (50 ng template) using the BigDye Terminator Cycle Sequencing 
Kit v1.1 (Applied Biosystems) and a 3130 Genetic Analyzer automatic sequencer (Applied 
Biosystems). PCR conditions and primer sequences are available upon request. 
 
Virus titration and infectious center assay. Viral titers were determined by plaque assay 
on Vero E6 cells. Six-well clusters containing confluent monolayers of Vero E6 cells were 
incubated with 0.5-ml volumes of 10-fold serial dilutions of CHIKV-containing samples. After a 
1-h incubation at 37°C, the inoculum was replaced with 2 ml of DMEM containing 1.2% Avicel 
RC-581 (FMC BioPolymer), 2% FCS, 25 mM HEPES, and antibiotics. After a 66-h incubation at 
36°C, monolayers were fixed with 3.7% formaldehyde in PBS and plaques were visualized by 
crystal violet staining. For infectious center assays 10-fold serial dilutions of electroporated 
cells were added to 6-well clusters already containing a monolayer of 1 x 106 BHK-21 cells 
per well. After a 1-h incubation at 37°C, a DMEM/Avicel overlay was applied and cells were 
incubated at 37°C for 48 h. Plaques were visualized as described above.
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RNA isolation, denaturing agarose electrophoresis and in-gel hybridization. Total 
RNA was isolated from 7 x 105 cells by lysis in 0.5 ml of 20 mM Tris-HCl (pH 7.4), 100 mM LiCl, 
2 mM EDTA, 5 mM DTT, 5% (w/v) lithium dodecyl sulfate, and 100 µg/ml proteinase K. After 
acid phenol (Ambion) extraction, RNA was precipitated with isopropanol, washed with 75% 
ethanol, and dissolved in 1 mM sodium citrate (pH 6.4). Samples containing RNA from 4.7 x 
104 cells were mixed with 3 volumes of 67% formamide, 23% formaldehyde, 6.7% glycerol, 13 
mM MOPS (pH 7.2), 6.7 mM NaAc, 2.7 mM EDTA, 0.07% SDS, and 0.03% bromophenol blue. 
After denaturation for 15 min at 75°C, RNA was separated in 1.5% denaturing formaldehyde-
agarose gels using the MOPS buffer system as described (159). RNA molecules were detected 
by direct hybridization of the dried gel with 32P-labeled oligonucleotides essentially as 
described previously (160). Positive-stranded genomic and subgenomic CHIKV RNAs were 
visualized with probe CHIKV-hyb4 (5’-TGTGGGTTCGGAGAATCGTGGAAGAGTT-3’) that is 
complementary to the 3’ end of the genome. Negative-stranded RNA was detected with 
probe CHIKV-hyb2 (5’-AACCCATCATGGATCCTGTGTACGTGGA-3’) that is complementary 
to the 3’ end of the minus strand. 18S ribosomal RNA (loading control) was detected with 
the oligonucleotide probe 5’-ATGCCCCCGGCCGTCCCTCT-3’. Probes (10 pmol) were labeled 
with 10 µCi [γ-32P]ATP (PerkinElmer) in a 1 h reaction using 10 U of T4 polynucleotide kinase 
(Invitrogen) in 10 µl of the supplied forward reaction buffer (Invitrogen). Prehybridization (1 h) 
and hybridization (overnight) were done at 55°C in 5x SSPE (0.9 M NaCl, 50 mM NaH2PO4, 5 mM 
EDTA, pH 7.4), 5x Denhardt’s solution, 0.05% SDS, and 0.1 mg/ml homomix I. Hybridized gels 
were washed twice in 5x SSPE with 0.05% SDS before they were exposed to Storage Phosphor 
screens. After scanning with a Typhoon-9410 scanner (GE Healthcare), quantification of RNA 
levels was done with Quantity One v4.5.1 (Biorad) and corrections for loading variations were 
made based on the quantity of 18S ribosomal RNA in the same lane. The results of two or 
three independent experiments were quantified (one representative experiment is shown in 
figures). 
Western blot analysis. Total protein samples were prepared by lysing 7 x 105 cells in 0.5 ml 
of 4x Laemmli sample buffer (100 mM Tris-HCl, pH 6.8, 40% glycerol, 8% SDS, 40 mM DTT, 0,04 
mg/ml bromophenol blue). Proteins were separated by SDS-PAGE in 12% polyacrylamide 
gels and were transferred to Hybond-LFP membranes (GE Healthcare) by semi-dry blotting. 
After blocking with 1% casein (Sigma) in PBS with 0.1% Tween-20 (PBST), membranes were 
incubated overnight with rabbit antisera against CHIKV nsP1 (raised using the peptide 
EVEPRQVTPNDHAN), nsP4 (raised using the peptide ASSRSNFEKLRGPV) or E2 (161) in PBST 
with 0.5% casein. Mouse monoclonal antibodies against β-actin (Sigma), or the transferrin 
receptor (Zymed) were used for detection of loading controls. Biotin-conjugated swine-α-
rabbit (DAKO) or goat-α-mouse (DAKO), and Cy3-conjugated mouse-α-biotin (Jackson) were 




Metabolic labeling with 3H-uridine. At various time points post infection approximately 2 
x 105 CHIKV-infected or mock-infected 293/ACE2 cells in 12-well clusters were incubated with 
40 µCi of 3H-uridine in medium and incorporation was allowed to proceed for 60 minutes at 
37°C. Total RNA was isolated and analyzed in a denaturing agarose gel as described above. 
For fluorographic detection of 3H-labeled RNA, the gel was soaked in methanol for 1 hour 
(one change) and then incubated with 3% 2,5-diphenyloxazole in methanol for at least 3 
hours. After incubation in milliQ for 30 minutes, the gel was dried and a Fuji RX film was 
placed on top. Films were developed after a 1-4 day exposure at -80°C and scanned with a 
Biorad GS-800 densitometer. To check equal sample loading, the gel was hybridized with a 
32P-labeled 18S ribosomal RNA-specific probe as described above. In addition, incorporation 
of 3H-uridine into RNA was quantified by analyzing 2-µl samples of isolated total RNA with a 
liquid scintillation counter (Beckman LS 6500 IC). In control samples, cellular transcription 
was inhibited by adding Actinomycin D (Sigma) to a final concentration of 5 µg/ml. 
Metabolic labeling of proteins with 35S-methionine and 35S-cysteine. At various time 
points post infection approximately 2 x 105 CHIKV-infected or mock-infected 293/ACE2 cells 
in 12-well clusters were starved in DMEM lacking L-methionine and L-cysteine (Invitrogen) for 
30 min., and subsequently incubated with 44 µCi EasyTag EXPRESS 35S protein labeling mix 
(PerkinElmer) for 30 min. Total protein samples were analyzed by SDS-PAGE as described 
above. Gels were stained with Coomassie to check equal sample loading and 35S-labeled 
proteins were detected by drying the gels and exposing them to a Storage Phosphor screen, 
which was scanned 1-2 days later with a Typhoon-9410 scanner (GE Healthcare).
Indirect immunofluorescence microscopy. CHIKV- or mock-infected Vero E6 cells grown 
on coverslips were fixed with 3% paraformaldehyde in PBS. After quenching with 10 mM 
glycine in PBS, cells were permeabilized with 0.1% Triton in PBS for 10 min. and coverslips 
were incubated with primary antibodies diluted in PBS with 5% FCS for 1 h. Double-stranded 
RNA was detected with a 1:200 dilution of mouse monoclonal antibody J2 (English & Scientific 
Consulting). CHIKV E2 was visualized with a 1:8000 dilution of a polyclonal rabbit antiserum 
(161). Detection of primary antibodies was done with donkey-α-mouse-Cy3, goat-α-rabbit-
Cy3 or goat-α-rabbit-Alexa488 (1:500; Jackson). Nuclei were stained with Hoechst 33342. The 
coverslips were mounted with Prolong (Invitrogen) and analyzed using an Axioskop2 Mot 
Plus fluorescence microscope with Axiocam HRc camera and AxioVision software (Zeiss). 
Virus neutralization assay. Mouse monoclonal antibodies raised against CHIKV particles 
of strain ITA07-RA1 (IZSLER, Brescia, Italy) were heat-inactivated for 30 min. at 56°C. Two-fold 
serial dilutions of the neutralizing monoclonal antibody 1H7 and non-neutralizing control 
antibody 3H9 (162) were incubated with an equal volume of medium containing 100 PFU of 
CHIKV. These mixtures were incubated for 60 min. at 37°C and transferred to 96-well clusters 
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containing 2 x 104 Vero E6 cells per well. After incubation at 37°C for 2 days, the wells were 
fixed with 3.7% formaldehyde and CPE was detected by staining with crystal violet.
Antiviral compound assays. Chloroquine, 6-aza-uridine and ribavirin were dissolved in 
PBS. Cyclosporin A and 3-deaza-adenosine were dissolved in DMSO. Mycophenolic acid was 
dissolved in ethanol. All compounds were obtained from Sigma. For CPE reduction assays, 
96-well clusters with ~1x104 Vero E6 cells/well were incubated with 50 PFU of virus per well, 
corresponding to a multiplicity of infection (MOI) of 0.005, and 2-fold serial dilutions of the 
compound in medium. Wells without cells, uninfected cells, infected untreated cells and 
infected cells treated with solvent alone were included as controls. Four days post-infection 
cell viability was assessed using the CellTiter 96® AQueous Non-Radioactive Cell Proliferation 
Assay (Promega). CPE reduction experiments with ribavirin were done with BHK-21 cells in a 
similar way, except that viability was assessed 2 days post infection. For eGFP reporter gene 
assays, ~1x104 Vero E6 cells/well in black 96-well plates were infected with CHIKV LS3-GFP at 
an MOI of 0.05. After a 42-h incubation in medium containing the compound, the cells were 
fixed with 3% paraformaldehyde in PBS. eGFP expression was quantified using a Berthold 
Mithras LB 940 plate reader, with excitation and emission wavelengths of 485 and 535 nm, 
respectively. The fluorescence in wells containing mock-infected cells was used to correct 
for background signal. IC50 and CC50 values were calculated with GraphPad Prism 5 using the 
nonlinear regression model.
 
Mouse experiments. All animal experiments described in this paper were carried out in 
the BSL3 facilities of the Erasmus Medical Center in accordance with the Dutch guidelines 
for animal experimentation and were approved by the institute’s independent animal ethics 
committee. Twelve-day old C57BL/6 mice were injected intraperitoneally with 100 TCID50 of 
CHIKV S27, CHIKV LS3 or CHIKV LS3-GFP. After the challenge the mice were monitored daily 
for signs of illness or death. The infection was considered lethal when the animals reached 
humane end-points and needed to be euthanized. Viral RNA was extracted from brain samples 
using the automated MagnaPure method (Total nucleic acid isolation kit, Roche Diagnostics, 
the Netherlands) according to the manufacturer’s instructions, and quantified using a one-
step RT-PCR TaqMan protocol (EZ-kit, Applied Biosystems) and an ABI PRISM 7500 detection 
instrument. The primers and probe used for CHIKV RNA quantification were essentially as 
described (163) except that probe Fam-CCAATGTCTTCAGCCTGGACACCTTT-Tamra was used. 
Dilutions of virus suspensions of known titer were included to make a calibration curve, 
which was used to express results as TCID50 equivalents per gram of brain tissue.
Ethics statement. All animal experiments described in this paper were carried out in the BSL3 
facilities of the Erasmus Medical Center in accordance with the Dutch guidelines for animal 
experimentation. A Dutch Government-approved and independent animal experimentation 
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ethical review committee (Stichting DEC Consult) approved the animal studies (permit nr. 
EMC2838/122-12-29).
Nucleotide sequence accession numbers. The GenBank accession numbers for the 
full-length cDNA clones pCHIKV-LS3, pCHIKV-LS3-GFP and pCHIKV-LS3-MCS are JX911334, 
JX911335, and JX911336 respectively. The Genbank accession numbers for the genomic 
RNA sequences of CHIKV LS3, LS3-GFP, LCS3-MCS and NL10/152 are KC149888, KC149887, 
KC149889, and KC862329, respectively.
RESULTS
In silico design and construction of synthetic CHIKV full-length cDNA clones. The 
complete genomes of the 13 CHIKV strains carrying the E1-A226V mutation (Table 1) that 
were available in GenBank at the time of in silico design (November 2009) were aligned using 
MAFFT (164) and the resulting consensus sequence formed the basis for the synthetic full-
length cDNA clones. A 40 nucleotide polyA tail was added to the 3’ end of the consensus 
sequence and a translationally silent point mutation (A7435G) was introduced to create 
a SacI restriction site required for cloning. The virus encoded by the resulting sequence 
was termed CHIKV LS3 (GenBank accession KC149888). Variants containing a duplicated 
subgenomic promoter and a multiple cloning site (CHIKV LS3-MCS; GenBank KC149889) or 
an eGFP reporter gene (CHIKV LS3-GFP; GenBank KC149887) were also designed. The eGFP 
reporter gene was placed under control of the native subgenomic promoter and upstream of 
a second subgenomic promoter that drives expression of the viral structural polyprotein, as 
this configuration was previously reported to result in a more stable reporter gene expression 
(114). The CHIKV cDNAs were placed downstream of a phi2.5 T7 promoter, and a unique 
SpeI site for linearization prior to in vitro transcription directly followed the polyA tail. The 
phi2.5 promoter was used because the 5’ ends of capped transcripts generated from this 
Figure 1. Schematic overview of the synthetic infectious clone pCHIKV-LS3-GFP. The ‘wild type’ full-length 
clone pCHIKV-LS3, which lacks the eGFP reporter gene, was generated by deleting the SacI fragment; the 
variant pCHIKV-LS3-MCS, containing a multiple cloning site (MCS) preceded by subgenomic promoter 1, 
was generated by removing the AsiSI-PacI fragment. 
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promoter with T7 polymerase and the m7GpppA cap analog are identical to the 5’ end of 
the genomes of naturally occurring CHIKV strains. In contrast, capped RNAs generated by in 
vitro transcription from the frequently used SP6 promoter will contain m7GpppG at their 5’ 
terminus, i.e. will contain an additional 5’-terminal G residue. However, existing CHIKV cDNA 
clones that contain the SP6 promoter also efficiently yield infectious virus and it is assumed 
that the additional 5’-terminal G residue is removed during subsequent rounds of replication. 
In line with this, in vitro transcribed RNA from pCHIKV-LS2, a variant of plasmid pCHIKV-LS3 in 
which the phi2.5 promoter was replaced with the SP6 promoter also yielded infectious virus. 
Plasmid pCHIKV-LS3-GFP, the infectious clone encoding the eGFP-expressing reporter virus, 
was created by assembling the chemically synthesized DNA fragments as described in the 
Materials and Methods section. Plasmid pCHIKV-LS3, the infectious clone encoding the 
synthetic ‘wild type’ strain CHIKV LS3, and plasmid pCHIKV-LS3-MCS were generated from 
pCHIKV-LS3-GFP by deleting specific restriction fragments, as described in Materials and 
Methods (Fig. 1). In the original alignment, strains DRDE-07 (GenBank U372006) and D570/06 
(GenBank EF012359) shared the highest sequence similarity with LS3, with 3 amino acid 
differences (Table 2). However, a BLAST search performed in March 2013, three years after 
the design of CHIKV LS3, and alignment of the retrieved complete CHIKV genomes revealed 
that strains IND-06-AP3 (GenBank EF027134), IND-GJ53 (GenBank FJ000065), and CHIK31 
(GenBank EU564335) share the highest degree of nucleotide sequence identity with CHIKV 
LS3 (>99.9%), with only 5-7 nucleotide differences respectively (supplemental table S1). 
Interestingly, these Indian strains were not included in the original alignment on which the 
Figure 2. Growth kinetics of CHIKV LS3, LS3-GFP and ITA07-RA1 on various cell lines. Growth kinetics of 
CHIKV on Vero E6 (A), 293/ACE2 (B) and mosquito C6/36 cells (C). Cells were infected at an MOI of 5 and 
the viral progeny titers in the supernatant were determined at various time points post infection. (D) 
Plaque morphology of ITA07, LS3 and LS3-GFP on Vero E6 cells. (E) Induction of CPE by ITA07 (upper 
panel) and LS3 (lower panel) on Vero E6 cells at different time points post infection. 
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LS3 sequence was based, as they do not contain the E1-A226V mutation (Table 1). However, 
nsP1234 of LS3 is identical to that of IND-06-AP3. At the amino acid level, CHIKV LS3 differs at 
4 positions from LR2006_OPY1 and at 3 positions from ITA07-RA1 (Table 2).
Growth kinetics of synthetic CHIKV strains and comparison to a natural isolate. To 
determine whether infectious virus could be generated from the synthetic CHIKV clones, in 
vitro transcribed RNA was electroporated into BHK-21 cells. Strong eGFP fluorescence was 
readily detected 16 h after transfection of CHIKV LS3-GFP RNA. For CHIKV LS3 and LS3-GFP 
RNA specific infectivities of approximately 105 PFU/µg of RNA were found in infectious center 
assays, which is similar to what has been found for other CHIKV cDNA clones (114, 116). Virus 
titers in cell culture supernatants 16 h after electroporation, were generally in the range of 
105 - 106 PFU/ml. This is lower than the peak viral titers that are obtained during infection 
experiments, but can be explained by the early time point of harvesting and the fact that not 
all cells were transfected. As expected, electroporation of BHK-21 cells with uncapped CHIKV 
RNA did not result in the release of infectious virus.
To assess the stability of eGFP reporter expression, CHIKV LS3-GFP was serially passaged 
(MOI 0.5) in both 293/ACE2 and Vero E6 cells. Virus harvested during each passage was 
used to infect Vero E6 cells at an MOI of 0.2 and immunofluorescence microscopy revealed 
that at passage 10, over 95% of the E2-positive foci still displayed robust eGFP expression. 
Sequencing of cDNA obtained by RT-PCR amplification of RNA extracted from extracellular 
virions revealed that, after 3 passages on Vero E6 cells, the consensus genome sequence 
of CHIKV LS3-GFP was identical to the original in silico designed sequence. These results 
demonstrated that the synthetic viruses are viable, genetically stable, and able to retain 
stable expression of the reporter gene. 
Since we aim to use CHIKV in siRNA screens and proteomics studies to identify host factors 
involved in replication, various human cell lines were evaluated for their ability to support 
CHIKV replication. CHIKV LS3-GFP was able to productively infect HeLa, MRC-5, Huh7, 293, 
and 293/ACE2 cells (data not shown). Infection of HeLa and Huh7 cells was not very efficient 
and these cells were therefore not used for any further experiments. 293/ACE2 cells were 
selected for this study, as they supported high levels of CHIKV LS3-GFP replication, could 
be efficiently transfected with siRNAs, and - unlike regular 293 cells - adhered well to tissue 
culture plastics. 293/ACE2 cells stably express angiotensin-converting enzyme 2 (ACE2), the 
receptor for SARS-coronavirus. ACE2 expression is not required for CHIKV infection, but these 
cells were chosen because of the aforementioned advantages and the fact that they have 
been previously used in our lab in siRNA screens for host factors that affect corona- and 
arterivirus replication ((165, 166); Wannee et al., in preparation). Using these cells in similar 
siRNA screens with CHIKV and other alphaviruses would allow direct comparison of data sets 
with those obtained for corona- and arteriviruses, which could lead to the identification of 
common (broad spectrum) pro- and antiviral host factors. 
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To determine whether the synthetic viruses behave like natural isolates, their growth kinetics 
in Vero E6, 293/ACE2, and C6/36 cells were compared to those of ITA07-RA1, which was 
isolated during the 2007 CHIKV outbreak in Italy (Fig. 2A-C). The growth curves of CHIKV LS3 
on all three cell lines were found not to differ significantly from those of ITA07-RA1, with virus 
titers reaching a maximum 14-18 h post infection (p.i.). Peak virus titers on mosquito cells 
were approximately 1-log higher than those on mammalian cells. CHIKV LS3-GFP replicated 
slightly slower than the other viruses in all three tested cell lines, which is not unusual for 
recombinant reporter viruses.
eGFP expression could be detected as early as 6 h p.i. and peaked around 22 h p.i. The plaque 
morphology of the synthetic viruses was similar to that of ITA07-RA1 (Fig. 2D). CHIKV LS3 
induced a cytopathic effect (CPE) indistinguishable from the natural isolate. On Vero E6 cells 
early signs of CPE started to appear around 12 h p.i. and CPE was complete by 24 h p.i. (Fig. 
2E). 
To study CHIKV-induced transcriptional host shut-off, the incorporation of 3H-uridine 
into cellular and viral RNA was analyzed by metabolic labeling of infected 293/ACE2 cells 
at various time points post infection (MOI of 5). A strong reduction in the incorporation of 
3H-uridine into RNA was observed at 10-12 h p.i. in cells infected with CHIKV LS3 or ITA07, 
as determined by liquid scintillation counting of total RNA samples (Fig. 3A). Inhibition of 
cellular transcription with actinomycin D for 30 min. prior to metabolic labeling at 12 h p.i. 
revealed the contribution of viral RNA synthesis to the total signal. Fluorographic detection of 
3H-labeled RNA analyzed in denaturing gels also showed a decrease in cellular transcription 
during the course of the infection, while the synthesis of CHIKV RNA became clearly detectable 
by 6 h p.i (Fig. 3B). Transcriptional shut-off occurred around 10-12 h p.i. and was induced 
Figure 3. Transcriptional and translational shut-off induced by CHIKV. 293/ACE2 cells were infected with 
CHIKV LS3 or ITA07-RA1 at an MOI of 5, and at the indicated time points post infection metabolic labeling 
with 3H-uridine (A, B) or 35S-Cys and 35S-Met (C) was performed to analyze total RNA and protein synthesis, 
respectively. (A) Incorporation of 3H-uridine into viral and cellular RNA as measured by liquid scintillation 
counting of total RNA samples taken at various time points post infection. (B) 3H-uridine incorporation 
into viral and cellular RNA during CHIKV LS3 infection as detected by denaturing gel electrophoresis and 
fluorography. In control samples (ActD) 5 ug/ml Actinomycin D was added 30 min. prior to metabolic 
labeling to inhibit cellular transcription. (C) Synthesis of 35S-labeled viral and cellular proteins during 
CHIKV LS3 infection. The control lane labeled CHX contains proteins from cells treated with the translation 
inhibitor cycloheximide prior to metabolic labeling. CHIKV-specific proteins are indicated with a *. 
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by CHIKV LS3 and ITA07 with similar kinetics, although LS3 seemed to act slightly faster. To 
examine CHIKV-induced translational shut-off, the synthesis of 35S-labeled viral and cellular 
proteins during the course of CHIKV LS3 infection was analyzed by metabolic labeling of 
infected 293/ACE2 cells with 35S-Met and 35S-Cys (Fig. 3C). A clear shut-off of host translation 
was observed 8-9 h p.i. Beyond 9 h p.i. the bulk of newly produced protein appears to be of 
viral origin, likely C, E1, E2 and their precursors (indicated with * in Fig. 3C). CHIKV ITA07 and 
LS3 induced translational host shut-off in a similar manner (only results obtained with LS3 
are shown in Fig. 3C).
Both CHIKV ITA07-RA1 and the synthetic viruses established non-cytopathic persistent 
infections in C6/36 mosquito cells. All characterization experiments have been performed in 
both 293/ACE2 and Vero E6 cells, with similar results. For simplicity only the results for 293/
ACE2 cells are shown, except for immunofluorescence experiments, which were done with 
Vero E6 cells as they had a more suitable morphology. 
Kinetics of RNA synthesis of CHIKV ITA07-RA1 and the synthetic viruses. The replication 
cycle of the synthetic viruses and ITA07-RA1 was characterized in more detail to assess 
whether the synthetic viruses behaved like their natural counterpart. The kinetics of RNA 
synthesis was analyzed by isolating total RNA from 293/ACE2 cells infected with CHIKV LS3, 
LS3-GFP, or ITA07-RA1 at various time points post infection. Negative- and positive-stranded 
RNAs were detected by hybridization with 32P-labeled oligonucleotide probes (Fig. 4A). Both 
negative- and positive-strand RNAs were readily detected in cells infected with the various 
strains starting at 6 h p.i. The negative-strand RNA was less abundant than the positive strand, 
it was easily detected relatively early in infection (Fig. 4A top panel, Fig. 4B), and appeared to 
decrease at later time points as has also been observed for other alphaviruses. This apparent 
decrease is probably not only due to degradation of minus strands, but at least partly due to 
a hampered detection caused by the large excess of positive-strand RNA present at late time 
points. This excess of positive-strand RNA competes with the radioactively labeled minus-
strand specific probe. In support of this, we observed that mixing RNA isolated from CHIKV-
infected cells at 6 h p.i. with in vitro transcribed positive-strand RNA reduced the amount of 
negative strand that could be detected (data not shown). Furthermore, when samples taken 
at 6 and 14 h p.i. were treated with single-strand-specific RNase A/T1 before hybridization, 
the negative-strand levels at the late time point were approximately 70% of that at 6 h p.i, 
instead of the approximately 50% in untreated samples (data not shown). Using a positive-
strand-specific probe, both the 49S genomic and 26S sgRNA could be detected, and both 
RNAs accumulated until 12 h p.i (Fig. 4A middle panel, Fig. 4C). The ratio of genomic to sgRNA 
varied between 1:3.5 and 1:5.5 during the course of infection, similar to the ratios reported 
for Semliki forest virus and SINV (167). The kinetics of RNA synthesis and RNA accumulation 
levels were similar in CHIKV LS3- and ITA07-RA1-infected cells. In cells infected with CHIKV 
LS3-GFP, the additional subgenomic RNA encoding the eGFP reporter gave rise to an extra 
band above the 26S RNA band, and its expression level was calculated to be approximately 
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half of that of the 26S RNA. The individual levels of the two sgRNAs expressed by CHIKV LS3-
GFP were lower than those of ITA07 or LS3, but their combined abundance was comparable 
to that of the viruses expressing a single sgRNA (Fig. 4C). 
CHIKV protein synthesis and dsRNA accumulation in cells infected with ITA07-RA1 
or the synthetic viruses. To monitor viral protein expression, 293/ACE2 cells were infected 
with CHIKV LS3, LS3-GFP, or ITA07-RA1 and total protein was isolated at various time points 
post infection. These samples were analyzed by Western blotting with antisera against the 
nonstructural proteins nsP1 and nsP4, and the structural protein E2. Expression of nsP1, E2, 
Figure 4. Accumulation of negative- and positive-strand CHIKV RNA in infected cells. (A) 293/ACE2 cells 
were infected with CHIKV LS3, LS3-GFP or ITA07-RA1 at an MOI of 5, total RNA was isolated at different 
time points post infection and strand-specific detection was performed with radioactively labeled 
oligonucleotides complementary to the 3’ end of either negative- (top panel) or positive-strand (middle 
panel) CHIKV RNA. Cellular 18S ribosomal RNA was probed as a loading control (lower panel). The 
positions of genomic RNA, the 26S sgRNA and the second eGFP-encoding sgRNA are indicated to the right 
of the middle panel. (B) Plot representing the kinetics of CHIKV negative-strand RNA accumulation, based 
on quantification of data from panel A. After correction for variations in sample loading based on the 18S 
rRNA signal, the relative abundance of the RNAs was determined by normalizing to the highest value 
observed (CHIKV LS3-GFP, 8 h p.i.). (C) Kinetics of CHIKV positive-strand RNA accumulation. The relative 
abundance of RNA was calculated as before, except that data were normalized to the value measured for 
LS3 sgRNA at 12 h p.i (100%). Genomic RNA levels are indicated with black lines, sgRNA levels with gray 
lines. The total level of both sgRNAs expressed by LS3-GFP is indicated with the gray dotted line. 
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and the E3E2 precursor could be detected as early as 6 h p.i. and the proteins accumulated 
over time, reaching a plateau around 12 h p.i. (Fig. 5). The RdRp nsP4 could not be detected 
in infected cells using a CHIKV nsP4-specific antiserum capable of detecting the purified 
bacterially expressed protein. This was probably due to the low affinity of the antibody, the 
low expression level and relative instability of nsP4 in infected cells, as was also observed 
for other alphaviruses (168). In addition, a quantitative proteomics study on CHIKV-infected 
cells also suggested that at 10 h p.i. the amount of nsP4 was at least 200-fold lower than that 
of nsP1 (121).
Indirect immunofluorescence analysis of Vero E6 cells infected with CHIKV LS3, LS3-GFP, or 
ITA07-RA1 at various time points showed that the localization and expression kinetics of 
E2 and dsRNA were similar for the natural isolate and the synthetic viruses (Fig. 6). Double-
stranded RNA, which is assumed to be generated during replication of CHIKV in infected 
cells (169), could be detected as early as 4 h p.i. and remained clearly visible throughout the 
infection. The dsRNA localized to foci throughout the cytoplasm. The E2 protein could be 
detected from 6 h p.i. onwards with maximum expression reached by 12 h p.i. The E2 protein 
mainly localized to the plasma membrane of infected cells. eGFP produced by the reporter 
virus was visible from 6 h p.i. onwards, reaching a maximum level around 12 h p.i. (Fig. 6C).
Neutralization of CHIKV LS3 by a monoclonal antibody raised against ITA07-RA1. 
CHIKV LS3 and ITA07-RA1 were compared in a neutralization assay using the neutralizing 
monoclonal antibody 1H7 that was raised in mice against CHIKV ITA07-RA1 virions, and 
appears to recognize a linear epitope in E2 (162). The non-neutralizing mAb 3H9 was used as 
a control. Both the natural isolate and CHIKV LS3 were neutralized with similar characteristics 
by 1H7, while their infectivity was not affected by 3H9 (Fig. 7). 
The synthetic viruses cause lethal infections in a mouse model. Newborn mice are 
highly susceptible to CHIKV infection and they develop symptoms as lethargy, dragging of 
Figure 5. Western blot analysis of CHIKV nsP1 and E2 expression at different time points post infection. 
293/ACE2 cells were infected with CHIKV ITA07, LS3 or LS3-GFP at an MOI of 5. At the indicated time points 
cells were lysed, proteins were separated by SDS-PAGE and viral proteins were detected by Western 
blotting. The anti-E2 antiserum also recognized the E3E2 (p62) precursor of E2. Actin and the transferrin 
receptor were used as loading controls.
Characterization of synthetic chikungunya viruses
43
2
hind limbs, flaccid paralysis, and reduced weight gain (170). 12-day old mice were injected 
intraperitoneally with 100 TCID50 of CHIKV LS3, LS3-GFP or prototype strain S27 as a control. 
The animals were euthanized when their humane end points were reached 3 or 4 days post 
infection and viral RNA levels in brain tissue were analyzed (Fig. 8). Both synthetic viruses 
behaved like the natural isolate in vivo, causing lethal infections with similar kinetics (Fig. 8A). 
In addition, the viral titers in the brains of CHIKV S27-infected mice were similar to those of 
mice infected with the synthetic viruses (Fig. 8B). 
Sensitivity to antiviral compounds. To evaluate their suitability for analyzing the potency 
and mechanism of action of antiviral compounds, the sensitivity of CHIKV LS3 and LS3-GFP 
to a number of such compounds was determined and compared to ITA07-RA1. Cyclosporin 
A, which through its effect on cellular cyclophilins inhibits the replication of a variety of 
viruses, had no specific effect on CHIKV replication, not even at a (cytotoxic) dose of 32 μM 
(data not shown). The compounds 3-deaza-adenosine, 6-aza-uridine, chloroquine, and 
mycophenolic acid were tested in CPE reduction assays with Vero E6 cells infected at an 
Figure 6. Immunofluorescence analysis of dsRNA and E2 expression in time. Vero E6 cells grown on 
coverslips were infected with CHIKV ITA07, LS3 or LS3-GFP at an MOI of 5. At the indicated time points the 
coverslips were fixed and stained with antibodies specific for dsRNA (A) or E2 (B). (C) eGFP fluorescence 
in CHIKV LS3-GFP infected cells (green). Nuclei (blue) were visualized by Hoechst staining. 
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MOI of 0.005 and analyzed 4 days p.i. They were all found to inhibit CHIKV replication with 
IC50s in the low micromolar range and with minimal cytotoxicity (Fig. 9A-D). No substantial 
differences were observed between the IC50 values calculated for ITA07-RA1, LS3 and LS3-
GFP. The four compounds also clearly reduced eGFP reporter gene expression in Vero E6 
cells infected with CHIKV LS3-GFP (Fig. 9F). Slightly lower IC50 values were obtained for 6-aza-
uridine and chloroquine, and a significantly higher IC50 was observed for 3-deaza-adenosine 
in this assay, compared to the CPE-based assay. This might be due to the mode of action 
of 3-deaza-adenosine and/or due to differences in experimental set-up compared to the 
CPE-based assay (MOI 0.05 vs. 0.005; measurement 42 h p.i. vs. 4 d p.i). Ribavirin is a known 
inhibitor of CHIKV replication, but in our CPE reduction assay with Vero E6 cells it was not 
very effective in inhibiting replication of the various strains, as IC50 values of over 400 μM were 
obtained (Fig. 9E, gray lines). This is likely due to the inefficient conversion of ribavirin to its 
active phosphorylated form in Vero E6 cells (171). Therefore, we have also analyzed the effect 
of ribavirin in a 2-day CPE reduction assays with BHK-21 cells, which are able to metabolize 
ribavirin (172, 173) and found IC50s of 15-21 μM for the various strains. Clinical isolate NL10/152 
was also included in the assays and appeared to be somewhat more sensitive to the antiviral 
compounds than LS3 and ITA07-RA1. However, the slower replication kinetics of this strain 
made it impossible to directly compare NL10/152 and LS3 in the same CPE reduction assays, 
despite the fact that virus yields and cytopathic effect of NL10/152 and LS3 were comparable 
(data not shown).  
DISCUSSION
The massive CHIKV outbreaks that have been occurring in Asia and the Indian Ocean region 
since 2005 are associated with the emergence of strains with the A226V substitution in the E1 
glycoprotein, which allowed their transmission by a novel mosquito vector, Aedes albopictus 
(10, 37, 39, 40, 42, 150). These East-Central-South African lineage-derived strains even appear 
to be replacing the Asian lineage CHIKV strains that have been endemic in the region for 
Figure 7. Neutralization of CHIKV ITA07 and LS3 by mouse monoclonal antibodies raised against ITA07-
RA1. 100 PFU of the CHIKV strains were incubated with serially diluted antibodies in 96-well clusters 
containing confluent monolayers of VeroE6 cells. After 2 days the wells were fixed with formaldehyde and 
stained with crystal violet. Either the neutralizing antibody 1H7 or non-neutralizing control antibody 3H9 
were used. 
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decades. Since the 1980s, the geographic distribution of Aedes albopictus has dramatically 
expanded and now also includes large parts of the USA and several European countries. This 
creates concern for locally transmitted outbreaks in Europe and the USA, which could be 
initiated by viraemic travelers arriving from countries where CHIKV is endemic, like India and 
Indonesia. Locally transmitted CHIKV infections have indeed already been reported from 
Italy in 2007 and France in 2010 (22, 25) and recent studies suggest that also the USA is at 
risk for locally transmitted CHIKV outbreaks (174, 175). Besides its large medical and societal 
impact in endemic countries, the increased risk of CHIKV outbreaks in Europe and the USA 
underlines the importance of studying the replication of this important human pathogen 
and its interactions with the host to develop safe and effective vaccines and antiviral therapy. 
Infectious cDNA clones have proven to be important tools to study many aspects of the viral 
life cycle, and molecular clones of a variety of natural isolates have been instrumental in 
several recent CHIKV studies (93, 114-116, 152-154). The existing CHIKV molecular clones 
can be considered to be derived from a single genome (or fragments of single genomes) 
out of the whole spectrum of viruses present in a CHIKV quasispecies population. In 
contrast, most of the complete CHIKV genome sequences that have been deposited in 
GenBank represent the consensus (or master sequence) of a viral quasispecies population. 
Figure 8. Replication of synthetic CHIKV strains in vivo. (A) Survival of mice after intraperitoneal injection 
with 100 TCID50 of CHIKV LS3, LS3-GFP or S27 (5 mice per group). (B) CHIKV titers (in TCID50 equivalents per 
mg of tissue) in the brains of the mice infected with the 3 CHIKV strains. 
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Figure 9. Effect of antiviral compounds on the replication of various CHIKV strains. Dose dependent 
reduction of CHIKV-induced CPE by (A) 3-deaza-adenosine, (B) 6-aza-uridine , (C) chloroquine and (D) 
mycophenolic acid in Vero E6 cells infected with CHIKV strains ITA07-RA1, LS3 and LS3-GFP (MOI 0.005). 
(E) Antiviral effect of ribavirin on CHIKV replication in BHK-21 (black lines) and Vero E6 cells (gray lines). 
Cell viability was normalized to untreated uninfected cells (100%). The 50% cytotoxic concentration (CC50) 
of the compounds is indicated in the top left of each panel. (F) Dose-response curves showing the effect of 
five antiviral compounds on the eGFP expression in Vero E6 cells infected with CHIKV LS3-GFP (MOI 0.05) 
at 42 h p.i. Values were normalized to eGFP fluorescence in untreated infected cells (100%). 
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The diversity (and evolution) of a CHIKV quasispecies population has probably been shaped 
by the characteristics of the individual host and the specific tissue source (serum) from which 
it was isolated. For Ross River virus it was observed that the level of intrahost genetic variation 
in patient serum samples, was considerably larger than that observed at the epidemiological 
scale, which can be explained by the purifying selection for replication in both arthropod 
and vertebrate hosts (155). Advances in sequencing techniques now allow a more detailed 
view on quasispecies diversity and intrahost evolution, and also for CHIKV a recent study 
has provided more insight into quasispecies dynamics and the effect of purifying selection 
by host alternation (176). A link was observed between increased fitness as a result of 
alternating passaging and reduced quasispecies complexity, which restricted adaptability to 
novel selective pressures like antiviral treatment or antibody-mediated neutralization (176). 
Individual CHIKV isolates or molecular clone derived viruses could have their specific 
properties in terms of replication kinetics, vector specificity, dissemination within the host, 
virulence, virus-host interactions or sensitivity to antiviral compounds. We were interested 
in studying the general characteristics of the life cycle and virus-host interactions of the 
E1-226V CHIKV strains that were circulating during the 2005-2009 outbreaks. Therefore, we 
have constructed a fully synthetic cDNA clone, CHIKV LS3, based on the consensus sequence 
of the aligned genomes of these recent E1-226V isolates, rather than on a single genome 
from a clinical isolate. In addition, a variant with a (duplicated) subgenomic promoter that 
expresses the eGFP reporter gene was created (CHIKV LS3-GFP). The current possibilities 
of gene synthesis allowed the design of these clones in silico, with sequences tailored to 
our requirements, e.g. already containing a reporter gene under control of a duplicated 
subgenomic promoter and including (translationally silent) mutations to create restriction 
sites that facilitate cloning and reverse genetics studies. 
Alignment of all 148 complete CHIKV genomes that were in GenBank by June 2013 yielded 
a consensus sequence that differed only at 3 nucleotide positions from the sequence of 
LS3 that was designed 3 years earlier. These were position 7,435 at which we introduced a 
translationally silent restriction site (G7435A), a synonymous U→C substitution at position 
3,397, and position 10,670, which is a C in 68% of all deposited genomes (strains with 
E1-226A), while the remaining (E1-226V) strains have a U at this position. An interesting 
observation was that 6% of the sequenced CHIKV strains, including the prototype strains S27 
and Ross, contain an arginine codon instead of the opal stop codon that is present between 
the nsP3- and nsP4-coding regions of most CHIKV isolates. The presence or absence of this 
opal codon might be influenced by the passage history of the isolate as has been observed 
for other alphaviruses (177). This might also explain why the sequence of the original clinical 
isolate of LR2006-OPY1 (Genbank DQ443544.2) contains the opal termination codon near the 
end of the nsP3 coding region, while the infectious clone of this strain (Genbank EU224268.1) 
contains an arginine codon at this position.
To assess whether the synthetic viruses are representative models, their characteristics were 
compared to those of the natural strain ITA07-RA1. Like the natural isolate, the synthetic 
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viruses caused cytopathic infections in Vero E6 and 293/ACE2 cells (Fig. 2E), whereas non-
cytopathic persistent infections were observed in the mosquito cell line C6/36. In vertebrate 
cells all strains caused a shut-off of cellular translation around 8-9 h p.i. and a strong inhibition 
of cellular transcription by 10-12 h p.i. The accumulation of negative- and positive-strand 
viral RNA, the kinetics of non-structural and structural viral protein expression, as well as the 
growth kinetics and plaque morphology of the synthetic viruses were indistinguishable from 
those of CHIKV ITA07-RA1 (Fig. 2-6). In addition, the synthetic viruses caused lethal infections 
in 12-day old mice, with virus spreading to the brain, as observed for natural isolates (Fig. 8). 
Although this demonstrates that the synthetic viruses replicate in vivo, this mouse model does 
not allow comparison of strains for more subtle differences in virulence and pathogenesis. 
The genomic stability of CHIKV LS3-GFP was assessed and after 3 passages its (consensus) 
sequence was found to be identical to the original in silico designed sequence. The expression 
of the eGFP reporter gene was stable for at least 10 passages, making the synthetic viruses 
suitable tools for high-throughput screens for antiviral compounds, (reverse genetics) studies 
into their mechanism of action, and systematic functional genomics screens for host factors 
affecting CHIKV replication. 
To evaluate whether CHIKV LS3 and LS3-GFP are suitable to analyze the potency and 
mechanism of action of antiviral compounds, their sensitivity to a number of such compounds 
was determined and compared to ITA07-RA1. The lysosomotropic agent chloroquine and 
nucleoside analog 6-aza-uridine inhibited the replication of the synthetic viruses and 
natural isolates with IC50s that were in the same range and comparable to values previously 
reported by others (77, 117, 178-181). The inhibitory effect of chloroquine on the replication 
of many viruses including alphaviruses has been known for decades. For CHIKV it is a useful 
reference compound in cell-based studies, but a small scale clinical trial on the island of La 
Reunion suggested it is not effective in the treatment of CHIKV infections in patients (178). 
The nucleoside analog 6-aza-uridine has previously been reported to inhibit the replication 
of a variety of viruses, including CHIKV (117, 181). The compound could interfere with cellular 
UTP metabolism and may be incorporated into CHIKV RNA, leading to chain termination 
and/or increased error frequency, ultimately resulting in ‘error catastrophe’. Mycophenolic 
acid is a non-competitive inhibitor of inosine monophosphate dehydrogenase (IMPDH), 
causing a depletion of the intracellular guanosine pool. It is a known inhibitor of various 
viruses, including CHIKV (117, 182). Ribavirin is a synthetic nucleoside analog with broad 
spectrum antiviral effect due to potential effects on the cellular IMPDH enzyme, viral RNA 
synthesis and capping (171). However, not all cell lines are able to perform the necessary 
conversion of this compound to its active phosphorylated form, explaining the contradictory 
reports on the antiviral activity of this compound (172, 173, 183). In our hands, ribavirin 
inhibited CHIKV replication in BHK-21 cells with an IC50 of around 18 µM, while it was hardly 
effective in Vero E6 cells, with IC50 values of over 400 M. The IC50 that we obtained with BHK-
21 cells is in the same range as those previously reported for the antiviral effect of ribavirin 
on CHIKV replication (117, 181). Cyclosporin A, which through its effect on the cellular 
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cyclophilins, inhibits the replication of a variety of viruses (for recent review see (184)), 
had no effect on CHIKV replication. We identified 3-deaza-adenosine as a novel inhibitor 
of CHIKV replication with an IC50 of approximately 6 µM and a CC50>50 µM. This compound 
has previously been identified as inhibitor of a broad spectrum of viruses, although many 
other +RNA viruses appeared to be rather insensitive or not affected at all (reviewed in 
(185)). The antiviral activity of 3-deaza-adenosine was attributed to its inhibitory effect on 
the cellular enzyme S-adenosylhomocysteine hydrolase, leading to an accumulation of 
S-adenosylhomocysteine, which inhibits S-adenosylmethionine-dependent methylation 
reactions (185). In this manner the enzyme plays a key role in S-adenosylmethionine-
dependent methylation reactions and inhibition of viral methylation reactions (e.g. of viral 
RNA) apparently can be achieved at compound concentrations that do not notably interfere 
with cellular methylation reactions. Our observation warrants a more detailed analysis of 
the mode of action of 3-deaza-adenosine and analogs, also to evaluate their potential for 
use in antiviral therapy to treat CHIKV infections. Overall, no large differences were observed 
between the IC50 values calculated for ITA07-RA1, LS3 and LS3-GFP, indicating that the 
synthetic viruses are suitable for use in antiviral screens. For most compounds, a faster and 
simpler assay with CHIKV LS3-GFP reporter virus showed a good dose-dependent response 
that correlated well with results obtained in the CPE-based assay. 
Clinical isolate NL10/152 exhibited slightly slower replication kinetics and appeared to be 
more sensitive to antiviral compounds than ITA07 and the synthetic viruses. Differences 
in the sensitivity to antiviral compounds among clinical isolates is not an uncommon 
phenomenon. NL10/152 differs at 7 amino acid positions from LS3 and it will be interesting 
to determine the contribution of these mutations, in particular the R88S substitution in nsP4, 
to the slower replication kinetics (and higher sensitivity to antivirals). 
Taken together the detailed characterization of the CHIKV replication cycle at the molecular 
level demonstrated that our new synthetic consensus-based viruses behave like natural 
isolates and are suitable tools to study various aspects of the CHIKV life cycle, which should 
ultimately provide a basis for the development of antiviral therapy. 
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TABLE 1. CHIKV E1-226V strains that were aligned to produce the CHIKV LS3 consensus sequence. 











































































































































































































































































































































Table S1. Comparison of CHIKV LS3 with the genome sequences 
of various closely related natural isolates. Only differences 
between LS3 and each of the other strains are summarized. 
Dots indicate that the nucleotide at that position is identical 
to that at the corresponding position in the sequence of LS3. 
Genomes were aligned with MAFFT and analyzed in Jalview. 
Numbering is based on the sequence of LR2006_OPY1 (and 
is equal to LS3 numbering). The nucleotide at position 10670 
(indicated in gray) determines whether the strain has the 
A226V mutation in the E1 protein. Strains with a T at this 
position have the A226V mutation. Differences not included 
in the comparison are the 35 nt, 5 nt and 23 nucleotides that 
are missing from the 3’UTR of the sequences of DRDE-07, 
D570/06 and ITA07-RA1, respectively. The missing first 19 nt, 
missing last 13 nt and the insertion of an A after position 11564 












































  T     
5’-UTR 1 A - . T . . . T
358 T . . . C . C .
459 A . . . C . C .
499 T . . C . . . .
568 C . . . . . T .
627 T . . . . C . .
757 T . . . . . . C
764 G . . . . . . A
862 G C . . . . . .
985 T . . . . . . C
1016 A . . . . T . .
1052 G . . . R . . .
1203 T . . . C . C .
1247 T . . C . . . .
1381 T . . . . . . G
ns
P1
1603 C . . . . T . .
2014 A . . . . . . G
2944 G . . . . A . .
3325 C . . . . . . T
3397 T . . . . . . C
3481 C . . . . . . T
ns
P2
3724 T . . . A . A .
4167 A . . . R . . .
4300 T . . C . . . .
5049 G . . . K . . .
5122 T . . . . . C .
5202 C . . . . . . T
5248 C . . . T . T .
5377 G . . . . . . A
5490 G . A . . . . .
ns
P3
5491 C . T . . . . .
5744 C . . . . . . T
6397 C . . . . T . .
6547 G . . . A . A .
6706 C . T . . . . .
7435 G A A A A A A A
ns
P4
7450 C . . . . . . T
7633 T . . . C . C .
7645 G . A . . . . A
7983 C . . . . . . TC
8127 C . . . . . . T
E3 8385 C . . . . T . . 
8910 T . . . C . C .
8985 T . . . . A . .
9114 A . . . . G . .
9207 T . . A . . . .
9633 T . . . C . C .
E2
9681 G . . . . . . A
10004 T . . . . C . .
10314 T . . C C . C .
10377 T . . . . . . C
10670 T C C C . . . .
10743 A . . . G . G .
11127 T . . . C . C .
E1
11256 T . . . . . C .
11360 T . . . . C . .
11499 G T . . . . . .
11600 C . . . . . . T
11640 A . . . . . . G
11723 T . - . . . . .
11762 T . . . . - . .
11763 C . . . . - . .
11765 C . . . . T . .
11770 C . . . . A . .





11784 G - . . . - . .
    
total nt difference 5 7 9 16 16 16 21
Table S1. Comparison of CHIKV LS3 with the 
genome sequences of various closely related 
natural isolates. Only differences between LS3 
and each of the other strains are summarized.
Dots indicate that the nucleotide at that position 
is identical to that at the corresponding position in 
the sequence of LS3. Genomes were aligned 
with MAFFT and analyzed in Jalview. Numbering 
is based on the sequence of LR2006_OPY1 (and 
is equal to LS3 numbering). The nucleotide at 
position 10670 (indicated in gray) determines 
whether the strain has the A226V mutation in the 
E1 protein. Strains with a T at this position have 
the A226V mutation. Differences not included in 
the comparison are the 35 nt, 5 nt and 23 
nucleotides that are missing from the  3’UTR of 
the sequences of DRDE-07, D570/06 and ITA07-
RA1, respectively. The missing first 19 nt, 
missing last 13 nt and the insertion of an A after 
position 11564 in the sequence of IND-06-AP3 
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Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes severe and often 
persistent arthritis. The virus re-emerged in 2004, causing large epidemics in the Indian 
Ocean region and Asia. It reached the Caribbean in December 2013, where it quickly spread. 
Presently, CHIKV is endemic in large parts of the world and encroaching on both Americas. 
CHIKV relies, as other RNA viruses, heavily on host factors for its replication. However, the 
identity of most of these proteins remains unknown. Identifying these proteins will greatly 
improve our understanding of the replication of this important human pathogen, and 
they can potentially include interesting targets for antiviral therapy. Kinases, for example, 
are a common drug target as they play a key role in numerous cellular processes, and are 
therefore likely also involved in virus replication. Here we describe a siRNA library-mediated 
screen targeting the human kinome to identify cellular factors involved in CHIKV replication. 
We identified numerous proviral factors that could be placed in distinct cellular pathways, 
including (control of) mitogen-activated protein kinase (MAPK) and ErbB (epidermal growth 
factor receptor family) signaling, indicating that these pathways may play an important role 
in CHIKV replication. We performed a secondary screen to validate a selection of our hits, 
including the 20 genes that scored highest on our annotated hit list. We were able to confirm 
the identification of 10 proviral and 2 potential antiviral factors, including FGFR2, SHC1, DUSP1 
and LATS2. The pro- and antiviral host factors described here expand our understanding of 
CHIKV replication and form perfect starting points for further in-depth mechanistic studies.





BUB1B budding uninhibited by benzimidazoles (yeast homologue) 1 beta
CDC2L5/CDK13 cell division cycle 2-like 5
COPB2 coatomer protein complex, subunit beta 2
DMPK  dystrophia myotonica protein kinase 
DUSP dual specificity phosphatase
FGFR2 fibroblast growth factor receptor 2
FN3K  fructosamine 3 kinase 
FN3KRP  fructosamine 3 kinase related protein 
LATS2 large tumor suppressor kinase 2
MAPKAPK3 mitogen-activated protein kinase-activated protein kinase 3
MAPK4 microtubule affinity-regulating kinase 4
MMP2 matrix metalloproteinase
PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatoase 3 
RPS6KC1  ribosomal protein S6 kinase, 52kDa, polypeptide 1
RPS6KL1 ribosomal protein S6 kinase-like 1
SHC1 Src homology 2 domain containing transforming protein
SOCS suppressor of cytokine signaling 1





Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that re-emerged in 2004 during 
an explosive outbreak of unprecedented magnitude, which took place in the Indian Ocean 
area. During this outbreak the virus acquired a mutation in its envelope protein (E1-A226V) 
that facilitated its spread via a novel vector, the Asian tiger mosquito (Aedes albopictus) (10, 
30, 37, 152). The E1-A226V mutation, in combination with the rapidly expanding geographical 
distribution of Aedes albopictus has dramatically increased the epidemic potential of CHIKV 
(30, 37, 186). By the end of 2013, the virus had reached the Caribbean and subsequently 
Latin America (8, 13, 14) and by the beginning of 2015 already over one million people in the 
Americas had been infected with CHIKV (12, 13). Consequently also thousands of infected 
travelers returned to the USA and Europe. Hence, CHIKV no longer only causes human 
suffering and financial loss in the regions where the virus is (now) endemic, but it also affects 
the quality of life of people in non-endemic countries. The recent outbreak in the Caribbean 
also puts the United States at risk for (limited) local outbreaks, and indeed local transmission 
has already occurred in Florida (28). CHIKV transmission has been reported from all inhabited 
continents, and especially Latin America is facing potentially large outbreaks. Its population 
is largely immunologically naïve while the local capacity for surveillance and diagnostic is 
limited, enabling initially unnoticed outbreaks that may expand quickly once established. 
CHIKV causes a fever that usually resolves within several days, a maculopapular rash and 
a characteristic, debilitating arthralgia that can be extremely painful and may persist for 
months (1, 2). A licensed vaccine or effective antiviral therapy are currently not available. 
Alphaviruses possess a ~12 kb positive-strand RNA genome that contains two open reading 
frames (ORFs). The 5’ ORF encodes the four nonstructural proteins (nsP1-4), whereas the 
structural proteins (capsid, E3, E2, 6K and E1) are produced from a subgenomic RNA (44, 
76). A portion of the four nonstructural proteins assemble into the replication complex, likely 
together with cellular co-factors, whereas another fraction of the nsPs is thought to have 
other functions, e.g. modulating the immune response, inducing host shut off and interfering 
with SG formation (62, 87, 90, 118, 187). Due to their relative small genome size, RNA viruses 
like CHIKV rely heavily on cellular host factors for all stages of their replicative cycle. However, 
till date only a handful of host factors involved in CHIKV replication have been identified (e.g. 
(62, 118, 119, 121, 122, 188)), and in general their exact role during viral replication is poorly 
understood. Many studies on the interplay between CHIKV infection and cellular proteins 
have focused on changes in the cellular proteome following CHIKV infection (121, 139-144). 
These studies provided valuable information on the cellular response to CHIKV infection, 
but do not necessarily provide insight into the factors that restrict infection or those that 
are required for virus replication. Another strategy to identify host factors involved in CHIKV 
replication encompasses screening for interacting partners of viral (nonstructural) proteins 
using Y2H (yeast two-hybrid) or VOPBA (viral overlay protein binding assay) (122, 188, 189), 
although a physical interaction does not necessarily translate into functional relevance. 
In addition, cellular proteins that interact with viral proteins indirectly or transiently will 
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be missed, as will host proteins that interact with the viral RNA. RNAi screening enables 
large-scale loss of function studies to identify cellular factors that are directly or indirectly 
involved in viral replication. It focusses on protein function rather than physical interaction, 
therefore potentially providing more biological relevant data. Making an inventory of the 
proteins involved in CHIKV replication will improve our understanding of this important 
human pathogen, and they may comprise useful starting points for the development of novel 
antiviral strategies. Antiviral strategies that target cellular factors instead of viral proteins are 
expected to be less sensitive to the development of antiviral resistance. RNAi screens have 
already been performed for a number of +RNA viruses, including Sindbis virus (SINV) (133), 
hepatitis C virus (HCV) (124-127), West Nile virus (128), yellow fever virus (129), and dengue 
virus (DENV) (130, 131). These studies have provided valuable insights into the cellular 
proteins and pathways involved in the replication of these viruses.
Here we describe a kinome-targeted RNAi library screen to identify cellular factors involved 
in CHIKV replication. Kinases play a key role in a wide range of cellular processes like 
proliferation, signaling and immunity, and are therefore also likely involved in the replication 
of various viruses. Indeed, previously several kinases have been found to be indispensable for 
viral replication, for example for HCV, DENV, severe acute respiratory syndrome coronavirus 
(SARS-CoV) and influenza virus (124, 131, 166, 190, 191). Little is known about the involvement 
of cellular kinases in alphavirus replication. We therefore set out to investigate which kinases 
and pathways are involved in the replicative cycle of CHIKV. In this study 66 proteins were 
identified that potentially play a proviral role in CHIKV replication. These proteins can be 
placed in specific pathways likely involved in the CHIKV replicative cycle, including (control 
of) the MAPK cascade and ErbB (epidermal growth factor receptor family) signaling. We 
confirmed a selection of hits by performing a secondary screen using different siRNA, and 
could confirm 10 potential proviral proteins and 2 potential antiviral proteins, including 
MAPKAPK3, FGFR2, MARK4, SHC1, DUSP1 (proviral), and CDC2L5 and LATS2 (antiviral).
MATERIALS AND METHODS
Cells, viruses and titration. MRC5 and Vero E6 cells were cultured as described previously 
(69, 192). The production and titration of virus stocks and routine infections were performed 
as described (69). The primary and secondary screens were executed with a CHIK reporter 
virus expressing eGFP from a duplicated subgenomic promoter (CHIKV LS3-GFP; GenBank 
KC149887). All procedures with live CHIKV were performed in a biosafety level 3 facility at the 
Leiden University Medical Center. 
  
RNA interference (primary screen). The ON-TARGETplus SMARTpool Protein Kinases 
siRNA library (# G-103505) and scrambled control siRNAs (Non-Targeting Pool; D-001810-
10) were obtained from Dharmacon. The Protein Kinases siRNA library contained 779 
SMARTpools, each comprised of 4 single siRNA duplexes, targeting the human kinome and 
some additional targets. MRC5 cells (1 x 104 per well of a 96-well plate) were transfected with 
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a final concentration of 100 nM siRNA using DharmaFECT1 (Dharmacon) according to the 
manufacturer’s instructions. At 48 h post-transfection (p.t.), the transfection and knockdown 
efficiency was determined using siRNAs targeting GAPDH (D-001830-10) in combination with 
the KDalertTM GAPDH assay kit (Ambion) to determine remaining GAPDH activity. Two days 
post transfection, the siRNA-treated cells were infected with CHIKV LS3-GFP at an MOI of 
0.05. At 24 h p.i., the cells were fixed with 3% paraformaldehyde in PBS and GFP expression 
was quantified using a Berthold Mithras LB 940 96-well plate reader. In duplicate plates, the 
viability of siRNA-transfected uninfected cells was assessed at 48 h p.t. using the CellTiter 96® 
AQueous Non-Radioactive Cell Proliferation Assay (Promega). Absorbance was quantified 
using a Berthold Mithras LB 940 96-well plate reader.
Data analysis (primary screen). Raw GFP measurements and cell viability data were 
analyzed using the Bioconductor/R package cellHTS2, with minor adaptations. Raw data 
were log2 transformed and normalized using the NPI (normalized percent inhibition) method 
to remove plate-to-plate variation. Log scores were calculated, resulting in log-fold changes 
that were calculated back to fold change. The variance of the normalized intensities was 
not adjusted (cellHTS2 default). Values were normalized to infected cells transfected with 
control siRNA, and mock-infected wells. The ranked list was further processed by removing 
hits of which the siRNA pools reduced cell viability to less than 80% (cut-off was based on 
our experience). Statistical significance was calculated by R using a two-tailed unpaired 
Student’s t-test. Values were considered to be significant if p<0.05. Each siRNA SMARTpool in 
a screen was tested in triplicate and the complete screen was performed 3 times. 
Pathway analysis. Proteins from the hit list were grouped according to their function using 
DAVID (http://david.abcc.ncifcrf.gov/). Visualization of protein interaction networks was 
performed using STRING (http://string-db.com). 
RNA interference (secondary screen). For the secondary screen, single siRNAs against 
selected targets were obtained from Sigma (MISSION pre-designed Nano Scale siRNA), with 
the exception of BLNK, COPB2, SHC1 and TRIM/TRAT, for which no Nano Scale siRNA were 
available and standard Sigma pre-designed siRNA were obtained. Transfection and infection 
procedures were identical as to those described for the primary screen.
Data analysis (secondary screen). Statistical significance was calculated by GraphPad5 
using a two-tailed unpaired Student’s t-test. Values were considered to be significant if 
p<0.05. All values represent the average of triplicate wells, experiments were performed in 
duplicate or triplicate. The values presented in the graphs represent the mean values of 
triplicate wells with the error bars indicating the standard deviation of the mean. P-value: 
*p<0.05, **p<0.01, ***p<0.001.
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Compound screening. BCl was obtained from Axon Medchem BV (cat. no. 2178) and 
dissolved in DMSO. MRC5 cells were infected with CHIKV (MOI 5 for 8 h) or CHIKV-GFP (MOI 
0.05 for 24h), and BCl was added to the culture media at 1 h p.i. To induce DUSP1 protein 
expression, cells were treated with various concentrations of arsenite (Sigma) in culture 
media for 30 min. Cells were washed with PBS and fresh culture medium was added. Five 
hours after arsenite treatment, the cells were harvested and protein expression was analyzed 
using western blotting. 
Western blot analysis. Western blot analysis was performed essentially as described 
previously (69). 
RESULTS
Kinome-targeted siRNA library screen identifies host factors involved in CHIKV 
replication. To identify host factors involved in CHIKV replication we screened a siRNA 
library targeting the human kinome. This library consists of siRNA targeting 779 genes, each 
gene is targeted with a SMARTpool containing 4 distinct siRNAs. The use of SMARTpools (i.e. 
a mix of siRNA duplexes) allows the use of a lower concentration of each single siRNA, which 
reduces their potential off-target effects. MRC5 cells were selected for this study as they are 
human cells (fibroblasts) that can be transfected efficiently before subsequent infection with 
CHIKV. Furthermore, MRC5 cells are not immortalized and exhibit a functional innate immune 
response (192). Transfected MRC5 cells were infected with a reporter virus (CHIKV-GFP) at a 
multiplicity of infection (MOI) of 0.05. The GFP expression was quantified as a measure for 
viral replication at 24 h post infection (p.i.) (Figure 1). In theory, this experimental set-up 
with multiple rounds of virus replication allows the identification of host factors involved in 
any step of the replicative cycle, including assembly and the release of infectious progeny 
virus. In duplicate plates the viability of siRNA-transfected uninfected cells was assessed 
using a colorimetric assay. The efficiency of siRNA delivery and knockdown was assessed 
using siRNAs targeting GAPDH and subsequent determination of the remaining GAPDH 
activity at 48 h post transfection (data not shown). The kinase siRNA library was screened 
three times, with each screen using triplicate wells for each siRNA pool, after which the data 
were analyzed using the R package cellHTS2. This package transformed raw measurements 
into an annotated hit list. The data were normalized using reference controls (scrambled 
siRNA and uninfected wells), and the ‘normalized percent inhibition’ (NPI) method, provided 
in cellHTS2. Normalization was applied on a per-plate basis to correct for plate effects. 
siRNA pools that induced cytotoxicity (<80% remaining cell viability as compared to the 
control siRNAs) were discarded. Targets were considered potential proviral factors when 
their knockdown reduced the CHIKV-driven GFP signal at least 3-fold. Analysis of the fold-
change scores identified 66 genes of which knockdown met these criteria, suggesting they 
are relevant for CHIKV replication. This means that ~8% of the genes targeted by the siRNA 
library influences CHIKV replication (Figure 2). This may appear a rather large fraction, but 
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one has to keep in mind that the library does not target a random selection of genes, but 
kinases that often occupy key positions in important cellular pathways. The largest reduction 
(32-fold) in CHIKV replication was induced by depletion of BUB1B (budding uninhibited by 
benzimidazoles (yeast homologue) 1 beta), a mitotic checkpoint kinase. Knockdown of the 
majority of the targets in our annotated hit list reduced CHIKV GFP expression 3- to 4-fold. 
Strikingly, we could not identify any strong antiviral hits, as depletion of none of the targeted 
proteins increased the CHIKV-GFP signal to a sizable extent. The strongest increase in GFP 
signal (a mere 1.4-fold) was observed when DMPK (Dystrophia myotonica protein kinase)) 
Figure 1. Schematic overview of the siRNA library screening set-up. MRC5 cells were transfected with 
siRNA pools targeting the human kinome. After two days the cells were transfected with CHIKV-GFP (MOI 
0.05) and GFP was quantified 24 h p.i. as a measure of viral replication. GFP values were normalized to 
cells transfected with control siRNAs. Potential cytotoxicity was determined in parallel plates using a 
colorimetric assay. 
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Accession GeneID pvalues fold increase 
NM_004409 DMPK 0.03715 1.41 
NM_014572 LATS2 0.00685 1.33 
NM_005627 SGK 0.02699 1.31 
NM_021158 TRIB3 0.05770 1.29 
NM_004439 EPHA5 0.07760 1.29 
NM_005406 ROCK1 0.20881 1.29 
NM_033116 NEK9 0.13891 1.27 
NM_133494 NEK7 0.27599 1.24 
NM_003557 PIP5K1A 0.28191 1.24 
NM_173354 SNF1LK 0.16225 1.24 
NM_018425 PI4KII 0.02370 1.24 
NM_006510 RFP 0.50783 1.22 
NM_002419 MAP3K11 0.24946 1.21 
NM_000024 ADRB2 0.24424 1.20 
NM_153273 IHPK1 0.08559 1.19 
NM_003718 CDC2L5 0.02539 1.19 
XM_291107 NEK1 0.38310 1.19 
NM_006260 DNAJC3 0.12814 1.19 
NM_138293 ATM 0.27700 1.18 
Accession GeneID pvalues fold reduction 
NM_001211 BUB1B 0.06686 32.7 
NM_020341 PAK7 0.05317 18.3 
NM_002627 PFKP NA 16.6 
NM_006549 CAMKK2 0.09021 11.5 
NM_004635 MAPKAPK3 0.09654 11.3 
NM_005374 MPP2 0.00664 7.3 
NM_013314 BLNK 0.03012 6.6 
NM_004417 DUSP1 0.00911 6.1 
NM_007199 IRAK3 0.01626 6.0 
NM_024046 CAMKV  0.00039 5.8 
NM_005607 PTK2 0.04976 5.7 
NM_000141 FGFR2 0.00004 4.9 
NM_016388 TRIM 0.00053 4.8 
NM_002019 FLT1 0.00378 4.3 
NM_003913 PRPF4B 0.07238 4.1 
NM_002654 PKM2 0.03065 4.1 
NM_031417 MARK4 0.01179 4.1 
NM_004766 COPB2 0.00116 4.0 
NM_005400 PRKCE 0.05786 4.0 
NM_025052 YSK4 0.01752 3.9 
NM_017859 URKL1 0.04994 3.9 
NM_018423 STYK1 0.00244 3.9 
NM_003029 SHC1 0.00079 3.8 
NM_002822 PTK9 0.09095 3.8 
NM_000616 CD4 0.00003 3.8 
NM_002461 MVD 0.02391 3.8 
NM_003674 CDK10 0.01997 3.8 
NM_005592 MUSK 0.01334 3.7 
NM_006206 PDGFRA 0.06630 3.7 
NM_001320 CSNK2B 0.00481 3.7 
XM_496631 TPRXL 0.00661 3.7 
NM_000222 KIT NA 3.7 
NM_016308 UMP-CMPK 0.01234 3.7 
NM_002715 PPP2CA 0.01109 3.6 
NM_004566 PFKFB3 0.01209 3.5 
NM_004420 DUSP8 0.02581 3.5 
NM_003745 SOCS1 0.00296 3.4 
NM_022740 HIPK2 0.00958 3.4 
NM_000291 PGK1 0.00131 3.4 
NM_002766 PRPSAP1 0.01596 3.4 
NM_006648 PRKWNK2 0.03450 3.3 
NM_002741 PRKCL1 0.05409 3.3 
NM_002611 PDK2 0.08607 3.3 
NM_024619 FN3KRP 0.00590 3.3 
NM_003390 WEE1 0.00770 3.3 
NM_022158 FN3K 0.00680 3.2 
NM_018571 ALS2CR2 0.00243 3.2 
NM_006182 DDR2 0.00733 3.2 
NM_005235 ERBB4 0.00402 3.2 
NM_016586 MBIP 0.02999 3.2 
NM_003646 DGKZ 0.00276 3.2 
Figure 2. Hit list of primary kinome-directed siRNA screen. Raw GFP data were converted to fold-change 
using Bioconductor/R package cellHTS2. Potential proviral factors are indicated in green, potential 
antiviral factors in red. Statistical significance was calculated by R using a two-tailed unpaired Student’s 
t-test. Statistical significance is indicated in yellow. Values were considered to be significant if p<0.05 
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was depleted (Fig. 2). This modest increase might still be relevant, and we therefore decided 
to include some potential antiviral hits in our follow-up experiments.
Analysis of primary screen data. Some of the proteins that were identified in this screen 
have clear, well-characterized functions and some have been implicated in the replication of 
other viruses or the immune response, which makes it easy to explain their effect on CHIKV 
replication. These hits help to confirm the validity of our data and lend more credibility to 
other identified potential host factors. One example is COPB2 (coatomer protein complex, 
subunit beta 2), a protein involved in retrograde vesicular transport. Blocking this transport 
has been shown to be detrimental for replication of several RNA viruses, including poliovirus, 
SARS-CoV, and HCV (124, 131, 133, 166, 193-198). Here, we could also confirm a role for COPB2 
during CHIKV replication. PLK1 (polo-like kinase 1) is often used as a positive control for 
siRNA transfection efficiency, as PLK1 depletion results in growth reduction and apoptosis 
(199, 200). Indeed, also in our hands siRNA targeting PLK1 reduced cell viability extensively 
(data not shown). SOCS1 (suppressor of cytokine signaling 1) is another proviral hit with an 
anticipated effect on CHIKV replication, which further corroborates the validity of the data 
yielded by this screen. SOCS1 is a member of the STAT-induced STAT inhibitors, and is part 
of a negative feedback system that regulates cytokine signal transduction (201). Depletion 
of this protein should result in a stronger antiviral response upon CHIKV infection. Indeed, 
it was previously shown that SOCS1 negatively regulates IFN signaling during HCV (202) and 
influenza virus infection (203). 
Furthermore, several proteins involved in ribosomal function were identified, such as 
RPS6KC1 and RPS6KL1. CHIKV relies on the host cellular translation machinery for the 
production of viral proteins, therefore disturbing this machinery should affect virus 
replication. However, these ribosomal proteins were not selected for additional validation, 
as they are indispensable for normal cellular function and are therefore not suitable as 
potential therapeutic targets.
Identification of cellular pathways involved in CHIKV replication. The potential proviral 
host factors of which depletion resulted in >2-fold reduction in CHIKV-GFP were functionally 
analyzed using Gene Ontology (GO) biological process terms. Not surprisingly, considering 
the fact that we tested a kinome-directed siRNA library, a strong enrichment for (protein) 
phosphorylation and protein modification processes was found (data not shown). Placing 
the hits in distinct pathways revealed a significant enrichment for several signaling pathways, 
including MAPK signaling, regulation of MAPK signaling, ErbB signaling, neurotrophin 
signaling, and the cell cycle (Figure 3). Mapping the network connectivity of the 66 potential 
proviral cellular proteins revealed that many of them are highly interconnected (Figure 4).
We identified several proteins that are involved in glucose metabolism (fructosamine 3 
kinase (FN3K), fructosamine 3 kinase related protein (FN3KRP), phosphofructokinase, 
platelet (PFKP), and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatoase 3 (PFKFB3)). 
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Several viruses have been described to depend on endogenous glucose or regulate glucose 
uptake and glycolytic flux, as enhancement of these processes leads to increased glycolytic 
ATP production (204-207). However, cellular glucose deprivation using either 2-deoxy-D-
glucose or glucose-free cell culture media did not specifically affect CHIKV replication, nor 
did the addition of extra glucose (data not shown). Extreme glucose deprivation had a 
strong negative effect on cell viability, which complicated further experiments, and made it 
impossible to determine whether it had an effect on CHIKV replication other than through its 
nonspecific effect on metabolism.
Evaluation of hits from the primary screen. In order to validate a selection of the hits from 
the primary screen, we performed a secondary screen using siRNAs from a different supplier 
and with different sequences. We selected 31 targets for this secondary screen, including 
the 20 siRNA pools that caused the largest reduction in CHIKV GFP expression (potential 
proviral factors), the 5 siRNA pools that caused the largest (significant) increase in CHIKV GFP 
expression (potential antiviral factors), and a few genes that were of special interest to us 
because of their particular function (e.g. DUSP5 and DUSP8). For each gene, we separately 
tested two individual siRNA duplexes for their effect on CHIKV GFP expression (Figure 5), 
except for BLNK, COPB2, SHC1 and TRIM/TRAT, for which only a single siRNA was tested as 
described in the materials and methods section. Cell viability was determined in parallel 
plates and transfection of none of the siRNAs duplexes was found to induce cytotoxicity (data 
not shown). A target was considered a confirmed hit if at least one of the two siRNA duplexes 
reduced CHIKV GFP expression by 40% or more (in
the case of potential proviral targets). Using this method, 10 (out of 25) potential proviral hits 
from the primary screen could be validated (indicated in bold in Fig. 5A), including MAPKAPK3, 
MARK4, WEE1, BLNK, COPB2, SHC1 and DUSP1. Of these confirmed targets, COPB2, SHC1 and 
WEE1 were also found in a genome-wide siRNA screen for SINV, a (distantly) related alphavirus 
(133). This indicates that these targets are most likely involved in alphavirus replication in 
general. In total we tested 46 single siRNA duplexes (targeting 25 potential proviral genes), of 
which 27 induced a significantly reduction in GFP expressed by CHIKV compared to the non-
targeting control siRNA. Together they covered 20 of the 25 genes (Fig. 5B).
Although only 10 genes met the cut-off criteria (40% reduction), this indicates that a larger 
fraction of the genes tested here may be true hits. The modest, but statistically significant 
effect on CHIKV-GFP may be due to sub-optimal siRNA design and/or modifications. 
Transfection of two (out of 12) single siRNA targeting potential antiviral hits resulted in the 
expected increase in CHIKV-GFP: CDC2L5 (also known as CDK13) and LATS2 (Figure 5B). 
Similar as in the primary screen, the observed increase in GFP expressed by CHIKV was 
modest (~130% and ~140% respectively), but statistically significant. 
Taken together, a substantial number of hits from the primary screen could be confirmed in 
the secondary RNAi screen. We were able to validate a larger fraction of the proviral factors 
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given the fact that also during the primary screen the observed increase in CHIKV-GFP was 
modest. The hits from the primary screen that we could not confirm might either constitute 
off-target hits, or the secondary siRNAs may have been less efficient. 
Regulation of MAPK signaling by DUSPs. Mitogen-activated protein kinase (MAPK) 
signaling and regulation thereof was strongly represented in our data set (Figure 2, 3). 
MAPKs are serine/threonine kinases that regulate gene expression, protein translation, 
protein stability, protein localization and enzyme activity, thus influencing cell proliferation, 
differentiation, survival and death (208-210). Depletion of MAPKAPK3, MAPKAPK5, MAPK12, 
MAPK3, MAPK8, MAPK9, MAP2K7, MAPK8IP1, Rac1, or PAK2 resulted in at least a 2-fold 
reduction of CHIKV-GFP expression. Depletion of MAPKAPK3 even resulted in an 11-fold 
lower expression of GFP, although it did not reach statistical significance due to a relatively 
Figure 4. Network connectivity of potential proviral factors. STRING analysis (string-db.com) was 
used to determine the network connectivity of the 66 potential proviral factors identified in this screen. 




large spread in GFP values. However, this high p-value does not reflect a lack of biological 
significance (as the effect on CHIKV-GFP was substantial); therefore we decided to include 
this hit in our secondary screen. MAPKAPK3 is phosphorylated by members of several 
MAPK signaling cascades (MEK/ERK, p38 MAPK and Jun N-terminal kinase), indicating that 
it is an integrative element of signaling of both mitogen- and stress-driven responses (211, 
212). MAPKAPK3 is one of potential proviral targets that we could confirm in our secondary 
























































































































































































* * * *
Figure 5. Secondary siRNA screen to validate potential proviral (A) or antiviral (B) factors. MRC5 cells were 
transfected with siRNA and 48h later infected with CHIKV-GFP, MOI 0.05. GFP expression was determined 
at 24 h.p.i. as a measure for viral replication and normalized to cells transfected with control siRNAs. Two 
single siRNA duplexes were used for each gene, with the exception of BLNK, COPB2, SHC1 and TRIM/TRAT, 
for which single siRNAs were tested. An initial hit was considered confirmed when at least one siRNA from 
the secondary screen reduced CHIKV-GFP with at least 40%. The values presented in the graphs represent 
the mean values of triplicate wells with the error bars indicating the standard deviation of the mean. 
P-value: * p<0.05, **p<0.01, ***p<0.001. 
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MAPK pathway is negatively regulated by dual specificity phosphatases (DUSPs). Our ranked 
hit list contains a substantial number of DUSPs/MKPs, including DUSP1/MKP-1, DUSP2/
PAC1, DUSP4/MKP-2, DUSP5, DUSP6/MKP-3 and DUSP8 (Figure 6B). Strikingly, this includes 
all members of the mitogen- and stress-inducible nuclear MKP subfamily (DUSP1, DUSP2, 
DUSP4 and DUSP5). Several DUSPs have been implicated in viral replication (213-215), and it 
is therefore likely that they are also involved in CHIKV replication. 
A
B
Accession GeneID pvalues fold reduction
NM_004417 DUSP1 0.00911 6.1
NM_004420 DUSP8 0.02581 3.5
NM_004419 DUSP5 0.01451 3.1
NM_004418 DUSP2 0.01179 2.4
NM_001946 DUSP6 0.00908 2.3
NM_001394 DUSP4 0.00287 2.1
NM_020185 DUSP22 0.01234 2.0
NM_007207 DUSP10 0.21584 1.2
Figure 6. Structure, localization and classification of the DUSPs. (A) DUSPs (dual-specificity phosphates), 
also known as MKPs (MAPK phosphates), can be divided in three subclasses. The classification is based on 
their localization, substrate specificity and sequence similarity. The JNK/p38-selective MKPs are evenly 
distributed between nucleus and cytoplasm and are therefore depicted to the side. With red shading 
is indicated which DUSPs were identified in our kinome-directed siRNA screen targeting host factors 
involved in CHIKV replication. Adapted from (216). (B) DUSPs/MKPs identified in the primary siRNA 
screen. DUSPs of which depletion induced >3-fold decrease in CHIKV-GFP were considered a proviral hit 
(indicated in green). Hits with p-values of p<0.05 were considered significant (indicated in yellow). 
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DUSP1 expression during CHIKV replication. Several viruses induce the expression 
of DUSP1 mRNA (213-215). Therefore, we examined if CHIKV infection would also result in 
higher DUSP1 levels. Arsenite treatment causes oxidative stress and can function as a positive 
control for DUSP1 induction. Indeed, treating cells with increasing concentrations of arsenite 
resulted in increased DUSP1 protein levels (Figure 7A). Next, we examined DUSP1 protein 
levels at different time points post CHIKV infection (Fig. 7B). 
DUSP1 remained undetectable in mock-treated, uninfected or CHIKV-infected cells. This 
suggests that CHIKV infection does not induce DUSP1 expression, at least not to levels that 
can be detected with our antibody. We cannot entirely exclude the possibility that the protein 
levels were too low to be detected by the antibody. 
BCl is an allosteric inhibitor of DUSP1 and DUSP6 phosphatase activity. We examined the 
effect of BCl-treatment on CHIKV replication. MRC5 cells were infected with CHIKV (MOI 5) 
and 1 h p.i. various concentrations of BCl were added (Fig. 7C). As expected, BCl treatment 
resulted in increased levels of phosphorylated p38 MAPK, confirming that the compound 
blocks phosphatase activity. In addition, BCl treatment strongly reduced CHIKV nsP2 levels 
at 8 h p.i., suggesting that DUSP1 is needed for CHIKV replication, which is in line with the 
results obtained using our siRNA screen. However, when BCl was used during a multiple cycle 
experiment (using an MOI of 0.05, analyzed at 24 h p.i.) the effect of BCl on CHIKV-GFP seemed 
mostly caused by a general cytotoxic effect induced by the compound (Fig. 7D). Possibly, this 
is caused by an intolerance of the cells to prolonged DUSP1 inhibition. Alternatively, since 
DUSP signaling is highly regulated, it is possible that the cells have adapted to the presence 
of the compound during the extended experiment.  
DISCUSSION
CHIKV is an arthrogenic alphavirus that re-emerged in 2004 and has caused unprecedented 
outbreaks in the years that followed. Licensed vaccines or approved antiviral drugs to prevent 
or treat CHIKV infection are currently not available. Alphaviruses rely, as other +RNA viruses, 
heavily on host factors for all steps of their replicative cycle. Unfortunately, the identity of the 
majority of these host factors involved in CHIKV replication remains elusive. Here we describe 
a kinome-directed RNAi study aimed at identifying host factors involved in CHIKV replication. 
We identified 66 potential proviral proteins that could be placed in cellular pathways likely 
involved in CHIKV replication, including DUSP-mediated control of MAPK signaling. Using 
a secondary screen we could confirm a substantial number of hits found in our primary 
screen, including DUSP1, MAPKAPK3, MARK4 and COPB2 (Figure 5). Not surprisingly, the 
dataset described here displays limited overlap with previously identified CHIKV host factors. 
Our approach focused mainly on kinases and related proteins, whereas the proteomics 
studies identified a varied subset of different proteins from the total cellular proteome. 
More importantly, the fundamentally different questions that are answered by siRNA and 
proteomics approaches (what happens to the virus if a host factor is depleted? vs. what 
happens to the host during infection?) obviously will lead to different results. We did identify 
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a handful of potential proviral proteins during CHIKV replication that were also found in a 
recent RNAi screen for SINV (COPB2, SHC1 and WEE1) (133). In addition, some proteins in our 
hit list were previously identified in various screens aimed at the identification of host factors 
involved in influenza virus replication. For example, knockdown of MAPK13 reduced CHIKV-
GFP expression by 2-fold in our screen, and was identified in three independent influenza 
virus screens (217-219). Knockdown of CAMK2B or CDC42BPA reduced CHIKV-GFP expression 
2-fold in our hands, and were both found in two influenza virus screens (193, 218, 219). FGFR2 
knockdown reduced CHIKV-GFP 5-fold in both our primary and secondary screen, and was 
previously found in two influenza virus screens (193, 218).
Strikingly, we identified mostly proviral host factors in this kinome screen. This might be due 
to our experimental set-up, or to the fact that CHIKV is already replicating optimally in the 
chosen cell line. Alternatively, antiviral proteins might work in concert (redundancy in antiviral 
mechanisms), and reducing the levels of just one factor is not sufficient to have a significant 
effect on viral replication. In addition, the virus might already have evolved mechanisms to 
evade its antiviral effect, thus depletion has no additive effect. Some of the proteins that are 
	
Figure 7. DUSP1 during CHIKV replication. (A) MRC5 or Vero E6 were treated with increasing concentrations 
of arsenite. DUSP1 protein levels were examined using western blot. (B) Cells were infected with CHIKV 
(MOI 5) and harvested at the indicated time points post infection. DUSP1 protein levels were examined 
using western blot. (C) MRC5 cells were infected with CHIKV (MOI 5), and 1 h p.i. various concentrations 
of the DUSP1/6 inhibitor BCl was added. Protein samples were harvested 8 h p.i. and the indicated 
protein levels were analyzed. (D) MRC5 cells were infected with CHIKV-GFP (MOI 0.05), and 1 h p.i. various 
concentrations of BCl was added. The cells were fixed 24 h p.i. and GFP expression was determined. 
Potential cytotoxicity was determined in parallel. 
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on the ‘antiviral’ side of the ranked hit list can easily be explained. For example, ROCK1 is 
described to be a pro-apoptotic protein. Depletion would increasecell viability and/or delay 
onset of (virus-induced) apoptosis. 
Targets confirmed in the secondary screen
MAPKAPK3
Mitogen-activated protein kinase-activated protein kinase 3 (MAPKAPK3), is a serine/
threonine protein kinase that is activated by stress and growth inducers. Main functions of 
MAPKAPK3 (or MK3/3pK) are cell cycle control, posttranscriptional regulation of cytokines 
(e.g. TNF-α and IL-6) and regulation of chromatin and actin remodeling (reviewed in (212)). 
MAPKAPK3 was previously reported to play a role during HCV infection. HCV replication 
induced MAPKAPK3 RNA and protein levels, and MAPKAPK3 silencing reduced viral protein 
and infectious progeny levels (220). It was found that MAPKAPK3 binds to the HCV core 
protein, and may therefore be a functional part of the viral replication machinery (220). 
MAPKAPK3 was also implicated in influenza virus infection, where virally induced activation 
of MAPKAPK3 indirectly inhibited PKR activation and thus the block of cellular protein 
translation (221). Both HCV and influenza virus replication induce the upregulation of 
MAPKAPK3 in the infected cell. It would therefore be interesting to see if CHIKV also affects 
MAPKAPK3 protein levels, and whether overexpression of MAPKAPK3 would reduce CHIKV 
replication. MAPKAPK5 is a paralog and its depletion reduced CHIKV-GFP with 2.8-fold.
MARK4
Microtubule affinity-regulating kinase 4 (MARK4) is a proviral hit that was also confirmed 
in our secondary screen. Both single siRNAs reduced CHIKV-driven GFP expression with 
at least 50% (Figure 5A). MARK4 is a serine/threonine protein kinase that phosphorylates 
microtubule-associated proteins (reviewed in (222)). Phosphorylated microtubule-
associated proteins detach from microtubules, which increases their dynamics and enables 
cell cycle control, cell division, and cell shape. Also MARK4 involvement with clathrin-coated 
vesicles during endocytosis was confirmed (223). CHIKV replication was demonstrated to be 
dependent on microtubules and clathrin-coated vesicle formation (224), possibly explaining 
its dependency on MARK4.
MMP2
Matrix metalloproteinase 2 (MMP2) belongs to a family that is involved in the breakdown 
of extracellular matrix in normal physiological processes. However, in recent years it was 
acknowledged that MMPs are also involved in other cellular processes, including host 
defence. At present, MMPs are considered important modulators of inflammation and innate 
immunity (reviewed in (225)), and may therefore very well be involved in CHIKV replication.




Fibroblast growth factor receptor 2 (FGFR2) is a membrane-spanning protein with a 
cytoplasmic kinase domain. The extracellular portion of the protein interacts with fibroblast 
growth factors, downstream inducing mitogenesis and differentiation. Ligand binding results 
in downstream activation of PLCγ, MAPK (MEK/ERK) and PI3-K/Akt signaling.
FGFR2 is an interesting confirmed hit, because it was also implicated in influenza virus 
replication in two independent RNAi screens (193, 218). Activated FGFR2 phosphorylates 
SHC1 (Src homology 2 domain containing transforming protein), another confirmed hit in 
our secondary screen. SHC1 is a signaling adapter protein that couples activated tyrosine 
kinases (such as FGFR2) to signaling pathways. For example, SHC1 can activate the Ras-Raf-
MEK-ERK cascade by recruitment of the GRB2/SOS complex. There are three SHC1 isoforms 
of which one is a downstream target of p53 and is needed for the induction of apoptosis by 
stress-activated p53 (226). Depletion of SHC1 would therefore delay the onset of apoptosis, 
for example upon viral infection. Silencing of SHC1 reduced WNV but not DENV replication 
(128), and SHC1 was also implicated in HCV entry (227).
DUSPs – negative regulators of MAPK signaling. MAPKs play important roles in many 
signaling transduction pathways and are activated by a range of stimuli, including virus 
infection. MAPK activation is tightly controlled by phosphatases including dual-specificity 
phosphatases (DUSPs). DUSPs that are specifically dedicated to MAPK control are dubbed 
MAP kinase phosphatases (MKPs, reviewed in (216)). The DUSPs/MKPs differ in substrate 
specificity, tissue distribution, subcellular localization and sensitivity to extracellular stimuli, 
and can be subdivided accordingly (Figure 6A) (reviewed in (216, 228)). They form a negative 
regulatory network and determine the duration, magnitude and spatiotemporal profile of 
MAPK responses after stimulation. DUSPs may be very specific for a single MAPK or able 
to regulate multiple MAPK pathways. They can provide mechanisms of crosstalk between 
distinct MAPK pathways, as well as between MAPK signaling and other signaling modules 
(216). 
Several DUSPs have been implicated in viral replication. For example, mRNA of DUSP4 
and DUSP5 is upregulated during influenza virus (delNS1) infection, and the coronavirus 
infectious bronchitis virus induces the expression of DUSP1 to counteract the induction of 
IL-6 and IL-8 (213, 214). DUSP1 was also found to be upregulated in HIV-infected cells (215). 
Another study showed that DUSP10/MKP5 expression is induced by influenza virus (229). 
DUSP10 was shown to directly dephosphorylate IRF3, thus dampening the innate immune 
response. DUSP10-/- mice displayed increased levels of IRF3 activation and IFN expression 
and were resistant to influenza infection (229). 
Here we show that siRNA-mediated depletion of DUSP1, DUSP2, DUSP4, DUSP5, DUSP6, 
DUSP8 and DUSP22 all resulted in at least a 2-fold reduction in CHIKV replication. We 
confirmed the involvement of DUSP1 and DUSP8 in our secondary screen. Transfection of 
siRNAs targeting DUSP5 had no effect in our secondary screen, but it needs to be noted that 
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knockdown efficiency was not determined. DUSP2, DUSP4, DUSP6 and DUSP22 did not 
meet our criteria for inclusion in the secondary screen. To our knowledge, this is the first time 
that DUSPs are linked to alphavirus replication. The kinase library also included DUSP22, 
but depletion of this target did not influence CHIKV replication. Of course, it is possible that 
sufficient knockdown was not achieved using this siRNA pool.
As mentioned earlier, several viruses can induce the upregulation of DUSP1 upon infection 
(213-215). Unfortunately, we were unable to demonstrate DUSP1 induction during 
CHIKV infection (Fig. 7B), although this does not necessarily mean it does not occur. High 
concentrations of arsenite were needed to visualize an induction of DUSP1 using western 
blot, indicating that the antibody might not be sensitive enough to show a more modest 
increase in DUSP1 protein levels upon CHIKV infection. RT-qPCR would be a more sensitive 
technique to monitor DUSP1 induction. Alternatively, it is possible that we examined DUSP1 
protein levels at a time point too late in infection, as DUSP1 signaling is highly regulated and 
possesses negative feedback loops.
DUSPs/MKPs are connected to the innate immune response. For example, DUSP1 induction 
reduces the anti-inflammatory response and excessive cytokine induction. Overexpression 
of DUSP1 efficiently blocks MAPK-dependent transcription. In line with these observations, 
DUSP1/MKP-1 and DUSP10/MKP5 knockout mice display enhanced innate immune 
responses and cytokine production (229, 230). DUSP family members are considered 
promising drug targets to manipulate MAPK-dependent immune responses, both to boost or 
subdue immune responses in cancer, infectious diseases and inflammatory responses (231). 
It would be very interesting to further explore the (immunomodulatory) role of DUSPs during 
CHIKV replication.
Concluding remarks 
With all large(r)-scale screens, concerns arise regarding the biological relevance of the data 
gathered. Off-target effects are an ever-present concern during siRNA experiments, especially 
during large-scale screens. Despite better-designed siRNA sequences and modifications, 
aimed to minimize off-target effects, it is unfortunately not possible yet to completely abolish 
these effects. The usage of siRNA pools does decrease the chance of off-target effects, as 
lower concentrations of each siRNA duplex can be used. However, caution still needs to be 
used when interpreting RNAi screening data, and independent validation is indispensable. 
False-positive or –negative hits remain a problem, which is illustrated by the fact that it is often 
difficult to confirm initial hits in secondary screens and additional follow-up experiments. 
In this study, we were able to confirm 12 of the 31 factors (~40%) tested in the secondary 
validation screen. It remains a possibility that we failed to confirm a number of initial hits 
because these genes are not expressed in the chosen cell line, and are thus to be considered 
false positives. 
Host factors and viral factors together form a complex interaction network, and understanding 
the role of a single protein in this virus-host interplay proves challenging. In this study we 
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describe the identification of numerous host factors that are potentially involved in CHIKV 
replication, which can be extrapolated to several pathways that appear to play a role during 
CHIKV replication. We confirmed the involvement of several proteins/networks previously 
described, such as COPB2 and ribosomal proteins (RPSs), but also identified novel cellular 
factors involved in CHIKV replication, including the DUSP/MKP family. This dataset provides a 
valuable starting point for further research into the role of the numerous cellular proteins and 
pathways that affect CHIKV replication, which might eventually even lead to the development 
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Mitogen-activated protein kinase (MAPK) signaling is an important part of the cellular 
response to viral infection. It plays an essential role in the expression of pro-inflammatory 
cytokines and is manipulated by many RNA viruses. With the exception of Venezuelan equine 
encephalitis virus (VEEV), little is known about the involvement of MAPK signaling in alphavirus 
replication. Activation of the extracellular signal-regulated kinase (ERK) cascade during VEEV 
infection was reported, and inhibition of ERK1/2 reduced virus replication. Surprisingly, 
ERK signaling responds differently to CHIKV infection. In contrast to VEEV infection, ERK1/2 
signaling was not activated by CHIKV replication, and inhibition of ERK1/2 did not have any 
effect. CHIKV did induce phosphorylation of p38 MAPK very late in infection, but this was 
likely linked to apoptosis. Neither chemical inhibition nor stimulation of ERK or p38 MAPK 
signaling affected CHIKV replication, suggesting that they do not play an important role in 
CHIKV replication.




Mitogen-activated protein kinase (MAPK) cascades are important cellular signaling pathways 
that regulate many processes, including gene expression, proliferation, differentiation and 
immune responses (reviewed in (208)). MAPK signaling can be activated by a range of stimuli 
and mediates physiological and pathological changes in cell function by phosphorylating a 
plethora of proteins, including other kinases and transcription factors. Each MAPK pathway is 
formed by a three-tiered kinase cascade, consisting of a MAP kinase kinase kinase (MAPKKK, 
MAP3K, MEKK or MKKK), a MAP kinase kinase (MAPKK, MAP2K, MEK or MKK) and a MAPK, 
mediating an extremely sensitive response to various stimuli. The MAPK family consists of 
three major subgroups: extracellular signal-regulated kinase (ERK), p38 MAPK and c-Jun 
N-terminal kinase (JNK). In general, the ERK pathway is activated by mitogenic stimuli, 
whereas the other two pathways are mainly activated by stresses or inflammatory cytokines. 
Generally speaking, ERK activation promotes cell survival, whereas activation of p38 
MAPK and JNK promotes apoptosis. Activation of MAPK signaling upon infection has been 
described for a number of RNA viruses, including influenza viruses (221, 232-235), hepatitis 
C virus (236), coxsackievirus B3 (237, 238) and infectious bronchitis virus (213). Except for 
Venezuelan equine encephalitis virus (VEEV) (239), little is known about the induction of 
MAPK signaling by alphaviruses and its involvement in replication. We therefore set out to 
determine the role of MAPK signaling during chikungunya virus (CHIKV) replication in cell 
culture. To investigate whether MAPK signaling is activated during CHIKV replication, we 
infected human fibroblast (MRC5) cells, which possess functional innate immune responses 
(192), and analyzed total and phosphorylated p38 MAPK and ERK1/2 levels (Fig. 1a). At 6 h 
p.i. no differences in p38 MAPK phosphorylation could be detected between infected and 
control cells, whereas a strong increase in phosphorylated p38 MAPK (p-p38 MAPK) levels 
was observed in infected cells by 12 h p.i. In contrast, ERK1/2 phosphorylation (p-ERK1/2) 
was not, or only marginally, induced by CHIKV infection at any of the time points analyzed. 
Figure 1. Phosphorylation of ERK1/2 and p38 MAPK in CHIKV-infected cells. (a)/(b) MRC5 cells were mock-
infected or infected with CHIKV LS3 at an m.o.i. of 5 and lysed at the indicated time points post infection, 
essentially as described (69). Expression levels of the indicated proteins were determined by Western 
blotting using polyclonal antibodies specific for p38 MAPK, ERK1/2, and their respective phosphorylated 




CHIKV infection of Vero E6 cells yielded similar results (data not shown), indicating that this 
is not a cell type-specific observation. The distantly related alphavirus VEEV was reported 
to induce phosphorylation of ERK1/2 during the first two hours of infection (239), and we 
therefore also assessed MAPK activation in the first three hours of CHIKV infection at 30-min 
intervals. We did observe a strong increase in phosphorylation of both p38 MAPK and ERK1/2 
at 30 min p.i., but this effect was detected in both CHIKV-infected and mock-infected cells 
(Fig. 1b). Therefore, it was most likely caused by the handling of the cells, which involved 
taking them out of the incubator and replacing the medium at 0 and 60 min p.i. The sharp 
increase in phosphorylated p38 MAPK observed at 30 min p.i. was short-lived, as barely any 
p-p38 MAPK could be detected by 60 min p.i., or at any of the other early time points tested 
(Fig. 1b). Also ERK1/2 phosphorylation was strongly reduced between 30 and 60 min p.i., 
although it slowly reappeared between 90 and 150 min p.i. Again, the same fluctuation in 
p-ERK1/2 levels was observed both in infected and control cells, indicating it did not result 
from CHIKV-infection, but rather from the experimental procedures (Fig. 1b). Taken together, 
these data suggest that also early in infection CHIKV did not induce p38 MAPK or ERK1/2 
phosphorylation.
Next, we examined the effect of commonly employed chemical inhibitors of p38 MAPK 
(SB203580) or ERK1/2 MAPK (U0126) on CHIKV replication. MRC5 cells were infected with a 
GFP-expressing reporter CHIKV (CHIKV-GFP; m.o.i. 0.05) and various concentrations of the 
compounds were added at 1 h p.i. At 24 h p.i., CHIKV-driven GFP expression was determined 
as a measure of viral replication (Fig. 2a, b). In parallel, the viability of compound-treated, 
uninfected cells was determined using a colorimetric assay (CellTiter 96 Aqueous Non-
Radioactive Cell Proliferation Assay; Promega), as described (69). Figures 2a and 2b show 
that CHIKV replication was not affected by these compounds, not even when cells were 
pretreated for 24 h (data not shown). To exclude the possibility that the absence of an effect 
on CHIKV replication was due to inactivity of the compound, we examined a downstream 
target of U0126.
This chemical inhibitor blocks MEK kinase activity and thus the phosphorylation of its 
downstream target ERK1/2 (240). Figure 2c shows that ERK1/2 phosphorylation was indeed 
blocked by U0126 at all concentrations tested, whereas it was not sensitive to SB203580 
treatment, as expected. To determine if U0126 was still capable of blocking ERK1/2 
phosphorylation during CHIKV infection, we treated infected (m.o.i. 5) and mock-infected 
MRC5 cells with various concentrations of U0126. Western blot analysis of samples harvested 
at 8 h p.i. showed that U0126 reduced the level of phosphorylated ERK1/2 to a similar extent 
in mock- and CHIKV-infected cells (Fig. 2c). Furthermore, treatment of cells with SB203580 
or U0126 did not affect CHIKV capsid protein levels (Fig. 2c), which is in line with the results 
obtained with the eGFP-expressing reporter virus (Fig. 2a, b). The observation that U0126 
does not affect CHIKV replication is in line with a previous publication on VEEV (239), although 
the same authors reported that another ERK1/2 inhibitor, Ag-126, did inhibit VEEV replication 
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(239). We therefore also tested this compound, but strikingly found that also Ag-126 does not 
affect CHIKV replication (Fig. 2d). 
It is possible that pharmacological inhibition of MAPK signaling has no effect on CHIKV 
replication because the virus already blocks MAPK signaling, which would preclude observing 
an additional effect of chemical inhibitors. To investigate this possibility we incubated 
CHIKV-infected cells with compounds that are known to activate p38 MAPK (sorbitol) or ERK 
(ceramide C6) signaling (241, 242). MRC5 cells were infected with CHIKV-GFP (m.o.i. 0.05 for 
24 h) and ceramide C6 or sorbitol was added at 1 h p.i. (Fig. 3a, b). Ceramide C6 reduced 
cell viability at concentrations above 5 µM. At non-cytotoxic concentrations (0.04-0.63 µM) it 
caused a slight stimulation of CHIKV replication, which did not reach statistical significance 
(Fig. 3a). Also in a single-cycle experiment (m.o.i. 5; analyzed at 8 h p.i.) ceramide C6 treatment 
did not stimulate replication, but even reduced CHIKV protein levels (nsP2) (Fig. 3c). The 
fact that ceramide C6 has no effect on the CHIKV-driven expression of GFP or the level of 
CHIKV nsP2, is in contrast with the data reported for VEEV, for which increased viral protein 
levels and progeny titers were reported upon ceramide C6 treatment (239). We therefore also 
Figure 2. Chemical inhibition of ERK1/2 and p38 MAPK signaling during CHIKV replication. MRC5 cells were 
infected with CHIKV-GFP at an m.o.i. of 0.05 and at 1 h p.i. SB203580 (a), U0126 (b) or Ag-126 (d) was 
added. Cells were fixed at 24 h p.i. and CHIKV-driven eGFP expression was determined using a Berthold 
plate reader as described (69). Cell viability was assessed using a colorimetric assay and is represented 
by the grey line. Both CHIKV-driven GFP expression and cell viability were normalized to an untreated 
control. (c) Western blot analysis of (p-)ERK1/2 and CHIKV capsid protein. MRC5 cells were infected with 
CHIKV LS3 (m.o.i. 5), the compounds were added 1 h p.i. and total cell lysates were harvested at 8 h p.i. In 
parallel, compound-treated mock-infected cells were analyzed as control. The values presented in graphs 
represent the mean values of triplicate experiments with the error bars indicating the standard deviation 
of the mean. 
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analyzed the production CHIKV infectious progeny by plaque assay and found that treatment 
with 2-4 µM of ceramide C6 slightly increased viral titers, but merely by 3-fold (Fig. 3e). 
Similar to ceramide C6 treatment, non-toxic concentrations of sorbitol (2-125 mM) had no 
effect on CHIKV-GFP replication in MRC5 cells. The induction of p38 MAPK phosphorylation 
was clearly observed when using 250-1000 mM sorbitol (Fig. 3d), and no differences 
were observed between CHIKV- and mock-infected cells (data not shown). The sorbitol 
concentrations that induced p38 MAPK phosphorylation did not stimulate CHIKV replication, 
but rather blocked nsP2 expression completely. Analysis of infectious progeny titers released 
from sorbitol-treated cells (Fig. 3f) indicated that sorbitol concentrations above 125 mM 
reduced CHIKV titers, likely due to a general negative effect on cellular physiology. Lower 
sorbitol concentrations (15-62.5 mM) had no effect on CHIKV titers. 
Taken together, our study establishes that, in contrast to what was reported for VEEV, 
the replication of CHIKV does not induce ERK1/2 signaling. CHIKV does induce p38 
MAPK signaling, but only late in infection (12 h p.i.), when host shut-off has already been 
established and the first signs of cytopathology become apparent. Therefore, at this time 
point, p38 MAPK phosphorylation is most likely associated with the onset of cell death/
apoptosis, rather than with a belated antiviral response. In addition, CHIKV replication was 
not affected by the pharmacological modulation of p38 MAPK or ERK1/2 signaling, which 
further strengthens the notion that p38 MAPK and ERK signaling do not play a prominent role 
during CHIKV replication. This is rather surprising, as especially the ERK signaling cascade 
has been associated with the replication of several RNA viruses. For example, replication 
of Influenza virus, coxsackievirus B3 and Junin virus activates ERK1/2 signaling (233, 238, 
243, 244). ERK1/2 are signal-transducing molecules that are activated in response to type I 
interferons (IFN α/β) (245, 246). Type I IFN is produced in many cells as an early innate immune 
response to virus infection, inducing an antiviral state and influencing the subsequent 
immune response. However, replication of many RNA viruses, including the aforementioned 
Influenza virus, coxsackievirus B3 and Junin virus, appears to benefit from the activation of 
ERK signaling, and inhibition of MEK/ERK reduces infectious viral progeny (233, 238, 243, 
244). Virus-induced upregulation of RAS-RAF-MEK-ERK is thought to result in downregulation 
of the IFN response, thus enhancing viral replication (247, 248). These studies suggest that 
an activated Ras-Raf-MEK-ERK pathway renders cells less responsive to type I IFN, which can 
be restored with MEK inhibitor U0126. It is therefore striking that CHIKV does not induce ERK 
signaling, nor is it affected by pharmacological manipulation of this pathway. 
This can be explained by the notion that CHIKV already blocks the IFN response at another 
level, for example by inducing transcriptional and translational host shut off (69, 249), or via 
the nsP2-mediated block in STAT phosphorylation (90). In addition, CHIKV does not induce 
a particular strong IFN response, especially when compared with other alphaviruses such as 
SFV. Nikonov et al. demonstrate that CHIKV generates less IFN-inducing RNAs that activate 
RIG-I signaling (250).
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Figure 3. Chemical stimulation of ERK1/2 and p38 MAPK signaling during CHIKV replication. MRC5 cells 
were infected with CHIKV-GFP at an m.o.i. of 0.05 and ceramide C6 (a) or sorbitol (b) was added at 1 h 
p.i. Cells were fixed at 24 h p.i. and CHIKV-driven eGFP expression was determined using a Berthold plate 
reader. Both CHIKV-driven GFP expression and cell viability was normalized to an untreated control. (c) 
Western blot analysis of (p-)ERK1/2 and CHIKV nsP2 protein levels. MRC5 cells were infected with CHIKV 
LS3 (m.o.i. 5), ceramide C6 was added 1 h p.i. and total cell lysates were harvested at 8 h p.i. (d) Western 
blot analysis of (p-)p38 MAPK and CHIKV nsP2 protein levels. MRC5 cells were infected with CHIKV LS3 
(m.o.i. 5), sorbitol was added at 1 h p.i. and total cell lysates were harvested at 8 h p.i. The transferrin 
receptor (TFR) was used as a loading control. Infectious progeny titers of ceramide C6 (e) or sorbitol (f) 
treated cells, determined by plaque assay. MRC5 cells were infected with CHIKV (m.o.i. 1), compound was 
added 1 h p.i. and viral titer was determined 24 h p.i. The values presented in graphs represent the mean 
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Stress granules (SGs) are protein-mRNA aggregates that are formed in response to 
environmental stresses, resulting in translational inhibition. SGs are generally believed to 
play an antiviral role and are manipulated by many viruses, including various alphaviruses. 
GTPase-activating protein (SH3 domain)-binding protein 1 (G3BP1) is a key component 
and commonly used marker of SGs. Its homolog G3BP2 is a less extensively studied SG 
component. Here, we demonstrate that chikungunya virus (CHIKV) infection induces 
cytoplasmic G3BP1- and G3BP2-containing granules that differ from bona fide SGs in terms 
of morphology, composition, and behavior. For several Old World alphaviruses it has been 
shown that nonstructural protein 3 (nsP3) interacts with G3BPs, presumably to inhibit SG 
formation, and we have confirmed this interaction in CHIKV-infected cells. Surprisingly, 
CHIKV also relied on G3BPs for efficient replication, as simultaneous depletion of G3BP1 
and G3BP2 reduced viral RNA levels, CHIKV protein expression, and viral progeny titers. The 
G3BPs colocalized with CHIKV nsP2 and nsP3 in cytoplasmic foci, but no colocalization with 
nsP1, nsP4, or dsRNA was observed. Furthermore, G3BPs could not be detected in a cellular 
fraction enriched for CHIKV replication/transcription complexes, suggesting that they are 
not directly involved in CHIKV RNA synthesis. Depletion of G3BPs did not affect viral entry, 
translation of incoming genomes, or nonstructural polyprotein processing but resulted in 
severely reduced levels of negative-stranded (and consequently also positive-stranded) RNA. 
This suggests a role for the G3BPs in the switch from translation to genome amplification, 
although the exact mechanism by which they act remains to be explored.




Chikungunya virus (CHIKV) causes a severe polyarthritis that has affected millions of people 
since its reemergence in 2004. The lack of approved vaccines or therapeutic options and the 
ongoing explosive outbreak in the Caribbean underline the importance of better understanding 
CHIKV replication. Stress granules (SGs) are cytoplasmic protein-mRNA aggregates formed in 
response to various stresses, including viral infection. The RNA-binding proteins G3BP1 and 
G3BP2 are essential SG components. SG formation and the resulting translational inhibition 
are generally considered an antiviral response, and many viruses manipulate or block this 
process. Late in infection, we and others have observed CHIKV nonstructural protein 3 in 
cytoplasmic G3BP1- and G3BP2-containing granules. These virally induced foci differed from 
true SGs and did not appear to represent replication complexes. Surprisingly, we found that 
G3BP1 and G3BP2 were also needed for efficient CHIKV replication, likely by facilitating the 




Chikungunya virus (CHIKV) is a reemerging arbovirus that is currently causing a large 
outbreak in the Caribbean, affecting 41 countries and territories with ~1 million suspected 
and ~22,500 confirmed cases (http://www.cdc.gov/chikungunya/geo/americas.html). CHIKV 
will likely continue to spread throughout the Americas, as competent vectors are present 
in many countries in the region, including parts of the United States. The magnitude of this 
recent outbreak and the fact that CHIKV might soon be endemic in many parts of the world 
stress the need for a deeper understanding of this important human pathogen.
In the past decade, there has been an increasing interest in stress granules (SGs) and their 
interplay with the replication of a variety of viruses (reviewed in references (251, 252)). SGs 
are cytoplasmic ribonucleoprotein condensations formed in eukaryotic cells in response to 
environmental stress, and their appearance is linked to inhibition of translation (253). SGs 
contain stalled translation preinitiation complexes and are characterized by the presence 
of cellular mRNAs, translation initiation factors (e.g., eIF3 and eIF4B), the small ribosomal 
subunit, and RNA-binding proteins such as T-cell-restricted intracellular antigen 1 (TIA-1), 
TIA-1-related protein (TIAR), and GTPase-activating protein (SH3 domain)-binding protein 
1 (G3BP1) (254-256). Environmental stress is sensed by double-stranded RNA (dsRNA)-
dependent protein kinase (PKR) (257), PKR-like endoplasmic reticulum kinase (PERK) (258), 
general control nonderepressible 2 (GCN2) kinase (259), or heme-regulated inhibitor kinase 
(HRI) (260). Upon their activation, these kinases phosphorylate the α-subunit of eukaryotic 
translation initiation factor 2 (eIF2α), which, in turn, leads to dephosphorylation of G3BP1 
and enables G3BP1 multimerization and subsequent SG formation (255). RNA-binding 
proteins TIA-1 and TIAR play a similar role in SG formation (261). The G3BP1 homolog G3BP2 
is relatively poorly characterized, but it also localizes to SGs (262, 263). The G3BPs share a 
conserved acidic domain, a nuclear transport factor 2-like domain, a number of SH3 domain 
binding motifs, an arginine/glycine-rich box, and an RNA recognition motif. The last two 
elements are associated with RNA binding. The G3BPs may be partly functionally redundant, 
but there are also functional differences. For example, G3BP1 has phosphorylation-dependent 
endoribonuclease activity, which has not been reported for G3BP2 (264). Furthermore, only 
G3BP2 binds the N-terminal domain of IκBα (265) and differences in the number of SH3 domain 
binding motifs (PxxP) suggest that G3BP1 and G3BP2 differ in their interactions with other 
proteins. RNA viruses commonly induce SG formation via dsRNA replication intermediates 
that are sensed by PKR, although in some cases activation of PERK by ER stress is involved 
(reviewed in reference (251)). Alphaviruses also induce the formation of SGs or aggregates 
resembling those, as G3BP1-containing foci have been observed in cells infected with Semliki 
Forest virus (SFV) and Sindbis virus (SINV) or transfected with a CHIKV replicon (62, 63, 66, 
138). Several laboratories have demonstrated colocalization and coimmunoprecipitation of 
alphavirus nsP2, nsP3, or nsP4 with G3BPs, and it was therefore speculated that these host 
proteins might be associated with the alphavirus replication machinery (62, 136-138, 266). 
The interaction of nsP3 with G3BP1 has been studied extensively (61, 137, 138, 266, 267), and 
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the induction of SGs by SFV has also been characterized in detail (61, 63, 66). SFV induces 
SGs early in infection; these are disassembled around 8 h postinfection (p.i.) following 
recruitment of G3BPs by nsP3 (63). Colocalization of G3BPs with SFV nsP1 and dsRNA 
suggests that they are recruited to replication and transcription complexes (RTCs) (63). Fros 
et al. showed that expression of CHIKV nsP3 was sufficient to induce G3BP-containing foci 
(62). The C-terminal repeat of SFV nsP3 that allows G3BP binding is conserved among Old 
World alphaviruses and was demonstrated to be responsible for the interaction between 
CHIKV nsP3 and both G3BPs as well (61), although earlier studies suggested the involvement 
of another nsP3 domain (62). In general, SG formation is considered an antiviral response 
that limits translation, and it has been hypothesized that alphaviruses prevent SG formation 
through the nsP3-mediated sequestering of G3BPs into cytoplasmic granules (62, 63). Despite 
the reported CHIKV nsP3-G3BP1 interaction and the SG-like aggregates that have been 
described to occur in cells transfected with a CHIKV replicon (62), it remains unclear whether 
such aggregates are formed in the context of a complete CHIKV infection and what the role 
of these SG-like G3BP aggregates might be. We therefore set out to elucidate the role of SGs, 
in particular that of the G3BPs, in the CHIKV replicative cycle. Rather than focusing only on 
G3BP1, we also analyzed the role of the often-overlooked G3BP2 and assessed the impact of 
their combined knockdown on CHIKV replication. We show that late in the CHIKV replication 
cycle, the bulk of G3BP1 and G3BP2 is not associated with the viral RTCs but sequestered 
in nsP3-G3BP aggregates, likely to prevent the formation of bona fide SGs. Surprisingly, we 
discovered that the G3BPs, in particular G3BP2, also have a proviral function early in CHIKV 
replication, as their knockdown delayed the accumulation of negative-stranded RNA. The 
G3BPs appear to play a regulatory role in the switch from genome translation to negative-
strand RNA synthesis, perhaps by clearing ribosomes from the viral RNA, thus enabling it to 




Cells, viruses, and virus titration. Vero E6 and 293/ACE2 cells (157) were cultured and 
infected with CHIKV Leiden Synthetic 3 (LS3) (GenBank accession number KC149888) 
or enhanced green fluorescent protein (eGFP)-expressing reporter virus CHIKV LS3-GFP 
(GenBank accession number  KC149887) as described previously (69). CHIKV LS3 is an 
infectious clone-derived virus with a genome sequence based on the consensus sequence 
of ‘recent A226V strains’, with growth kinetics and other properties similar to those of natural 
isolates (69). All experiments were performed with this virus unless indicated otherwise. 
CHIKV variants expressing  Renilla  luciferase either as an nsP3 fusion (ICRES1-P3Rluc) or 
from a duplicated subgenomic RNA (sgRNA) promoter (ICRES1-2SG-Rluc) were generated by 
standard cloning techniques, based on previously described constructs (117). The ICRES1 
CHIKV variants were based on the sequence of natural isolate LR2006-OPY1. A replication-
deficient variant (ICRES1-P3Rluc-nsP4-GAA) was created by mutating the GDD motif of nsP4 
(amino acids [aa] 465 to 467) to GAA using QuikChange site-directed mutagenesis. CHIKV 
strain ITA07-RA1 (GenBank accession number  EU244823) was isolated during the 2007 
outbreak in Italy (69). Virus titers were determined by plaque assay on Vero E6 cells in six-well 
clusters in medium containing 1.2% Avicel RC-581 (FMC BioPolymer) as described previously 
(69). All work with live CHIKV was performed inside biosafety cabinets in a biosafety level 3 
facility. CHIKV LR2006-OPY1-nsP4/FLAG, which was used for colocalization studies, encodes 
a 3× FLAG-tagged nsP4 (unpublished data). SINV-GFP was created by cloning eGFP into the 
previously described SINV MRE16 infectious clone (268) using standard techniques (details 
available upon request). CVB3-GFP (269) was a kind gift from Frank van Kuppeveld (Utrecht 
University, the Netherlands).
In vitro transcription and RNA transfection. In vitro  transcription and RNA transfection 
were essentially performed as described previously (69). The ICRES1-P3Rluc and ICRES1-
2SG-Rluc plasmids were linearized with NotI and transcribed using the mMessage mMachine 
SP6 kit (Ambion).
Indirect immunofluorescence microscopy. For visualization of SGs, Vero E6 cells were 
grown on coverslips and treated for 60 min with 0.5 mM sodium arsenite (Sigma). Disassembly 
of SGs was induced by treatment with 100 μg/ml of cycloheximide (CHX) for 30 min. Cells 
were processed for indirect immunofluorescence microscopy as described previously (69). 
Double-stranded RNA was detected using mouse monoclonal antibody J2 (English & Scientific 
Consulting; 10010500). Mouse anti-G3BP1 (BD Transduction Laboratories; 61126) or rabbit 
anti-G3BP1 (Aviva; ARP37713) was used to detect G3BP1. G3BP2 was detected with a rabbit 
antiserum (262) generously provided by Christer Larsson (Lund University, Sweden) or using 
a commercially available antibody (Assay Biotech; C18193-2). Other SG components were 
visualized using antibodies against eIF3α (Santa Cruz; sc-16377), TIA-1 (Santa Cruz; sc-1751), 
TIAR (Santa Cruz; sc-1749), p-eIF2α (Cell Signaling; 9721), or PABP (Santa Cruz, sc-32318). 
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Primary antibodies were detected with Cy3- or Alexa 488-conjugated secondary antibodies 
(Jackson/Life Technologies). Nuclei were stained with Hoechst 33342. The coverslips were 
analyzed using a Leica TCS SP5 confocal microscope and LAS AF Lite software (Leica).
To assess colocalization of G3BPs with CHIKV nsPs, Vero cells were grown on coverslips and 
infected with CHIKV LR2006-OPY1-nsP4/FLAG at a multiplicity of infection (MOI) of 5. At 6 
h p.i. cells were fixed with 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) 
and permeabilized with ice-cold methanol. The nsPs were visualized using mouse anti-
FLAG, rabbit anti-o’nyong-nyong nsP1, anti-CHIKV helicase (nsP2), and anti-CHIKV nsP3 
sera. Primary antibodies were detected with Alexa 488- or Alexa 568-conjugated secondary 
antibodies. The coverslips were analyzed using a Zeiss LSM 710 confocal microscope.
Western blot analysis. Western blot analysis was performed basically as described 
previously (69) using the primary antibodies listed in the previous paragraph. In addition, 
rabbit antisera against CHIKV nsP1 and nsP4 (raised against bacterially expressed full-
length recombinant proteins), nsP2 (aa 453 to 798), and nsP3 (aa 1 to 320) were used. Rabbit 
antiserum against CHIKV E2 (161) was kindly provided by Gorben Pijlman (Wageningen 
University, the Netherlands).
Cellular fractionation experiments. The subcellular fractionation and isolation of active 
replication complexes from CHIKV-infected Vero E6 cells have been described elsewhere 
(270). Briefly, CHIKV LS3-infected cells were harvested at 6 h p.i. by trypsinization and lysed 
using a Dounce homogenizer. Unlysed cells, debris, and nuclei were pelleted by centrifugation 
at 1,000 × g, and the resulting postnuclear supernatant (PNS) was further fractionated in a 
15,000 × g pellet (P15) and supernatant (S15).
RNA interference. ON-TARGETplus SMARTpool small interfering RNAs (siRNAs) targeting 
G3BP1 (L-012099-00), G3BP2 (L-015329-01), the corresponding G3BP2-specific deconvoluted 
pool, and scrambled (non-targeting pool) control siRNAs (D-001810-10) were obtained from 
Dharmacon. C911 mutant siRNAs (271) and a nontargeting control siRNA were custom made 
by Sigma. 293/ACE2 cells were transfected with a final concentration of 50 to 100 nM siRNA 
using DharmaFECT1 (Dharmacon) according to the manufacturer’s instructions. Cells that 
were transfected with two siRNA pools, targeting both G3BPs, received in total the same 
amount of siRNA and transfection reagent as the cells transfected with one SMARTpool. At 
48 h posttransfection (p.t.), cells were infected with CHIKV or harvested to determine the 
silencing efficiency by Western blotting. To quantify the replication of the eGFP-expressing 
reporter virus, siRNA-transfected cells in 96-well clusters were infected with CHIKV LS3-GFP. 
Cells were fixed with 3% paraformaldehyde in PBS at 16 to 24 h p.i., depending on the MOI that 
was used. In parallel, the viability of siRNA-transfected cells was assessed at 48 h p.t. using 
the CellTiter 96 AQueous nonradioactive cell proliferation assay (Promega). Absorbance and 
eGFP expression were quantified using a Berthold Mithras LB 940 96-well plate reader.
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Rescue experiments with an siRNA-resistant G3BP2 expression plasmid. G3BP2 
expression plasmid pCMV-FLAG-G3BP2 was created by cloning the G3BP2 coding sequence 
obtained from MRC5 cDNA into p3xFLAG-CMV-10 (Sigma). Transcripts from the resulting 
construct are resistant to G3BP2 siRNAs 2 and 4, which target the 3′ untranslated region (UTR) 
of the natural G3BP2 mRNA. During rescue experiments the G3BP2 expression plasmid or 
the empty vector was cotransfected with the G3BP2 siRNAs using Lipofectamine 2000 (Life 
Technologies) according to the manufacturer’s instructions. These cells were infected with 
CHIKV at 24 h p.t.
 
RNA isolation, gel electrophoresis, and in-gel hybridization. CHIKV RNA isolation 
using acid phenol, denaturing gel electrophoresis, and detection by in-gel hybridization 
with 32P-labeled oligonucleotides specific for positive or negative-strand RNA were performed 
as described previously (69).
qRT-PCR. An internally controlled multiplex quantitative TaqMan real-time PCR 
(qRT-PCR) was used to determine the copy number of CHIKV genomic RNA (probe 
in nsP1-coding region) and total RNA (probe in E1-coding region). Briefly, forward 
(CTAGCTATAAAACTAAUAGAGCAGGAAATTG) and reverse (GACTTTTCCTGCGGCAGATGC) 
primers and a probe (Texas red-TCCGACATCATCCTCCTTGCTGGCG-black hole quencher 2 
[BHQ2]) in the nsP1-encoding region were used in combination with a set of primers and 
6-carboxyfluorescein (FAM)-labeled probe specific for the E1-coding region that has been 
described previously (272). Samples were analyzed using the SensiFast Probe (Bioline) or 
TaqMan Fast Virus 1-Step (ABI) qRT-PCR kit and a CFX384 Touch Real-Time PCR detection 
system (Bio-Rad) according to the manufacturers’ instructions. Serial dilutions of  in vitro-
transcribed RNA were used as standards for copy number determination, and the cellular 
PGK1 mRNA was used as an internal control in multiplex reactions.
Luciferase assays. 293/ACE2 cells (5 × 103  per well) were seeded in 96-well plates and 
transfected with siRNAs (described above). After 48 h, the cells were infected with ICRES1-
P3Rluc or ICRES1-2SG-Rluc at an MOI of 5. Alternatively, the cells were transfected with 
100 ng of  in vitro-transcribed full-length viral RNA (ICRES1-P3Rluc, ICRES1-2SG-Rluc, or 
ICRES1-P3Rluc-nsP4-GAA) using Lipofectamine 2000. At the desired time points, cells were 
lysed in passive lysis buffer (Promega) and luciferase substrate was added according to the 
manufacturer’s instructions. Luciferase activity was measured in a GloMax 96 microplate 
luminometer (Promega).
Metabolic labeling and immunoprecipitation. Proteins synthesized in infected 293/
ACE2 cells were labeled with [35S]methionine and [35S]cysteine ([35S]Met/Cys) as described 
previously (69). Cells were lysed in Laemmli sample buffer, and antibody binding was carried 
out overnight at 4°C in AVIP buffer (20 mM Tris-HCl [pH 7.6], 150 mM NaCl, 1% NP-40, 0.1% 
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SDS, 0.5% deoxycholine) containing a final concentration of 0.5% SDS. Immune complexes 
were pulled down using a 1:1 mixture of protein A/G-Sepharose beads (GE Healthcare). 
Beads were washed three times in AVIP buffer before elution by boiling in Laemmli sample 
buffer for 5 min. Eluted proteins were separated in 10% polyacrylamide gels, and detection 
was done by autoradiography with phosphorimager screens and a Typhoon-9410 scanner 
(GE Healthcare).
Data analysis. Band intensities were quantified using Quantity One v4.5.1 (Bio-Rad) or 
ImageQuant TL software (GE Healthcare). Two or three independent experiments were 
quantified (one representative experiment is shown in figures). Statistical significance was 





CHIKV replication induces G3BP-containing foci that resemble SGs. A variety of 
viruses, including alphaviruses, induce the formation of SGs or SG-like cytoplasmic 
granules. To investigate whether CHIKV infection induces SGs, Vero E6 cells were infected 
and the localization of the SG marker G3BP2 was monitored (Fig. 1A). Arsenite, commonly 
used to induce SGs via oxidative stress, was employed as a positive control. In uninfected 
cells, G3BP2 displayed a diffuse cytoplasmic distribution, whereas in CHIKV-infected cells, 
G3BP2-containing foci appeared by 6 to 8 h p.i., continued to grow in size until ~10 h p.i., 
and remained present thereafter. Similar observations were made for G3BP1 (data not 
shown), and costaining for G3BP1 and G3BP2 revealed that the two proteins localize to the 
same puncta (Fig. 1B). These G3BP puncta did not possess the typical rounded morphology 
of arsenite- or heat shock-induced SGs but had a more rod-like appearance (Fig. 1A to C). 
Genuine SGs are dispersed upon cycloheximide (CHX) treatment, which stabilizes polysomes 
and prevents their disassembly, a crucial step in SG formation. As expected, arsenite-induced 
G3BP1 puncta readily dispersed upon CHX treatment. However, the CHIKV-induced G3BP1 
puncta were not affected by CHX treatment (Fig. 1C). Identical observations were made 
when the granules were stained for G3BP2 (data not shown). To exclude the possibility 
that the induction of G3BP-containing puncta was a unique feature of the infectious clone-
derived strain LS3, which is based on the consensus sequence of several CHIKV strains, we 
also analyzed cells infected with other strains. Natural isolate CHIKV ITA07-RA1 and CHIKV 
LR2006-OPY1-nsP4/FLAG, which is based on a clinical isolate from La Reunion, induced 
similar G3BP2-containing granules (Fig. 1D), suggesting that this is a general CHIKV property.
The composition of CHIKV-induced granules differs from that of genuine SGs.The 
composition of the CHIKV-induced granules was examined by immunostaining for several 
SG markers. In arsenite-induced SGs, G3BP1, G3BP2, TIA-1, TIAR, PABP, and eIF3 could 
readily be detected (Fig. 2). However, the CHIKV-induced granules were labeled only for 
G3BP1 and G3BP2, demonstrating that they differ not only in morphology and response to 
CHX treatment but also in protein composition. Some viruses, e.g., poliovirus (273), block 
SG formation by cleaving key SG components, like G3BP1. To assess whether the CHIKV-
induced granules lack SG components due to their degradation or downregulation, the 
expression level of a number of SG markers in CHIKV-infected cells was determined. Western 
blot analysis showed that G3BP1 and G3BP2 protein levels did not change during the course 
of CHIKV infection (Fig. 3). Also, the expression levels of eIF3 and PABP remained unchanged 
during CHIKV infection. As expected, the level of eIF2α phosphorylation increased strongly in 
CHIKV-infected cells between 6 and 12 h p.i. (Fig. 3). The expression level of TIA-1 and TIAR 
proteins increased ~2-fold within 6 h p.i. (Fig. 3). 
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G3BPs colocalize with CHIKV nsP2 and nsP3 but not with nsP1, nsP4, or dsRNA. To 
investigate if the G3BP granules represent CHIKV replication complexes, we analyzed the 
possible colocalization of G3BP2 with CHIKV nsPs and dsRNA. Vero cells were infected with 
CHIKV at an MOI of 5, fixed at 6 h p.i., and immunostained for G3BP2 and CHIKV nsPs. This 
staining confirmed the previously reported nsP3-G3BP2 colocalization in cytoplasmatic 
granules (Fig. 4A). In addition, we observed nsP2-G3BP2 colocalization in similar foci. 
Strikingly, no colocalization of G3BP2 with nsP1 or nsP4 could be detected (Fig. 4A). Next, 
we analyzed the distribution of dsRNA and G3BP2 in CHIKV-infected cells (Fig. 4B). Only early 
in infection (4 h p.i.), when the dsRNA and G3BP2 signals were barely detectable, did there 
appear to be some colocalization of G3BP2 and dsRNA. At 6 h p.i. there was a very limited 
overlap between the dsRNA- and G3BP2-containing puncta, and at 8 h p.i. most of the dsRNA 
and G3BP2 signals were clearly not colocalizing (Fig. 4B). We did not observe complete 
Figure 1. Induction of G3BP-containing foci by CHIKV replication. (A) Vero E6 cells were infected with 
CHIKV (MOI, 5), fixed at the indicated time points postinfection, and immunostained for G3BP2 and 
CHIKV. A longer exposure of mock-infected cells is shown to visualize diffuse G3BP2 staining. (B) CHIKV-
induced granules (MOI, 5; 8 h p.i.) were costained for G3BP1 and G3BP2. (C) Vero E6 cells were infected 
with CHIKV (MOI, 5; analyzed at 8 h p.i.) or treated with arsenite (0.5 mM for 1 h) to induce SG formation 
and subsequently incubated with CHX (100 μg/ml for 30 min), followed by immunostaining for G3BP1. (D) 
G3BP2 immunostaining of Vero cells that were infected with CHIKV ITA07-RA1 or LR2006-OPY1-nsP4/FLAG 
(MOI, 5) and fixed at 6 h p.i. Scale bar: 10 μm.
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colocalization between the nsP1 and nsP4 foci and the dsRNA puncta, which makes it 
impossible to unequivocally pinpoint the intracellular location of the RTC. This is likely 
because only a fraction of nsP1 and nsP4 is located within RTCs. Nonetheless, regardless 
of which of these markers most accurately identifies the CHIKV RTCs, clearly none of them 
colocalized with the G3BPs, suggesting that the G3BP granules did not represent the RTCs. 
All 4 nsPs are needed to form the RTC, but nsP2 and nsP3 also have other functions and 
different intracellular localizations outside the membrane-associated RTC. Thus, it is likely 
that the previously reported nsP3-G3BP interaction occurs with the pool of nsP3 that is not 
associated with the RTC.
Figure 2. Composition of arsenite-induced SGs and CHIKV-induced granules. Vero E6 cells were treated 
with arsenite or infected with CHIKV-GFP (MOI, 5; fixed at 8 h p.i.). After fixation, the localization of the 
SG markers indicated to the left of each row was analyzed by immunofluorescence microscopy. The 
rightmost column shows the overlays of the signals of the SG marker and eGFP. Scale bar: 10 μm.
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G3BPs are not associated with membrane-bound CHIKV replication complexes. 
To independently confirm that the G3BP granules observed in our immunofluorescence 
microscopy analysis were not the (membrane-associated) CHIKV RTCs, subcellular 
fractionation experiments were performed. CHIKV-infected cells were fractionated into a 
crude membrane fraction (P15) and a cytosolic fraction (S15). The P15 fraction contained 80 
to 90% of the in vitro RNA synthesizing activity and was enriched in negative-strand RNA and 
nsP4, suggesting that it contained the majority of the membrane-associated RTCs (Fig. 4C). 
The bulk of nsP3 was found in the cytosolic S15 fraction. G3BP1 and G3BP2 were detected 
exclusively in the S15 fraction, suggesting that they are not associated with the RTCs. This 
supports the idea that the pool of nsP3 that associates with G3BPs differs from the one that 
is part of the RTC. The subcellular distribution of G3BPs in mock-infected cells was similar to 
that in CHIKV-infected cells (data not shown).
Depletion of G3BPs inhibits CHIKV replication. To further study the role of G3BP1 and 
G3BP2 in CHIKV replication, we assessed the effect of their knockdown on viral replication 
(Fig. 5). It was previously shown that G3BP expression is controlled by an apparent feedback 
mechanism that results in the upregulation of one G3BP when the expression of the other 
Figure 3. Levels of stress granule proteins during CHIKV infection. 293/ACE2 cells were infected with CHIKV 
(MOI, 5), and whole-cell lysates were prepared at the indicated time points postinfection. The expression 
level of the indicated proteins was determined by Western blotting. Mock-infected cells (m) were included 
as a negative control, and actin was used as a loading control.
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is reduced (274). These observations suggest that the proteins are functionally linked, and 
therefore, the impact of simultaneous knockdown of G3BP1 and G3BP2 was also examined. 
Transfection of cells with the G3BP1-specific siRNA pool resulted in an ~90% reduction in 
G3BP1 expression and an ~2-fold increase in G3BP2 levels. The G3BP2 siRNA treatment 
achieved an ~80% reduction of G3BP2 levels, accompanied by an ~2-fold increase in G3BP1 
expression (Fig. 5A). After treatment with a combination of G3BP1- plus G3BP2-targeting 
siRNAs, cells displayed about 40% and 30% of their original levels of expression of G3BP1 
Figure 4. Localization of CHIKV nonstructural proteins, dsRNA, and G3BP. (A) Vero cells were infected with 
a CHIKV encoding nsP4-FLAG (LR2006-OPY1- nsP4/FLAG) at an MOI of 5, fixed at 6 h p.i., and stained for 
G3BP2, nsP1, nsP2, nsP3, and nsP4/FLAG. The bottom part of panel A shows the staining of uninfected cells, 
with the antibodies indicated in each frame. (B) Vero E6 cells were infected with CHIKV (MOI, 5), fixed at 
the indicated time points p.i., and stained for G3BP2 and dsRNA. Open arrowheads indicate colocalization 
of dsRNA with G3BP2, whereas closed arrowheads indicate some examples of nonoverlapping signals. 
Scale bar: 10 μm. (C) Distribution of G3BPs and CHIKV nsPs between the “heavy membrane” fraction 
P15 and “cytoplasmic” fraction S15. Vero E6 cells were infected with CHIKV (MOI, 5) and then harvested, 
lysed, and subjected to subcellular fractionation at 6 h p.i. The presence of CHIKV negative-stranded RNA 
was determined by hybridization with a specific probe (hyb). The RNA synthesizing activity was assessed 
with an in vitro assay in which the incorporation of [32P]CTP into CHIKV RNA was determined (270). The 
levels of CHIKV nsP3, nsP4, G3BP1, and G3BP2 in the P15 and S15 fractions were determined by Western 
blotting (WB).
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and G3BP2, respectively. The siRNA-transfected cells were infected with a CHIK reporter virus 
at MOIs of 0.05, 1, and 5, and cells were fixed at 24, 20, and 16 h p.i., respectively. The eGFP 
expression was quantified, and cell viability assays performed in parallel showed no negative 
effect of G3BP depletion (Fig. 5B). Despite efficient knockdown, G3BP1 depletion had little 
effect on CHIKV replication. G3BP2 depletion reduced eGFP levels in cells infected at an MOI 
of 0.05 by ~55%, and the combined depletion of G3BP1 and G3BP2 reduced eGFP levels 
even further (~80%). The effect of G3BP depletion was less pronounced in cells infected at 
an MOI of 1 or 5 (Fig. 5B). Because silencing of G3BP1 alone had little effect, and because 
the simultaneous depletion of both G3BPs exerted a stronger effect on CHIKV replication 
than depletion of G3BP2 alone (Fig. 5C), all subsequent knockdown experiments were done 
with siRNA pools that targeted G3BP1 and G3BP2 simultaneously. The combined depletion 
of G3BP1 and G3BP2 resulted in severely reduced negative-strand RNA levels, which were 
about 85 to 90% lower (6 to 8 h p.i.) than in control cells (Fig. 5D). Consequently, positive-
stranded RNA levels were also affected (80 to 85% lower than in control cells). The strongly 
reduced genomic RNA levels in G3BP-depleted cells resulted in a reduction of nsP and E2 
levels (Fig. 5E). It is noteworthy that G3BP depletion affected the accumulation of nsP3 more 
strongly than the other nsPs, as the amount of protein could not be quantified at 6 h p.i., and 
was ~80% lower at 8 h p.i. than in control cells. Viral progeny titers from G3BP-depleted cells 
were approximately 1 log lower at 8 h p.i. (Fig. 5F). In conclusion, G3BP2 depletion caused an 
~2-h delay in the accumulation of viral RNA and proteins and the production of infectious 
progeny, while a less pronounced effect was observed at later time points, suggesting that 
the G3BPs play a role early in the CHIKV replication cycle.
The sensitivity of CHIKV replication to G3BP depletion is striking, as SINV was previously 
reported to replicate slightly better in G3BP-depleted cells (274). We therefore also infected 
G3BP-depleted cells with a SINV reporter virus (SINV-GFP) to investigate the effect of G3BP 
depletion. As observed for CHIKV, simultaneous depletion of the two G3BPs also inhibited 
SINV replication in our experimental setup (Fig. 5G). Depletion of G3BP1 alone barely affected 
SINV replication, whereas depletion of G3BP2 alone strongly affected SINV replication (Fig. 
5G).
To ensure that the observed inhibition of CHIKV (and SINV) replication was not due to a general 
negative effect of G3BP2 depletion on cellular homeostasis, we infected G3BP-depleted cells 
with an unrelated reporter virus: the picornavirus coxsackie B3 virus (CVB3-GFP). CVB3 is not 
expected to be negatively affected by G3BP2 depletion, as its protease has been reported 
to cleave G3BP1 (275) and possibly also G3BP2. Indeed, G3BP2-depletion had no effect on 
GFP expression by CVB3, and depletion of G3BP1 alone or both G3BPs simultaneously even 
enhanced CVB3-GFP replication (Fig. 5G). This demonstrated that CVB3 replication was not 
negatively affected in G3BP-depleted cells, suggesting that the knockdown did not lead to 
serious negative effects on cellular physiology.
Another issue that needs to be addressed when using siRNAs is the possibility that the 
observed phenotype is due to off-target effects. Therefore, the pools of four G3BP siRNAs 
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were deconvoluted and the siRNA duplexes were tested individually. As anticipated based on 
the results obtained with the G3BP1 pool, none of the four single G3BP1 siRNAs had a strong 
effect on CHIKV replication, despite the fact that 3 out of 4 siRNAs (1 to 3) significantly reduced 
G3BP1 levels (data not shown). Transfection of 3 out of the 4 individual G3BP2 siRNAs (2, 
3, and 4) resulted in a strong reduction in G3BP2 expression (Fig. 5H), whereas transfection 
of siRNA 1 was somewhat less effective in reducing G3BP2 protein levels. Single siRNA 
duplexes 2 to 4 reduced CHIKV replication to various extents, but all single siRNAs reduced 
GFP expression by ~50% or more (Fig. 5H). It should be noted that a larger effect was not 
expected, as depletion of G3BP2 alone with the SMARTpool resulted in a similar reduction in 
GFP expression (Fig. 5B and C). The correlation between the level of CHIKV replication and 
remaining G3BP expression indicates that the siRNA-mediated inhibition is unlikely due to 
off-target effects. This is further supported by the fact that expression of an siRNA-resistant 
form of G3BP2 restored CHIKV replication to ~30 to 90% of that in control cells (Fig. 5I). The 
rescue of CHIKV replication by G3BP2 overexpression was more efficient in cells in which 
G3BP2 was depleted with siRNA 4 than in those transfected with siRNA 2. This suggests that 
besides G3BP2 depletion, siRNA 2 also caused some off-target effects. To further exclude 
potential off-target effects, we employed C911 mutant siRNAs (271), in which the “targeting” 
Figure 5. Effect of siRNA-mediated depletion of G3BP1 and G3BP2 on CHIKV replication. (A) Western blot 
analysis of the protein levels of G3BP1 and G3BP2 in 293/ACE2 cells transfected with control siRNAs or 
those targeting G3BP1, G3BP2, or both. The transferrin receptor (TFR) and actin were used as loading 
controls. (B) Cell viability and CHIKV-driven eGFP expression in cells that were depleted of G3BP1 
and G3BP2 and subsequently infected with reporter virus CHIKV LS3-GFP at an MOI of 5 (black bars), 
1 (dark gray bars), or 0.05 (light gray bars). Cell viability was determined at 48 h p.t. (white bars), and 
eGFP expression was quantified at 16, 20, or 24 h p.i., depending on the MOI used. (C) G3BP-depleted, 
CHIKV-infected cells (MOI, 0.05) were analyzed for E2 expression (by Western blotting using cyclophilin B 
as a loading control) and positive-strand RNA levels (by in-gel hybridization [hyb]) at 24 h p.i. (D) In-gel 
hybridization analysis of CHIKV RNA levels with probes specific for negative-strand (−RNA) or positive-
strand (+RNA) RNA in G3BP-depleted 293/ACE2 cells. The cells were infected with CHIKV (MOI, 5) 48 h after 
siRNA transfection, and total RNA was isolated at the indicated time points. cntrl, control. (E) Western 
blot analysis of CHIKV protein expression levels after G3BP depletion. 293/ACE2 cells were transfected 
with control or G3BP-specific siRNAs and 48 h later infected with CHIKV (MOI, 5). Cell lysates for Western 
blot analysis were harvested at the indicated time points and analyzed for the viral proteins indicated, 
using actin as a loading control. (F) Infectious progeny titers of CHIKV-infected cells (MOI, 5) that were 
transfected with control or G3BP-specific siRNAs. (G) G3BP-depleted 293/ACE2 cells were infected with 
SINV-GFP or CVB3-GFP (MOI, 1) and fixed at 16 or 10 h p.i., respectively. The level of GFP expressed by 
the viruses was normalized to infected cells transfected with control siRNAs. (H) 293/ACE2 cells were 
transfected with 50 nM individual siRNA duplexes (deconvoluted pool) and infected with CHIKV-GFP (MOI, 
1) 2 days later, followed by quantification of GFP expression at 20 h p.i. The (remaining) level of G3BP2 
expression was determined by Western blotting. (I) Analysis of GFP expressed by CHIKV in cells depleted 
for G3BP2 with siRNA 2 or 4 and cotransfected with a plasmid encoding siRNA-resistant G3BP2 (G2) or 
an empty vector (ev). (J) Cells were transfected with C911 mutant siRNAs (C911) or the corresponding 
G3BP2-targeting siRNAs (wt), followed 24 h later by infection with CHIKV-GFP (MOI, 1) and quantification 
of GFP expression at 20 h p.i. GFP levels were normalized to cells transfected with a nontargeting control 
siRNA (100%). G3BP2 knockdown efficiency at 24 h p.t. was determined by Western blotting.
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residues 9 to 11 are mutated. These mutant siRNAs should no longer induce knockdown of 
the target while still causing the same off-target effects as the corresponding targeting siRNA. 
We designed and tested C911 mutant siRNA corresponding to G3BP2 single siRNAs 2 and 4 
(Fig. 5J). These custom-synthesized targeting siRNAs did not deplete G3BP2 protein levels 
to the same extent as the original (modified) Dharmacon siRNAs and only reduced CHIKV 
replication by ~30%. However, no reduction in CHIKV-driven eGFP expression was observed 
in cells transfected with the corresponding C911 mutant siRNAs, indicating that the inhibition 
of CHIKV replication was due to G3BP2 depletion rather than off-target effects of the siRNAs 
(Fig. 5J).
G3BP levels do not influence nonstructural polyprotein processing. We noticed 
that—especially early in infection—G3BP depletion affected the level of structural proteins 
(E2) more than that of nsPs (Fig. 5E). The expression of structural proteins is dependent 
on sgRNA synthesis, which for alphaviruses is controlled by the extent to which nsP123 is 
proteolytically processed (64). SFV mutants lacking the G3BP-binding domain exhibited 
delayed polyprotein processing, resulting in the appearance of an extra uncleaved processing 
intermediate (63). Therefore, we assessed CHIKV polyprotein processing in G3BP-depleted 
cells. Pulse-chase metabolic labeling with [35S]Met/Cys, followed by immunoprecipitation of 
nsP3, showed no differences in the kinetics of processing of the P123 precursor when G3BP-
depleted and control cells were compared (Fig. 6A). The total level of viral protein was lower 
in G3BP-depleted cells at this early time point, but P123 was processed at the same rate and 
no additional uncleaved intermediates were found, indicating that polyprotein processing 
was not specifically affected by the absence of G3BP.
G3BP levels do not affect CHIKV entry or RNA synthesis. We noticed that viral protein 
accumulation, as analyzed by Western blotting, appeared to be delayed by ~2 h in G3BP-
depleted cells. Comparison of the kinetics of CHIKV RNA accumulation in control and 
G3BP-depleted cells by qRT-PCR revealed that RNA production was also delayed by ~2 h 
but occurred at the same rate, since a semilog plot of the copy number over time had the 
same slope as the curve obtained for control cells (Fig. 6B). These results suggested a role 
for G3BPs early in the CHIKV replication cycle. We therefore investigated whether G3BPs 
are involved in viral entry by transfecting control and G3BP-depleted cells with  in vitro-
transcribed CHIKV full-length genomic RNA, a procedure that bypasses virion attachment 
and entry. The transfection of control cells with CHIKV RNA led to readily detectable amounts 
of negative-strand RNA by 4 h p.t., after which genome and sgRNA levels increased rapidly in 
the next 2 h (Fig. 6C). Also in G3BP-depleted cells replication of transfected CHIKV RNA was 
detected, although negative-strand RNA levels were much lower than in control cells and the 
accumulation of positive-strand RNA was impaired (Fig. 6C). The observation that bypassing 
CHIKV entry still resulted in a delayed replication indicates that the G3BPs are involved in 
an early, but postentry, step of the CHIKV replication cycle. The effect of G3BP depletion in 
G3BPs play a proviral role during CHIKV replication
105
5
these transfection experiments appeared to be smaller than that observed upon (low-MOI) 
infection (Fig. 5D). This may have been due to the large amount of RNA transfected into the 
cells, probably mimicking a very high-MOI infection, which makes the effect of G3BP depletion 
less pronounced (as shown in  Fig. 5B) for reasons discussed below. However, we cannot 
formally exclude a (minor) additional role for the G3BPs during entry and/or uncoating.
G3BP depletion does not affect translation, but G3BPs appear to regulate the switch 
to minus-strand synthesis. Our experiments indicated that the G3BPs are likely involved 
in an early step of the CHIKV replication cycle. This could be either translation or early 
(negative-strand) RNA synthesis. Unfortunately, it is difficult to study translation and genome 
replication separately, as these processes are interdependent. Incoming viral genome first 
serves as an mRNA for nsP production and then is copied into the negative-strand template 
for genome replication, which produces novel positive-strand RNA that, in turn, serves as 
an mRNA for polyprotein production. However, infection at a very high MOI is thought to 
provide enough input RNA to render translation largely independent of newly synthesized 
Figure 6. Effect of G3BP depletion on CHIKV nonstructural polyprotein processing, rate of RNA synthesis, 
and entry. 293/ACE2 cells were transfected with siRNAs targeting the G3BPs and 48 h later infected with 
CHIKV (MOI, 5) or transfected with in vitro-transcribed CHIKV genomic RNA. (A) Cells were metabolically 
labeled at 5 h p.i. and chased for 0, 45, or 90 min before lysis and immunoprecipitation. (B) Total RNA from 
infected cells was isolated at the indicated time points, and CHIKV genome copy numbers were determined 
using qRT-PCR. (C) G3BP-depleted cells were transfected with 1 μg of viral RNA (in vitro transcript) and 
harvested at the indicated time points. CHIKV RNA was analyzed using in-gel hybridization using probes 
specific for negative- or positive-strand RNA. The 18S rRNA was probed as a loading control.
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RNA, enabling analysis of the translation of incoming genomes. To investigate if the incoming 
CHIKV genome is translated normally in G3BP-depleted cells, these cells were infected at 
an MOI of 50, and total cell lysates were harvested at the desired time points. Western blot 
analysis revealed only minor differences in nsP levels between G3BP-depleted and control 
cells (Fig. 7A). Only the nsP3 level was clearly lower in G3BP-depleted cells. In contrast, the 
accumulation of CHIKV negative-strand RNA and (consequently also) positive-strand RNA 
was strongly reduced in G3BP-depleted cells infected at an MOI of 50 and analyzed at 5 h p.i. 
(Fig. 7B), indicating that the G3BPs are involved in (early) RNA synthesis. To further examine 
the effect of G3BP depletion on CHIKV translation and RNA synthesis, reporter viruses were 
used that express Renilla luciferase either as part of the nonstructural polyprotein (fused to 
nsP3; P3Rluc) or under the control of a duplicated subgenomic promoter (2SG-Rluc). G3BP-
depleted and control cells were infected with these reporter viruses (MOI, 5). Quantification 
of luciferase activity at 8 h p.i. showed a decrease in luciferase expressed from the duplicated 
subgenomic promoter in G3BP-depleted cells (Fig. 7C). This is in line with the effect of G3BP 
depletion on eGFP reporter gene expression (from the second sgRNA) that was observed 
with our reporter virus. Surprisingly, G3BP depletion resulted in an increased luciferase signal 
from P3Rluc virus, indicating that the translation of genomic RNA was not affected or even 
slightly enhanced by G3BP depletion. The increase of nsP3-Rluc signal in the luciferase assay 
contrasts with the apparent nsP3 decrease shown by Western blotting but can be explained 
by the fact that the degradation signal present in nsP3 (276) was lost in the nsP3-Rluc fusion. 
Alternatively, a larger amount of nsP3-Rluc could have been solubilized from G3BP-depleted 
cells compared to control cells, in which the protein is expected to be in G3BP-containing 
aggregates. Taken together, these data suggest that G3BP depletion does not directly affect 
translation and might even slightly stimulate nonstructural polyprotein translation.
In addition to performing infections at an MOI of 50, we have employed a replication-
deficient CHIKV RNA (nsP4 GDD motif mutated to GAA), encoding luciferase fused to nsP3. 
G3BP-depleted or control cells were transfected with replication-deficient CHIKV nsP3-
Rluc RNA, and the luciferase expression was quantified at various time points (Fig. 7D). 
Translation of this transfected RNA resulted in a peak of luciferase activity around 5 h p.t., 
followed by a decrease at later time points, likely due to degradation of the nonreplicating 
RNA and luciferase turnover. The luciferase signals in G3BP-depleted and control cells were 
very similar, indicating that G3BP depletion did not affect the translation of the CHIKV 
genome into nonstructural polyproteins (Fig. 7D). We performed a similar experiment with 
replication-competent CHIKV-nsP3-Rluc RNA, which allowed us to study translation as well 
as genome amplification. In control cells, an initial peak of luciferase activity was detected 
at 4 h posttransfection. After a small decrease in luciferase expression at 6 h p.i. (likely due to 
degradation of mRNA), a further increase in luciferase signal was observed, likely driven by 
translation of newly synthesized positive-strand RNA (Fig. 7E). Strikingly, this second increase 
did not occur in G3BP-depleted cells, indicating that the G3BPs play a role not in translation 
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but in the switch from translation of the (incoming) positive-strand RNA to negative-strand 
synthesis and RNA replication.
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Figure 7. Effect of G3BP depletion on translation of genomic RNA and early negative-strand RNA synthesis. 
(A) Cells transfected with control (cntrl) or G3BP1- and G3BP2-targeting (G1 + 2) siRNAs were infected 
with CHIKV at an MOI of 50 and harvested at the indicated time points, after which viral protein levels 
were analyzed by Western blotting. (B) siRNA-treated cells were infected with CHIKV (MOI, 50), and viral 
RNA was isolated at 5 h p.i. and analyzed by in-gel hybridization. The 18S rRNA was probed as a loading 
control. (C) G3BP-depleted cells were infected with reporter viruses that express Renilla luciferase either 
fused to nsP3 (P3Rluc) or from a duplicated subgenomic promoter (2SG-Rluc) at an MOI of 5. Luciferase 
activity was determined at 8 h p.i. and normalized to the activity in cells transfected with control siRNAs. 
(D) Replication-deficient CHIKV-P3Rluc RNA was transfected into control and G3BP-depleted cells and 
luciferase activity was assessed at the indicated time points. (E) Replication-competent CHIKV-P3Rluc 
RNA was transfected into control and G3BP-depleted cells, followed by measurement of luciferase activity 
at the indicated time points.
DISCUSSION
Many viruses manipulate the formation and dynamics of SGs, likely because their formation 
results in inhibition of translation. G3BP1 is an extensively studied SG marker, while the related 
G3BP2 remains less well characterized. These proteins, collectively referred to as G3BPs, are 
multifunctional RNA-binding proteins that have been implicated in the replication of several 
RNA viruses (273, 277-280). G3BPs have also been implicated in the alphavirus replication 
cycle, as they have been identified as binding partners of SINV nsP2, nsP3, and nsP4 (136-
138, 266, 274) and SFV nsP3 (63, 66). Replication of a CHIKV replicon was shown to induce 
G3BP1-containing granules, and the expression of nsP3 alone was sufficient to sequester 
G3BP1 into granules (62). In addition, CHIKV-induced G3BP1-capsid protein foci have been 
described (281).
We found that late in infection, CHIKV induced foci that contained both G3BP1 and G3BP2 
but that differed from bona fide SGs in morphology, CHX sensitivity, and composition (Fig. 
1). These granules are probably similar to those observed in an earlier study using a CHIKV 
replicon (62). CHIKV-induced granules did not contain other SG markers, like TIA-1, TIAR, eIF3, 
or PABP, and the nsP3-G3BP aggregates therefore likely block the formation of genuine SGs by 
sequestering G3BPs. The expression level of these other SG components did not change over 
the course of infection, with the exception of TIA-1 and TIAR, which even slightly increased 
(Fig. 3). Therefore, the lack of these proteins in the CHIKV-induced granules was not due to 
their absence in the infected cell. SFV- and CHIKV replicon-induced G3BP-granules also lack 
other typical SG markers (62, 63). 
SGs and G3BPs are generally thought to exert an antiviral effect on alphavirus replication. 
Surprisingly, we found by siRNA-mediated depletion that G3BPs were also required for 
efficient CHIKV replication (Fig. 5). CHIKV replication was affected most strongly when 
G3BP1 and G3BP2 were depleted simultaneously, which resulted in reduced viral RNA 
levels, diminished CHIKV protein expression, and an ~10-fold reduction in progeny titers. 
G3BP1 is generally considered an antiviral protein, and it was therefore surprising that 
depletion of G3BP1 did not stimulate CHIKV replication. However, proviral roles have also 
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been described for G3BPs in the replication of respiratory syncytial virus (277) and hepatitis 
C virus (HCV) (278). The observed inhibition of CHIKV replication in siRNA-transfected cells 
could be rescued by expressing siRNA-resistant G3BP2, demonstrating that it was not due 
to off-target effects. This was further corroborated by the use of C911 mutant siRNAs and by 
demonstrating that coxsackievirus replication was not affected in G3BP2-depleted cells. Our 
results demonstrate that simply studying the role of G3BP1 in viral replication, without taking 
G3BP2 into consideration, can lead to the misinterpretation or underestimation of the role 
of the G3BPs, as these homologous proteins can likely complement each other (in part) but 
also possess unique properties. This is illustrated by the fact that knockdown of G3BP1 did 
not affect CHIKV replication, possibly due to the concomitant increase in G3BP2 expression.
Our data show that G3BP2 colocalized with CHIKV nsP2 and nsP3 in cytoplasmic granules 
but not with nsP1, nsP4, or dsRNA. In addition, subcellular fractionation experiments 
demonstrated that G3BPs were undetectable in the fraction (P15) enriched for CHIKV 
RTCs, suggesting that G3BPs are not associated with the active membrane-associated 
RTCs that can be isolated from infected cells (Fig. 4). SFV induces true SGs very early in 
infection, which disappear and are replaced by different nsP3-containing structures later 
in infection (63). For SINV, two types of nsP3-containing granules have been described: one 
type is likely associated with RTCs, while the other lacks dsRNA (137). Our findings suggest 
that most CHIKV nsP3 (and interacting G3BPs) is in the second type of granule. In contrast, 
G3BPs were found to be present in a fraction containing active SFV RTCs in a proteomics 
analysis of isolated cytopathic vacuoles (119). Which proportion of total cellular G3BPs 
was present in this fraction, however, was not determined. Clearly, we cannot formally 
exclude that trace amounts of G3BPs were present in our CHIKV RTC-containing membrane 
fraction. Unfortunately, technical limitations did not allow us to study the composition 
and in vitro activity of the early (negative-strand RNA-synthesizing) RTCs. Therefore, it is well 
possible and even likely (see below) that G3BPs play a role in negative-strand RNA synthesis. 
This is supported by the fact that G3BP depletion caused a delay in the replication cycle and 
affected an early postentry step. Translation of viral mRNA and nonstructural polyprotein 
processing were not impaired in G3BP-depleted cells, suggesting a role for G3BPs in early 
RNA synthesis. Indeed, infecting G3BP-depleted cells at a very high MOI in order to render viral 
mRNA translation to a certain extent independent from RNA synthesis showed that negative-
strand RNA levels were severely reduced, despite the production of almost normal nsP levels 
(Fig. 7A and B). Therefore, G3BPs appear to be involved in the switch from translation of the 
incoming genome to negative-strand RNA synthesis. The G3BPs might clear the viral genome 
of proteins and/or translating ribosomes that would otherwise interfere with a negative-
strand-synthesizing RTC moving in the opposite direction. A similar proviral role has been 
proposed for G3BPs during HCV replication, in which they were shown to be important during 
viral genome amplification but not translation (278). By analogy, impairing G3BP-induced 
CHIKV mRNA clearance would not affect nsP synthesis, which is in line with the observed 
close-to-normal nsP levels and the slightly enhanced luciferase signal of a recombinant 
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virus expressing an nsP3-Rluc fusion protein in G3BP-depleted cells. A less efficient switch 
from translation to genome amplification after G3BP depletion would explain the observed 
reduction of RNA levels and structural protein expression, which is dependent on sgRNA 
synthesis.
Our findings that G3BP depletion reduced CHIKV replication may appear to disagree with 
data from an earlier study on SINV (274). Cristea et al. observed enhanced SINV polyprotein 
expression (similar to what we found for CHIKV), but they also found similar or even slightly 
(though not statistically significant) increased RNA levels and virion production. It is possible 
that G3BP2 protein levels were not sufficiently depleted in this earlier study, as only mRNA 
levels were analyzed, which does not necessarily mean there was a similar reduction in G3BP 
protein levels. If G3BP2 protein levels were not sufficiently depleted, it would be compatible 
with our observation that G3BP1 depletion alone had little effect on CHIKV replication. 
When we analyzed SINV in G3BP2-depleted cells using our own experimental setup, we did 
observe reduced replication, similar to what we found for CHIKV (Fig. 5G). Of course, the 
differences between our data and those previously reported by Cristea et al. may also be 
due to differences in experimental setup or the cell lines used. We have not analyzed the 
effect of G3BP depletion on SINV in much detail, and it remains possible that CHIKV and SINV 
respond differently to G3BP depletion. Previous reports have identified at least one other 
RNA-binding protein that has different effects on CHIKV and SFV replication (119), so a similar 
difference between SINV and CHIKV would not be unimaginable.
Commonly, G3BP1 is implicated in SG formation, and therefore, its effect on viral replication 
has often been attributed to this function. However, both G3BPs possess multiple domains 
and a wide range of other functions unrelated to SG formation, which may (also) be relevant 
for CHIKV replication. G3BPs are part of the HCV replication complex (278), but it is unlikely that 
they are essential components of the CHIKV RTC, at least not in the membrane-associated 
complexes that produce the bulk of the genomic and sgRNA during the later stages of the 
replication cycle. This is in line with the recently identified interaction between CHIKV nsP3 
and G3BPs (61, 62) that we have confirmed in this study (Fig. 4A). This interaction between 
nsP3 and G3BPs appears to occur not in RTCs (Fig. 4) but in SG-like structures that differed 
in composition and behavior from traditional SGs. The at-first-sight contradicting pro- and 
antiviral roles of G3BPs could perhaps be reconciled in a more refined model that would 
discriminate between early and late events in the replication cycle. Early in infection, nsP3 
is present at low levels (and as part of the polyprotein), and it could then recruit G3BPs to 
the genomic RNA that is being translated, to mediate or support the switch from translation 
to the synthesis of negative-strand RNA. G3BPs might be involved in clearing ribosomes or 
proteins from the RNA and/or stabilize the naked viral RNA. Alternatively, G3BPs could be 
involved in a very early step of RTC formation, although they do not appear to be a major 
component of, or required for the activity of, the positive-strand RNA-synthesizing RTCs. Later 
in infection, when negative-strand RNA synthesis ceases, and higher levels of fully processed 
nsP3 are present, a cytosolic (non-RTC-associated) pool of nsP3 might sequester G3BPs 
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into the aggregates that prevent the formation of true SGs, which could otherwise exert an 
antiviral effect on the translation of viral mRNAs. This model is supported by the notions 
that the G3BPs seem to play a (proviral) role only early in CHIKV replication and that at this 
stage genuine SGs can still be formed in alphavirus-infected cells, as we and others (63) have 
observed. Indeed, at 4 h p.i. we observed some colocalization of dsRNA and G3BPs, while at 
8 h p.i. there clearly was no colocalization of dsRNA with the nsP3- and G3BP2-containing 
granules.
Since G3BP1 and G3BP2 have so many (sometimes poorly understood) functions (reviewed in 
reference (282)), they might be involved in more steps of the CHIKV replication cycle, besides 
their proposed role in the translation-replication switch. For example, the G3BPs could be 
involved in stabilizing viral RNAs via their RNA-binding properties or even in NF-κB signaling 
or ubiquitin-mediated degradation, in which they have also been implicated (265, 283). NF-
κB phosphorylation and protein levels were suggested by Zhang et al. to be affected by G3BP 
depletion (284), but we could not detect any changes in NF-κB protein levels or intracellular 
localization (data not shown). Another intriguing observation was that nsP3 levels appeared 
to be more strongly affected by G3BP depletion than the other nonstructural proteins, 
suggesting a role for G3BPs in stabilizing nsP3. Future work should assess the additional roles 
that the G3BPs might play during CHIKV replication.
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RIG-I is a cytosolic sensor critically involved in the activation of the innate immune response 
to RNA virus infection. In the present study, we evaluated the inhibitory effect of a RIG-I 
agonist on the replication of two emerging arthropod-borne viral pathogens, dengue virus 
(DENV) and chikungunya virus (CHIKV), for which no therapeutic options currently exist. 
We demonstrate that when a low, noncytotoxic dose of an optimized 5′triphosphorylated 
RNA (5′pppRNA) molecule was administered, RIG-I stimulation generated a robust antiviral 
response against these two viruses. Strikingly, 5′pppRNA treatment before or after challenge 
with DENV or CHIKV provided protection against infection. In primary human monocytes 
and monocyte-derived dendritic cells, the RIG-I agonist blocked both primary infection and 
antibody-dependent enhancement of DENV infection. The protective response against DENV 
and CHIKV induced by 5′pppRNA was dependent on an intact RIG-I/MAVS/TBK1/IRF3 axis 
and was largely independent of the type I IFN response. Altogether, this in vitro analysis of the 
antiviral efficacy of 5′pppRNA highlights the therapeutic potential of RIG-I agonists against 
emerging viruses such as DENV and CHIKV.
IMPORTANCE
DENV and CHIKV are two reemerging mosquito-borne viruses for which no therapeutic 
options currently exist. Both viruses overlap geographically in tropical regions of the world, 
produce similar fever-like symptoms, and are difficult to diagnose. This study investigated 
the inhibitory effect of a RIG-I agonist on the replication of these two viruses. RIG-I 
stimulation using 5′pppRNA before or after DENV or CHIKV infection generated a protective 
antiviral response against both pathogens in immune and nonimmune cells; interestingly, 
the protective response against the viruses was largely independent of the classical type I 
interferon response. The antiviral efficacy of 5′pppRNA highlights the therapeutic potential 
of RIG-I agonists against emerging viruses such as DENV and CHIKV.




During infection, nucleic acids synthesized by viral replicases are the main pathogen-
associated molecular patterns (PAMPs) recognized by the innate immune system (285). 
Sensing of PAMPs results in the control of the first waves of viral infection through the 
production of antiviral effector molecules and contributes to the mobilization of the adaptive 
arm of the immune response (286-288). Double-stranded RNA (dsRNA), generated during 
the replicative cycle of many viruses, is sensed by receptors such as Toll-like receptor 3 
(TLR3) and different members of the RIG-I-like receptor (RLR) family, including RIG-I (retinoic 
acid-inducible gene I), MDA5 (melanoma differentiation factor 5), and LGP-2 (laboratory of 
genetics and physiology-2). RIG-I and MDA5 consist of two N-terminal caspase activation and 
recruitment domains (CARD), a DExD/H-box RNA helicase-sensing domain, and a C-terminal 
regulatory domain (RD). LGP-2 contains the RNA helicase-sensing domain and the RD but 
lacks the CARD (288-292). 
Viral RNA extracted from infected cells has been shown to potently activate RIG-I (293, 
294). Chemically or enzymatically synthesized dsRNA molecules bearing an exposed 
5′-triphosphate end (5′ppp) were first identified as RIG-I inducers (295, 296), with the presence 
of the 5′ppp moiety being essential for RIG-I activation. Further characterization of a potent 
RIG-I ligand demonstrated that the presence of a blunt base pairing at the 5′ end, as well 
as a minimum length of 20 nucleotides, were essential for optimal RIG-I recognition of the 
molecule (295, 296). While short dsRNAs bearing a 5′ppp end are preferentially recognized 
by RIG-I, long dsRNA lacking the triphosphate moiety, such as poly(I:C), are recognized by 
TLR3 and MDA5 (297). More recently, a SELEX technology identified RNA aptamers that 
specifically target the RIG-I protein. The selected aptamers contained poly(U) motifs that 
were crucial for RIG-I activation of the immune response but, unexpectedly, activated RIG-I in 
a 5′-triphosphate-independent manner (298).
Binding of 5′ppp dsRNA to RIG-I leads to a conformational alteration, resulting in 
dissociation of the CARD from the helicase domain and exposure of the CARD (299, 300). 
This conformational change results in the generation of an active state characterized by ATP 
hydrolysis and ATP-driven translocation of RNA along the RIG-I molecule (299-302). RIG-I first 
forms a small binding unit upon recognition of the 5′ppp dsRNA, which occurs independently 
of ATP binding (303). In a second step, RIG-I oligomerizes on the 5′ppp dsRNA in an ATP 
hydrolysis-dependent manner, and the length of dsRNA dictates the strength of the type I 
interferon (IFN) response (303). Activated RIG-I is then able to interact with its mitochondrial 
adaptor MAVS via a CARD-CARD interaction. MAVS triggers the activation of IRF3, IRF7, and 
NF-κB through the IKK-related kinases TBK1 and IKKε, leading to the induction of type I 
IFN (IFN-β and IFN-α), proinflammatory cytokines, and selected antiviral genes, such as 
IFN-stimulated gene 15 (ISG15), ISG54, and ISG56 (304). Expansion of the antiviral response 
is then driven by the binding of type I IFN on its receptor, which activates the induction of 
hundreds of ISGs through the JAK-STAT pathway (287, 288, 305-308).
Chapter 6
116
Given the importance of the innate immune response for host survival, TLR and RLR agonists 
have been the subject of intense study. Treatment with agonists of TLRs 2, 3, 4, 5, 7, and 
9 inhibited hepatitis B virus as well as herpes simplex virus-2 replication in a type I IFN-
dependent manner (309-311). Furthermore, pretreatment of cells with poly(I:C) also inhibited 
the replication of hepatitis C virus (HCV), human immunodeficiency virus (HIV), influenza 
virus, respiratory syncytial virus (RSV), DENV, and CHIKV (312-318). More recently, an RNA-
based agonist of RIG-I was shown to block the replication of multiple viruses, including 
influenza virus, HIV, HCV, vesicular stomatitis virus (VSV), and vaccinia virus  in vitro, as well 
as influenza virus in vivo (319). This broad-spectrum antiviral activity was in part attributed 
to the potent and specific stimulation of antiviral and inflammatory genes through IRF3/7, 
STAT1, and NF-κB transcription factors (319). 
DENV and CHIKV are arthropod-borne viruses belonging to the  Flavivirus  and 
Alphavirus genera, respectively. Illness caused by CHIKV is usually diagnosed based on febrile 
symptoms and arthralgia and is often confused with dengue fever, given the similarities in 
clinical signs. CHIKV causes a severe arthralgia that may persist for many months but is not 
associated with the hemorrhagic fever that develops in a small proportion of severe dengue 
cases. Most DENV infections are asymptomatic or cause a self-limiting dengue fever, while a 
small proportion of infections leads to severe and potentially lethal manifestations, such as 
dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), which are associated 
with antibody-dependent enhanced infections (320-322). Dengue fever, with millions of cases 
reported each year (320, 321), is already a leading infectious disease in tropical areas, while 
chikungunya fever is a lesser-known disease also affecting the same subtropical regions of the 
world. After a 50-year period of relative quiescence (76), CHIKV has reemerged with millions 
of estimated cases since 2005 (323, 324). The dramatic geographic expansion and increased 
incidence of DENV infections, as well as the emergence of CHIKV strains with an increased 
epidemic potential, highlight the increased burden of both viruses in tropical regions. The 
current lack of vaccines and effective antivirals stresses the importance of investigating new 
strategies to combat these serious human pathogens. Ideally, such strategies should target 
both viruses, as they cause similar symptoms, have an overlapping geographic distribution, 
and occur in regions in which the capacity to perform (differential) diagnosis is often limited.
The present study describes the protective innate immune response against DENV and CHIKV 
infection triggered by a well-characterized 5′ triphosphorylated RIG-I agonist. The current 
study demonstrates that treatment with 5′pppRNA triggers a protective antiviral response 
sufficient to prevent DENV and CHIKV infection in both immune and nonimmune cells. The 
protective antiviral response was largely independent of the IFN-α/β receptor (IFNAR)/STAT1 
axis but dependent on an intact RIG-I/MAVS/TBK1/IRF3 axis.




In vitro synthesis of 5′pppRNA. The sequence of 5′pppRNA was derived from the 5′ and 
3′ untranslated regions (UTR) of the VSV genome as previously described (299). In vitro-
transcribed RNA was prepared as previously described (319). Briefly, RNA was prepared using 
the Ambion MEGAscript T7 kit according to the manufacturer’s guidelines (Invitrogen, NY, 
USA). 5′pppRNA was purified using the Qiagen miRNA minikit (Qiagen, Valencia, CA). An RNA 
with the same sequence but lacking the 5′ppp moiety was purchased from IDT (Integrated 
DNA Technologies Inc., IA, USA). This RNA generated results identical to those obtained with 
5′pppRNA that was dephosphorylated enzymatically with calf intestinal alkaline phosphatase 
(Invitrogen, NY, USA).
Cell culture and transfections. A549 cells were grown in F12K medium (ATCC, Manassas, 
VA) supplemented with 10% fetal bovine serum (FBS) and antibiotics. C6/36 insect cells 
were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% FBS 
and antibiotics. Lipofectamine RNAiMax (Invitrogen, NY, USA) was used for transfections of 
5′pppRNA in A549 cells according to the manufacturer’s instructions. For short interfering 
RNA (siRNA) knockdown, A549 cells were transfected with 50 nM (30 pmol) human RIG-I (sc-
6180), IFN-α/βR α chain (sc-35637) and β chain (sc-40091), STING (sc-92042), TLR3 (sc-36685), 
MDA5 (sc-61010), MAVS (sc-75755), interleukin-28R (IL-28R; sc-62497), IL-10Rβ (sc-75331), 
STAT1 p844/91 (sc-44123), IRF1 (sc-35706), IRF3 (sc-35710), IRF7 (sc-38011), and control siRNA 
(sc-37007) (Santa Cruz Biotechnology, Dallas, T) using Lipofectamine RNAiMax according to 
the manufacturer’s guidelines.
MRC-5 cells (ATCC CCL-171) were grown in Earle’s minimum essential medium (EMEM) 
supplemented with 10% FBS, 2 mM  L-glutamine, 1% nonessential amino acids (PAA), 
and antibiotics. For siRNA-mediated knockdown of gene expression, MRC-5 cells were 
transfected with 16.7 nM (10 pmol) siRNA using Dharmafect1 (Dharmacon) according to the 
manufacturer’s guidelines.
Mouse embryonic fibroblast cells (MEFs) were grown in DMEM with 10% FBS and antibiotics.
Primary cell isolation. Human peripheral blood mononuclear cells (PBMC) were isolated 
from the blood of healthy volunteers in a study approved by the institutional review board 
and by the VGTI-FL Institutional Biosafety Committee (2011-6-JH1). Written informed 
consent, approved by the VGTI-FL Inc. ethics review board (FWA number 161), was provided 
and signed by study participants. Research conformed to ethical guidelines established 
by the ethics committee of the OHSU VGTI and Martin Health System. Briefly, PBMC were 
isolated from freshly collected blood using Ficoll-Paque plus medium (GE Healthcare Bio, 
Uppsala, Sweden) per the manufacturer’s instructions. Monocytes were then isolated using 
the negative selection human monocyte enrichment kit (Stem Cell, Vancouver, Canada) per 
the kit’s instructions and used for further experiments. To obtain monocyte-derived dendritic 
cells (MDDC), monocytes were allowed to adhere to 100-mm dishes for 1 h in serum-free 
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RPMI at 37°C. After adherence, remaining platelets and nonadherent cells were removed by 
two washes with serum-free RPMI. The cells were differentiated into MDDC by culturing for 7 
days in MDDC differentiation medium (Miltenyi Biotec, Auburn, GA). Medium was replenished 
after 3 days of differentiation.
Virus production, quantification, and infection. Confluent monolayers of C6/36 insect 
cells were infected with DENV serotype 2 strain New Guinea C (DENV NGC) at a multiplicity 
of infection (MOI) of 0.5. Virus was allowed to adsorb for 1 h at 28°C in a minimal volume 
of serum-free DMEM. After adsorption, the monolayer was washed once with serum-free 
medium and covered with DMEM containing 2% FBS. After 7 days of infection, medium was 
harvested, cleared by centrifugation (500 × g, 5 min), and concentrated down by centrifugation 
(2,000 × g, 8 min) through a 15-ml Millipore Amicon centrifugal filter unit (Millipore, Billerica, 
MA). The virus was concentrated by ultracentrifugation on a sucrose density gradient (20% 
sucrose cushion) using a Sorvall WX 100 ultracentrifuge (ThermoScientific, Rockford, IL) for 
2 h at 134,000 × g and 10°C with the brake turned off. Concentrated virus was then washed 
to remove sucrose using a 15-ml Amicon tube. After 2 washes, the virus was resuspended 
in DMEM plus 0.1% bovine serum albumin (BSA) and stored at −80°C. Titers of DENV stocks 
were determined by fluorescence-activated cell sorting (FACS), infecting Vero cells with 10-
fold serial dilutions of the stock, and then immunofluorescence staining of intracellular DENV 
E protein at 24 h post infection (p.i.). Titers were expressed as IU/ml. DENV titers in cell culture 
supernatants from 5′ppp-treated and control cells were determined by plaque assay on 
confluent Vero cells. Cells in 6-well clusters were incubated with 10-fold serial dilutions of the 
sample in a total volume of 500 μl of DMEM without serum. After 1 h of infection, the inoculum 
was removed and cells were overlaid with 3 ml of 2% agarose in complete DMEM. The cells 
were fixed and stained, and plaques were counted 5 days post infection.
In infection experiments, A549 cells, monocytes, or MDDC were infected in a small volume of 
medium without FBS for 1 h at 37°C and then incubated with complete medium for 24 to 72 h 
prior to analysis. All procedures with live DENV were performed in a biosafety level 2+ facility 
at the Vaccine and Gene Therapy Institute, Florida.
CHIKV strain LS3 and enhanced green fluorescent protein (EGFP)-expressing reporter virus 
CHIKV LS3-GFP have been described (69). Virus production, titration, and infection were 
performed essentially as described previously (69). Working stocks of CHIKV were routinely 
produced in Vero E6 cells at 37°C, and infections were performed in EMEM with 25 mM HEPES 
(Lonza) supplemented with 2% fetal calf serum (FCS), L-glutamine, and antibiotics. After 1 h, 
the inoculum was replaced with fresh culture medium. All procedures with live CHIKV were 
performed in a biosafety level 3 facility at the Leiden University Medical Center.
Flow cytometry analysis. The percentage of cells infected with DENV was determined by 
standard intracellular staining (ICS) with a mouse IgG2a monoclonal antibody (MAb) specific 
for DENV-E protein (clone 4G2), followed by staining with a secondary anti-mouse antibody 
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coupled to phycoerythrin (PE) (BioLegend, San Diego, CA). Cells were analyzed on an LSRII 
flow cytometer (Becton, Dickinson, New Jersey, USA). Calculations as well as population 
analyses were done using FACS Diva software.
Cell viability analysis. Cell surface expression of phosphatidylserine was measured 
using an allophycocyanin (APC)-conjugated annexin V antibody, as recommended by the 
manufacturer (BioLegend, San Diego, CA). Briefly, specific annexin V binding was achieved 
by incubating A549 cells in annexin V binding buffer (Becton, Dickinson, NJ, USA) containing 
a saturating concentration of APC-annexin V antibody and 7-amino-actinomycin D (7-AAD) 
(Becton, Dickinson, New Jersey, USA) for 15 min in the dark. APC-annexin V and 7-AAD 
binding to the cells was analyzed by flow cytometry, as described previously, using an LSRII 
flow cytometer and FACS Diva software. Alternatively, the viability of siRNA- or 5′pppRNA-
transfected cells was assessed using the CellTiter 96 aqueous nonradioactive cell proliferation 
assay (Promega). Absorbance was measured using a Berthold Mithras LB 940 96-well plate 
reader.
Protein extraction and immunoblot analysis. DENV-infected cells were washed twice 
in ice-cold phosphate-buffered saline (PBS) and lysed in radioimmunoprecipitation assay 
(RIPA) buffer (50 mM Tris-HCl, pH 8, 1% sodium deoxycholate, 1% NP-40, 5 mM EDTA, 
150 mM NaCl, 0.1% sodium dodecyl sulfate), and the insoluble fraction was removed by 
centrifugation at 17,000 ×  g for 15 min (4°C). Protein concentration was determined using 
the Pierce bicinchoninic (BCA) protein assay kit (Thermo Scientific, Rockford, IL). Protein 
extracts were resolved by SDS-PAGE on 4 to 20% acrylamide Mini-Protean TGX precast gels 
(Bio-Rad, Hercules, CA) in a 1× Tris-glycine-SDS buffer (Bio-Rad, Hercules, CA). Proteins 
were electrophoretically transferred to an Immobilon-PSQpolyvinylidene difluoride (PVDF) 
membrane (Millipore, Billerica, MA) for 1 h at 100 V in a buffer containing 30 mM Tris, 200 
mM glycine, and 20% methanol. Membranes were blocked for 1 h at room temperature 
in Odyssey blocking buffer (Odyssey, USA) and then probed with the following primary 
antibodies: anti-IRF1 (Santa Cruz Biotechnology, Dallas, TX), anti-pIRF3 at Ser 396 (EMD 
Millipore, MA, USA), anti-IRF3 (IBL, Japan), anti-IRF7 (Cell Signaling, MA, USA), anti-RIG-I 
(EMD Millipore, MA, USA), anti-IFIT1 (Thermo Fisher Scientific, Rockford, IL, USA), anti-ISG15 
(Cell Signaling Technology, Danvers, MA), anti-pSTAT1 at Tyr701 (Cell Signaling, MA, USA), 
anti-STAT1 (Cell Signaling, MA, USA), anti-STING (Novus Biologicals, Littleton, CO), anti-
DENV (Santa Cruz Biotechnology, USA), and anti-β-actin (Odyssey, USA). Antibody signals 
were detected by immunofluorescence using the IRDye 800CW and IRDye 680RD secondary 
antibodies (Odyssey, USA) and the LiCor imager (Odyssey, USA). Protein expression levels 
were determined and normalized to β-actin using ImageJ software (National Institutes of 
Health, Bethesda, MD).
CHIKV-infected cells were lysed and proteins were analyzed by Western blotting as described 
previously (69). CHIKV proteins were detected with rabbit antisera against nsP1 (a generous 
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gift of Andres Merits, University of Tartu, Estonia) and E2 (161). Mouse monoclonal antibodies 
against β-actin (Sigma), the transferrin receptor (Zymed), cyclophilin A (Abcam), and 
cyclophilin B (Abcam) were used for detection of loading controls. Biotin-conjugated swine 
α-rabbit (Dako), goat α-mouse (Dako), and Cy3-conjugated mouse α-biotin (Jackson) were 
used for fluorescent detection of the primary antibodies with a Typhoon-9410 scanner (GE 
Healthcare).
RT-qPCR. Total RNA was isolated from cells using an RNeasy kit (Qiagen, Valencia, CA) per 
the manufacturer’s instructions. RNA was reverse transcribed using the SuperScript VILO 
cDNA synthesis kit according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA). 
PCR primers were designed using Roche’s Universal Probe Library Assay Design Center 
(Roche). Quantitative reverse transcription-PCR (RT-qPCR) was performed on a LightCycler 
480 system using LightCycler 480 probes master (Roche, Penzberg, Germany). All data 
are presented as a relative quantification with efficiency correction based on the relative 
expression of target gene versus glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
as the invariant control. The N-fold differential mRNA expression of genes in samples was 
expressed as 2ΔΔCT. Primers used in this study were the following: DENV2 (probe 5) forward, 
5′-ATCCTCCTATGGTACGCACAAA-3′; reverse, 5′-CTCCAGTATTATTGAAGCTGCTATCC-3′; GAPDH 
(probe 60) forward, 5′-AGCCACATCGCTCAGACAC-3′; reverse, 5′-GCCCAATACGACCAAATCC-3′; 
IFNA2 (probe 49) forward, 5′-AATGGCCTTGACCTTTGCTT-3′; reverse, 
5′-CACAGAGCAGCTTGACTTGC-3′; IFNAR1 (probe 65) forward, 5′-ATTTACACCATTTCGCAAAGC-3′; 
reverse, 5′-CACTATTGCCTTATCTTCAGCTTCTA-3′; IFNAR2 (probe 87) forward, 
5′-TAGCCTCCCCAAAGTCTTGA-3′; reverse, 5′-AAATGACCTCCACCATATCCA-3′; IFNB1 (probe 20) 
forward, 5′-CTTTGCTATTTTCAGACAAGATTCA-3′; reverse, 5′-GCCAGGAGGTTCTCAACAAT-3′; 
ILA (probe 66) forward, 5′-TGACGCCCTCAATCAAAGTA-3′; reverse, 
5′-TGACTTATAAGCACCCATGTCAA-3′; IL-6 (probe 7) forward, 5′-CAGGAGCCCAGCTATGAACT-3′; 
reverse, 5′-GAAGGCAGCAGGCAACAC-3′; IL28RA (probe 12) forward, 
5′-CCCCCACTGGATCTGAAGTA-3′; reverse, 5′-GAGTGACTGGAAATAGGGTCTTG-3′; IL-29 (probe 
75) forward, 5′-CCTGAGGCTTCTCCAGGTG-3′; reverse, 5′-CCAGGACCTTCAGCGTCA-3′; TNFA 
(probe 79) forward, 5′-GACAAGCCTGTAGCCCATGT-3′; reverse, 5′-TCTCAGCTCCACGCCATT-3′.
RNA isolation, denaturing agarose electrophoresis, and in-gel hybridization. CHIKV 
RNA isolation and analysis were performed essentially as described previously (69). Briefly, 
total RNA was isolated by lysis in 20 mM Tris-HCl (pH 7.4), 100 mM LiCl, 2 mM EDTA, 5 mM 
dithiothreitol (DTT), 5% (wt/vol) lithium dodecyl sulfate, and 100 μg/ml proteinase K. After acid 
phenol (Ambion) extraction, RNA was precipitated with isopropanol, washed with 75% ethanol, 
and dissolved in 1 mM sodium citrate (pH 6.4). RNA samples were separated in 1.5% denaturing 
formaldehyde-agarose gels using the morpholinepropanesulfonic acid (MOPS) buffer 
system. RNA molecules were detected by direct hybridization of the dried gel with 32P-labeled 
oligonucleotides. CHIKV genomic and subgenomic RNAs (sgRNAs) were visualized with 
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probe CHIKV-hyb4 (5′-TGTGGGTTCGGAGAATCGTGGAAGAGTT-3′), and negative-stranded 
RNA was detected with probe CHIKV-hyb2 (5′-AACCCATCATGGATCCTGTGTACGTGGA-3′). 
Probes (10 pmol) were labeled with 10 μCi [γ-32P]ATP (PerkinElmer). Prehybridization (1 h) 
and hybridization (overnight) were done at 55°C in 5× SSPE (0.9 M NaCl, 50 mM NaH2PO4, 5 
mM EDTA, pH 7.4), 5× Denhardt’s solution, 0.05% SDS, and 0.1 mg/ml homomix I. Storage 
Phosphor screens were exposed to hybridized gels and scanned with a Typhoon-9410 
scanner (GE Healthcare), and data were quantified with Quantity One v4.5.1 (Bio-Rad).
Statistical analysis. Values were expressed as the means ± standard errors of the means 
(SEM), and statistical analysis was performed with Microsoft Excel using an unpaired, two-





5′pppRNA inhibits DENV infection. To determine the capacity of the 5′pppRNA RIG-I agonist 
to induce a protective antiviral response to DENV infection, A549 cells were challenged with 
DENV at different multiplicities of infection (MOI); infection and replication were monitored 
by flow cytometry, RT-qPCR, plaque assay, and immunoblotting (Fig. 1A  to  F). DENV 
established infection in A549 cells which was completely abrogated in cells pretreated with 1 
ng/ml of 5′pppRNA (Fig. 1A). A similar antiviral effect was observed at higher concentrations 
of 5′pppRNA (10 ng/ml). Importantly, the antiviral effect was strictly dependent on the 
5′ppp moiety, as transfection of cells with the identical RNA sequence lacking the 5′ppp 
did not prevent DENV infection (Fig. 1B). Pretreatment of cells with 5′pppRNA also led to 
an 8.5-fold decrease in DENV RNA synthesis (Fig. 1C). Release of infectious DENV was 
completely suppressed by 5′pppRNA treatment (4.3 × 106 PFU/ml in untreated cells versus 
undetectable in 5′pppRNA-treated cells) (Fig. 1D), leading to a complete inhibition of DENV E 
protein expression (Fig. 1D, lane 3). To compare the effect of 5′pppRNA to that of the dsRNA 
ligand poly(I:C), A549 cells were pretreated with 5′pppRNA or poly(I:C) (0.1 to 1 ng/ml) and 
subsequently challenged with DENV (Fig. 1E). Treatment with 1 ng/ml of 5′pppRNA almost 
completely suppressed DENV infection, whereas at the same concentration, only a 1.8-fold 
decrease of the number of DENV-infected cells was observed upon poly(I:C) treatment (Fig. 
1E). Cytosolic delivery of dsRNA by transfection was required in A549 cells, as demonstrated 
by the absence of a protective antiviral effect in cells in medium to which 5 μg/ml of 
5′pppRNA or poly(I:C) had just been added (Fig. 1E). To determine whether pretreatment 
with 5′pppRNA maintained a protective effect, A549 cells were transfected with 5′pppRNA 
prior to DENV challenge and the virus was allowed to replicate up to 72 h p.i. (Fig. 1F). The 
combination treatment completely inhibited DENV infection at all time points for up to 72 h 
p.i. (Fig. 1F). The viability of uninfected cells and cells protected from infection by 5′pppRNA 
was indistinguishable (Fig. 1G). Altogether, these results demonstrate the antiviral potential 
of 5′pppRNA against DENV infection in nonimmune cells. 
To assess the potential of 5′pppRNA as a post-infection treatment, A549 cells were first infected 
with DENV, subsequently treated with the RIG-I agonist at 4 h and 8 h after infection, and 
analyzed 48 h later to detect DENV infection. Interestingly, infection was almost completely 
inhibited even when cells were treated at 8 h p.i., as shown by the 12.4-fold reduction of 
the number of DENV-infected cells (Fig. 2A). This suggests that as DENV replicates over time, 
5′pppRNA prevents further spread of the virus by protecting uninfected cells and clearing 
virus from infected cells. The observed effects of 5′pppRNA on DENV infection were confirmed 
by RT-qPCR, yielding a 3.6-fold (+4 h) and 10.8-fold (+8 h) decrease in DENV viral RNA levels at 
48 h p.i. (Fig. 2B). Cell viability was not significantly affected by a 24-h 5′pppRNA treatment, 
and an ~20% decrease in viability was observed at 48 h p.i. in cells protected from infection 
by 5′pppRNA (Fig. 2C and D).
To investigate the antiviral response triggered by 5′pppRNA, various signaling parameters 
were monitored by immunoblotting and RT-qPCR in cells treated with increasing doses of 
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5′pppRNA in the presence or absence of DENV infection (Fig. 2E and F). Interferon signaling 
was detected by immunoblotting in 5′pppRNA-treated cells, both in the presence or absence 
of DENV, as demonstrated by increased STAT1 Tyr701 phosphorylation and ISG expression 
of STAT1, RIG-I, and IFIT1 (Fig. 2E, lanes 2 to 8). Although DENV can evade the host innate 
response (325-327), we did not observe a significant inhibition of IFN signaling based on the 
expression of antiviral markers STAT1, RIG-I, and IFIT1 in infected or uninfected cells (Fig. 
2E, lanes 2 to 8). 5′pppRNA treatment elicited a strong antiviral response in uninfected and 
DENV-infected A549 cells (Fig. 2E), and delivery of 5′pppRNA at 4 h p.i. potently stimulated 
type I IFN and inflammatory responses via the upregulation of genes, such as those of IFN-α, 
IFN-β, IL-6, and IL-1α (Fig. 2F). 
5′pppRNA-restricted DENV infection requires an intact RIG-I pathway. Introduction of 
RIG-I siRNA (10 and 30 pmol) into A549 cells severely reduced RIG-I as well as IFIT1 induction 
in response to 5′pppRNA treatment (Fig. 3A, lanes 5 to 8). Induction of the type I and type 
III IFNs, as well as the inflammatory response, were all dependent on intact RIG-I signaling, 
since the mRNA levels of IFN-β, IFN-α, IL-29, and tumor necrosis factor alpha (TNF-α) were 
drastically decreased in the absence of a functional RIG-I sensor (Fig. 3B). To explore the 
respective involvement of RIG-I, TLR3, and MDA5 in the 5′pppRNA-mediated anti-DENV 
effect, the expression of these immune sensors was knocked down in A549 cells by siRNA 
(Fig. 3C). While impairing RIG-I expression completely suppressed the 5′pppRNA-mediated 
antiviral effect, this was not the case upon knockdown of TLR3/MDA5 (Fig. 3C). The efficacy 
of poly(I:C) in preventing DENV infection was reduced to a larger extent in the absence of 
TLR3/MDA5 than in the absence of RIG-I, suggesting a predominant role for TLR3/MDA5 in 
mediating poly(I:C) antiviral effect in A549 cells (Fig. 3C). To demonstrate that the antiviral 
activity of 5′pppRNA against DENV relies on a functional RIG-I axis, the expression of RIG-I, 
STING, MAVS, and TBK1 was depleted in A549 cells using specific siRNAs. In addition, suitable 
knockout MEFs were used (Fig. 3D to F). Following 5′pppRNA treatment, DENV viral replication 
was assessed by flow cytometry. Whereas ~35% of A549 cells were infected with DENV in 
the untreated population, the absence of RIG-I led to an ~1.5-fold increase in the number 
of infected cells (Fig. 3D). Transient knockdown of RIG-I resulted in the abrogation of the 
protective response induced by 5′pppRNA in control cells (Fig. 3D), whereas the absence of 
STING did not affect DENV infection and did not significantly reduce the 5′pppRNA-induced 
antiviral response (Fig. 3D). Similar results were observed with A549 cells depleted for the 
mitochondrial adaptor MAVS; depletion of MAVS strongly reduced the 5′pppRNA-mediated 
protective antiviral response (Fig. 3E). Finally, TBK1-deficient MEFs were more susceptible 
to DENV infection than wild-type MEFs and were not responsive to the 5′pppRNA treatment, 
as demonstrated by the high level of DENV infection (Fig. 3F). In conclusion, 5′pppRNA 




Figure 1. Pretreatment with 5′pppRNA inhibits DENV replication  in vitro. (A and B) A549 cells were 
pretreated with various concentrations of 5′pppRNA (0.01 to 10 ng/ml) or control (Ctrl) RNA lacking the 
5′ppp at the same concentrations for 24 h prior to DENV challenge. The percentage of DENV-infected cells 
was determined by intracellular staining (ICS) of DENV E protein expression using flow cytometry. Data 
are from two independent experiments performed in triplicate and represent the means ± SEM. *, P < 
0.05. FSC, forward scatter. (C and D) A549 cells were pretreated with 5′pppRNA (1 ng/ml) for 24 h prior 
to DENV challenge (MOI, 0.1). DENV RNA level (C), viral titers (D), and DENV E protein expression level 
(D) were determined by RT-qPCR, plaque assay, and Western blotting, respectively. Error bars represent 
SEM from three independent samples. *, P < 0.05. One representative DENV E protein Western blot out 
of three independent triplicates is shown. (E) A549 cells were transfected using Lipofectamine (Lipo.) 
RNAiMax with increasing concentrations of 5′pppRNA and poly(I:C) (0.1 to 1 ng/ml) or treated with the 
same dsRNA sequences (5,000 ng/ml) in the absence of transfection reagent. Cells were then challenged 
with DENV (MOI, 1), and the percentage of infected cells was determined by FACS 24 h after infection. 
Data are the means ± SEM from two independent experiments performed in triplicate. *, P < 0.05. (F and 
G) The percentage of A549 DENV-infected cells and cell viability were assessed by flow cytometry and 
determined at 24 h (black bars), 48 h (gray bars), and 72 h (white bars) after DENV challenge (MOI, 0.01). 
Cells were pretreated with 5′pppRNA (1 ng/ml) for 24 h before DENV challenge. Data are the means ± SEM 
from a representative experiment performed in triplicate. *, P < 0.05.
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5′pppRNA generates an IRF3-dependent and IFNAR/STAT1-independent antiviral 
protective effect. To determine whether the potent RIG-I activation could compensate for 
the type I and type III IFN response, expression of the type I IFN receptor (IFN-α/βR) as well 
as the type III IFN receptor (IL-28R plus IL-10Rβ) was knocked down using siRNA in A549 cells 
(Fig. 4A to C). Expression of both type I and III IFN receptor was efficiently reduced, as shown 
by the downregulation of IFNAR1 (IFN-α/βR α chain), IFNAR2 (IFN-α/βR β chain), and IL-28R 
mRNA expression levels (Fig. 4A). Furthermore, knockdown of type I IFN signaling was highly 
efficient, as demonstrated by the reduction of IFIT1 and RIG-I induction following IFN-α2b 
stimulation (6.2-fold reduction of IFIT1 versus control siRNA [siCTRL]; Fig. 4B, lane 3 versus 
lane 6). Knocking down the type III IFN receptor did not interfere with the ability of 5′pppRNA 
and IFN-α2b to induce IFIT1 and RIG-I expression Fig. 4B, lanes 2 and 3 versus lanes 8 and 9). 
Interestingly, induction of IFIT1 but not RIG-I was only partially reduced following 5′pppRNA 
treatment in the absence of type I IFN receptor (1.6-fold reduction of IFIT1 versus siCTRL; Fig. 
4B, lane 2 versus lane 5), suggesting that certain ISGs were upregulated by 5′pppRNA in an 
IFN-independent manner. Knocking down expression of both type I and type III IFN receptors 
did not limit IFIT1 induction by 5′pppRNA, as the increase of IFIT1 was only reduced 1.9 times 
compared to the siRNA control (Fig. 4B). This type I and III IFN-independent activation of 
the innate system was sufficient to suppress DENV infection in A549 cells stimulated with a 
higher (10 ng/ml) but not a low dose (0.1 to 1 ng/ml) of 5′pppRNA (Fig. 4C). To further confirm 
that type I IFN signaling was not necessarily required to mediate an immune response to 
5′pppRNA, STAT1 was depleted in A549 cells using siRNA (Fig. 4D, lanes 5 to 8). The increased 
expression of IFIT1 following 5′pppRNA treatment was not impacted by the absence of the 
STAT1 transcription factor (Fig. 4D, lanes 2 to 4 versus lanes 6 to 8). The STAT1-independent 
induction of the antiviral response was sufficient to block DENV infection in A549 cells 
stimulated with a high 5′pppRNA concentration (Fig. 4E). Finally, to determine which IRF 
transcription factor downstream of RIG-I was involved in the antiviral protective effect, 
IRF1, IRF3, and IRF7 expression was knocked down using siRNA (Fig. 4F). Depletion of these 
different transcription factors was highly efficient, as shown in Fig. 4F. Only IRF3 knockdown 
resulted in inhibition of the protective antiviral response generated by 5′pppRNA treatment. 
Indeed, the absence of either IRF1 or IRF7 did not impair 5′pppRNA-mediated antiviral 
protection (Fig. 4G). Altogether, these data demonstrate that the 5′pppRNA-mediated anti-
DENV effect in vitro is largely independent of the type I or type III IFN responses but requires 
the activation of a functional RIG-I/IRF3 axis to mediate its protective effect.
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Figure 2. Post-infection treatment with 5′pppRNA inhibits de novo DENV infection. (A) A549 cells were 
treated with 5′pppRNA (1 ng/ml) 4 h (black bars) or 8 h (gray bars) following DENV challenge (MOI, 
0.01). The percentage of DENV-infected cells was determined by intracellular staining (ICS) of DENV E 
protein expression using flow cytometry at 48 h after infection. Data represent the means ± SEM from a 
representative experiment performed in triplicate. *, P < 0.05. (B) DENV RNA levels were determined by 
RT-qPCR (48 h after infection) on A549 cells treated with 5′pppRNA (1 ng/ml) 4 h (black bars) and 8 h (gray 
bars) after infection. *, P < 0.05. (C and D) Cell viability of A549 cells was measured by flow cytometry 24 h 
(black bars) and 48 h (gray bars) after infection. Cells were treated with 5′pppRNA 4 h after DENV infection. 
Data are the means ± SEM from a representative experiment performed in triplicate. (E) A549 cells were 
challenged with DENV (MOI, 0.1) for 4 h and transfected with 5′pppRNA (0.1 to 10 ng/ml) and incubated 
for an additional 20 h. Whole-cell extracts (WCEs) were prepared and subjected to immunoblot analysis 
24 h post-infection. Data are from one representative experiment. (F) A549 cells were infected with 
DENV at different MOI and were transfected with 5′pppRNA (1 ng/ml) 4 h after infection. The expression 
level of genes was determined by RT-qPCR 24 h after DENV challenge. Data are the means ± SEM from a 
representative experiment performed in triplicate. *, P < 0.05.
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Figure 3. 5′pppRNA inhibits DENV infection  in vitro  in a RIG-I/MAVS/TBK1-dependent manner. (A) A549 
cells were transfected with control or RIG-I siRNA (10 or 30 pmol), and 48 h later they were treated with 
5′pppRNA (10 ng/ml) for 24 h. Expression of IFIT1, RIG-I, and β-actin was evaluated by Western blotting. 
RIG-I knockdown and impairment of the 5′ppp-induced immune response is representative of at least 3 
independent experiments. (B) A549 cells were transfected with control siRNA or RIG-I siRNA (30 pmol), 
and 48 h later they were treated with 5′pppRNA (10 ng/ml) for 24 h. mRNA expression level of IFN-β, 
IFN-α, TNF-α, and IL-29 was evaluated by RT-qPCR. Data are from a representative experiment performed 
in triplicate and show the means ± SEM. *, P < 0.05. (C) A549 cells were transfected with control (black 
bars), RIG-I (gray bars), or a combination of TLR3/MDA5 (white bars) siRNA (30 pmol each), and 48 h 
later they were treated with 5′pppRNA (10 ng/ml) or poly(I:C) (1 ng/ml). Cells were then infected with 
DENV (MOI, 0.5), and at 24 h p.i. the percentage of infected cells was assessed by intracellular staining of 
DENV E protein using flow cytometry. Data are from a representative experiment performed in triplicate 
and show the means ± SEM. *, P < 0.05. (D and E) A549 cells were treated with 5′pppRNA (0.1 to 10 ng/
ml) for 24 h 2 days after transfection with 30 pmol of control (black bars), RIG-I (gray bars), or STING 
Chapter 6
128
(white bars) siRNA (D) or with 30 pmol of control (black bars) or MAVS (gray bars) siRNA (E). Cells were 
then challenged with DENV (MOI, 0.1) for 24 h. The percentage of DENV-infected cells was determined 
by intracellular staining of DENV E protein and flow cytometry 24 h after infection. Data are the means 
± SEM from a representative experiment performed in triplicate. *, P < 0.05. (F) TBK1+/+ (black bars) and 
TBK1−/− (gray bars) MEF cells were treated with 10 ng/ml of 5′pppRNA 24 h before DENV challenge at an 
MOI of 5. The percentage of DENV-infected cells was evaluated by flow cytometry. Data are the means ± 
SEM of a representative experiment performed in triplicate. *, P < 0.05.
Figure 4. 5′pppRNA-induced antiviral effect is IRF3 dependent but IFNAR and STAT1 independent. 
(A) A549 cells were transfected with control, IFN-α/βR α chain (IFNAR1), IFN-α/βR β chain (IFNAR2), or 
IL-28R siRNA, and 48 h later mRNA levels of IFNAR1, IFNAR2, and IL-28R were evaluated by RT-qPCR. Data 
are from a representative experiment performed in triplicate. *, P < 0.05 (B) A549 cells were transfected 
with the control siRNA, IFN-α/βR or IL-28R siRNA, or a combination of both. After 48 h, cells were treated 
with 5′pppRNA (10 ng/ml) or IFN-α2b (100 UI/ml) for 24 h. Expression of IFIT1, RIG-I, and β-actin was 
evaluated by Western blotting. The evaluation of 5′ppp-induced immune response by Western blotting 
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in the absence of type I IFN receptor, representative of three independent experiments, and in the 
absence of type III IFN receptor, representative of one experiment. (C) After siRNA knockdown of IFN-α/
βR as described for panel B, cells were treated with increasing concentrations of 5′pppRNA (0.1 to 10 
ng/ml) and then infected with DENV (MOI, 0.1). The percentage of DENV-infected cells was evaluated by 
flow cytometry. Data are the means ± SEM of a representative experiment performed in triplicate. *, P < 
0.05. (D) A549 cells were transfected with control and STAT1 siRNA, and 48 h later they were treated with 
5′pppRNA (0.01 to 1 ng/ml) for 24 h. Expression of STAT1, IFIT1, and β-actin was evaluated by Western 
blotting. The induction of 5′ppp-induced immune response in the absence of STAT is representative of 
two independent experiments. (E) A549 cells were transfected with control or STAT1 siRNA and incubated 
for 48 h. Cells were treated with increasing concentrations of 5′pppRNA (0.1 to 10 ng/ml) and then infected 
with DENV (MOI, 0.1). The percentage of DENV-infected cells was evaluated by flow cytometry. Data are 
the means ± SEM from a representative experiment performed in triplicate. *,  P  < 0.05. (F) A549 cells 
were transfected with control, IRF1, IRF3, or IRF7 siRNA for 48 h, and the protein expression level of these 
transcription factors was evaluated by Western blotting. This panel is representative of one experiment. 
(G) A549 cells were transfected with control IRF1, IRF3, or IRF7 and then treated as described for panel E. 
The percentage of DENV-infected cells was evaluated by flow cytometry. Data are the means ± SEM from 
a representative experiment performed in triplicate. *, P < 0.05.
A protective antiviral response against DENV in primary human myeloid cells. Cells of 
the myeloid lineage, including monocyte/macrophages and dendritic cells, are the primary 
target cells for DENV infection among human peripheral blood mononuclear immune cells 
(328, 329). Severe and potentially lethal manifestations associated with secondary DENV 
infection are often related to antibody-dependent enhancement (ADE) of infection (320-322). 
To address the impact of 5′pppRNA on ADE-mediated DENV infection, we demonstrated, 
using isolated human monocytes, that anti-DENV E 4G2 antibody increased DENV infectivity 
from 16.4% to 24.4% (Fig. 5A), whereas a control isotype IgG2a antibody did not significantly 
increase viral infectivity (Fig. 5A). Both primary and ADE DENV infections were completely 
suppressed by 5′pppRNA treatment (16.4% and 24.4% in untreated cells versus 0.1% and 0.3% 
in 5′pppRNA-treated cells, respectively). Similarly, in primary human MDDC, which are highly 
permissive to DENV, infection decreased 8.4-fold in the presence of 5′pppRNA in combination 
with Lyovec (Fig. 5B), and cell viability was not affected by increasing concentrations of 
5′pppRNA (Fig. 5C). MDDC treated with 5′pppRNA at 4 h p.i. were assessed for markers of 
activation of the innate immune response (Fig. 5D). Increased levels of phosphorylated 
IRF3 and STAT1 were observed, and a 2- to 10-fold increase in the expression of ISGs RIG-I 
and IFIT1 following 5′pppRNA treatment were observed (Fig. 5D, lane 2). A similar response 
was observed with DENV infection alone (Fig. 5D, lane 3). The innate DNA sensor STING was 
previously shown to be cleaved and inactivated by DENV NS2/3 protease (325); in the current 
experiments, STING expression was not modulated by 5′pppRNA or DENV infection alone 
(Fig. 5D, lane 2 and 3). Also, post-infection treatment with 5′pppRNA moderately increased 
the levels of the following markers of the innate immune response compared to virus alone: 
phospho-STAT1 (3-fold increase), STAT1 (1.4-fold increase), IFIT1 (1.3-fold increase), and RIG-I 
(1.3-fold increase) (Fig. 5D, lanes 3 and 4). Surprisingly, 5′pppRNA did not further increase the 
level of phospho-IRF3 compared to DENV infection alone (Fig. 5D, lane 3 and 4), an observation 
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Figure 5. 5′pppRNA treatment protects human myeloid cells from primary and ADE DENV infection. 
(A) Negatively selected monocytes were challenged with DENV (MOI, 20) in the presence or absence of 
the enhancing antibody 4G2 (0.5 μg/ml) for 4 h. They were subsequently transfected with 5′pppRNA 
(100 ng/ml) using Lyovec and incubated for 20 h. An IgG2a antibody (0.5 μg/ml) served as a negative 
control. The percentage of DENV-infected cells was determined by flow cytometry 24 h after infection. (B) 
CD14− MDDCs were challenged with DENV (MOI, 10) for 4 h, followed by transfection with 5′pppRNA (100 
ng/ml) and incubation for an additional 20 h. Data represent the means ± SEM of an experiment performed 
in triplicate. *, P < 0.05. (C) Cell viability was assessed by flow cytometry on CD14− MDDC and determined 
24 h after 5′pppRNA treatment (10 to 500 ng/ml) in the presence of Lyovec. Data are the means ± SEM of 
a representative experiment performed in triplicate. (D) CD14− MDDCs were challenged with DENV (MOI, 
10) for 4 h and then were treated with 5′pppRNA (100 ng/ml) for an additional 20 h. WCEs were resolved by 
SDS-PAGE and analyzed by immunoblotting for phospo-IRF3, IRF3, phospho-STAT1, STAT1, IFIT1, RIG-I, 
STING, and β-actin. Results are from one representative experiment that was repeated once.
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that is in part attributable to the early and transient kinetics of IRF3 phosphorylation. These 
data demonstrate that RIG-I activation by 5′pppRNA triggers an immune response capable of 
inhibiting DENV in both primary and ADE models of infection.
5′pppRNA treatment inhibits CHIKV replication in a RIG-I-dependent manner. To 
explore the potential of the 5′pppRNA agonist to prevent CHIKV infection, human fibroblast 
MRC-5 cells were pretreated with increasing concentrations of 5′pppRNA prior to challenge 
with a CHIKV LS3-GFP reporter virus (Fig. 6A). CHIKV replication was strongly inhibited in a 
dose-dependent manner in cells treated with 5′pppRNA 1 h prior to infection (Fig. 6A); as little 
as 1 ng/ml completely blocked CHIKV EGFP reporter gene expression, and the 5′pppRNA 
concentration required to completely block CHIKV replication in MRC-5 cells was 10-fold 
lower than that required to inhibit DENV in A549 cells. It is currently unclear whether this 
is due to virus-specific immune evasion or cell type-specific differences, as CHIKV does 
not replicate in A549 cells. Also, introduction of control RNA lacking the 5′ triphosphate 
moiety only led to a minor reduction of GFP reporter gene expression in CHIKV LS3-GFP-
infected cells (Fig. 6A). Cell viability, monitored in parallel, was not significantly affected by 
transfection of either 5′pppRNA or control RNA lacking the 5′ triphosphate (Fig. 6B). Analysis 
of intracellular RNA of CHIKV-infected cells pretreated with 5′pppRNA or control RNA showed 
that treatment with 0.1 ng/ml 5′pppRNA reduced CHIKV positive- and negative-strand RNA 
accumulation to minimally detectable levels (Fig. 6C), and at higher doses of 5′pppRNA 
viral RNA was undetectable. Transfection of cells with control RNA prior to infection had 
no significant effect on the accumulation of CHIKV RNA (Fig. 6C). To determine the effect of 
RIG-I agonist treatment on the expression of CHIKV nonstructural proteins (translated from 
genomic RNA) and structural proteins (translated from the sgRNA), cells were pretreated with 
5′pppRNA or control RNA and infected with CHIKV, and nsP1 and E2 expression was analyzed 
by Western blotting (Fig. 6D). Transfection of 0.1 ng/ml 5′pppRNA led to a 4-fold reduction 
in nsP1 expression and an 8-fold reduction in E2 expression. Higher doses of 5′pppRNA 
reduced nsP1 and E2 expression over 30-fold (Fig. 6D). Transfection of control RNA lacking 
the 5′ triphosphate had no noticeable effect on CHIKV protein expression (Fig. 6D). Finally, 
the effect of 5′pppRNA treatment on the production of infectious progeny was determined. 
Compared to untreated cells, transfection of MRC-5 cells with 0.1 ng/ml of 5′pppRNA 1 h prior 
to CHIKV infection led to an ~1 log reduction in virus titer, while transfection with 1 ng/ml 
and 10 ng/ml 5′pppRNA reduced viral progeny titers by ~2 and ~3 logs, respectively (Fig. 
6E). Transfection of control RNA lacking the 5′ triphosphate did not significantly affect CHIKV 
progeny titers (Fig. 6E).
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Figure 6. Treatment with 5′pppRNA inhibits CHIKV replication in a RIG-I-dependent manner. (A) MRC-
5 cells were treated with 0.015 to 4 ng/ml of control RNA or 5′pppRNA from 1 h prior to infection to 24 
h post-infection with CHIKV LS3-GFP (MOI, 0.1). At 24 h p.i., cells were fixed and EGFP reporter gene 
expression was quantified. *,  P  < 0.05. cntrl, control. (B) To assess potential cytotoxicity, MRC-5 cell 
viability was measured 24 h posttransfection of 5′pppRNA or control RNA lacking the 5′ triphosphate. 
Data are represented as the means ± SEM from a representative experiment performed in quadruplicate. 
(C) The intracellular accumulation of CHIKV positive- and negative-strand RNA was determined by in-gel 
hybridization of RNA isolated from MRC-5 cells that were treated with 5′pppRNA (0.1 to 10 ng/ml) 1 h prior 
to infection (MOI, 0.1). (D) CHIKV E2, E3E2, and nsP1 protein expression was assessed by Western blotting 
of lysates of MRC-5 cells that were treated with various concentrations of control RNA or 5′pppRNA 1 h prior 
to infection with CHIKV. Data are representative of at least two independent experiments. (E) The effect 
of 5′pppRNA and control RNA treatment on CHIKV progeny titers as assessed by plaque assay. (F) siRNA-
transfected MRC-5 cells were either left untreated or were transfected with 5′pppRNA, after which they 
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were infected with CHIKV LS3-GFP (MOI, 0.1). CHIKV-driven EGFP reporter gene expression was measured 
at 24 h p.i. and was normalized to the expression level in CHIKV-infected cells that had been transfected 
with a nontargeting scrambled siRNA (scr). *, P < 0.05. (G) MRC-5 cells were transfected with 10 pmol of 
scrambled siRNA (siScr) or siRNA targeting RIG-I, STAT1, or STING 48 h prior to treatment with 1 ng/ml 
of 5′pppRNA. Expression levels of RIG-I, STAT1, STING, and IFIT1 were monitored by Western blotting. 
Cyclophilin A or B was used as a loading control. Data are representative of at least two independent 
experiments.
To determine which innate immune pathways are involved in the 5′pppRNA-mediated 
inhibition of CHIKV replication, several key proteins of the IFN signaling pathway (RIG-I, STAT1, 
and STING) were depleted in MRC-5 cells using siRNAs. Knockdown levels were assessed 
by Western blotting (Fig. 6G). Subsequently, cells depleted for RIG-I, STAT1, or STING were 
treated with 5′pppRNA and infected 1 h later with CHIKV LS3-GFP (Fig. 6F). CHIKV-driven 
GFP reporter gene activity was reduced to almost background levels in 5′pppRNA-treated 
cells that were depleted for STAT1 and STING, suggesting these proteins are not involved 
in the 5′pppRNA-mediated antiviral response to CHIKV. In contrast, CHIKV replication was 
observed in cells depleted of RIG-I and treated with 5′pppRNA, although EGFP reporter gene 
expression was ~30% of that in untreated cells transfected with scrambled (or RIG-I-targeting) 
siRNAs (Fig. 6F). This partial recovery of replication might be due to incomplete knockdown 
of RIG-I in a fraction of the cells and/or paracrine IFN signaling of those cells, which could 
affect CHIKV replication of RIG-I-depleted cells. CHIKV replication in cells depleted for RIG-I, 
STAT1, or STING, but not treated with 5′pppRNA, was similar or slightly increased compared 
to that of cells transfected with a scrambled control siRNA. In parallel, the siRNA-treated 
cells were transfected with 1 ng/ml 5′pppRNA, and 24 h later the IFN signaling response 
was analyzed by monitoring the upregulation of IFITI or STAT1 (Fig. 6G). Knockdown of RIG-I 
expression resulted in a strong reduction of 5′pppRNA-induced IFITI upregulation, whereas 
the 5′pppRNA-induced upregulation of IFITI was not affected by STAT1 depletion. siRNA-
mediated knockdown of STING also did not block the 5′pppRNA-induced upregulation of 
STAT1, indicating that STAT1 and STING are dispensable for the response to 5′pppRNA, 
whereas RIG-I is required.
Post-infection treatment with 5′pppRNA inhibits CHIKV replication and stimulates 
the RIG-I pathway in both uninfected and CHIKV-infected cells. To explore the antiviral 
potential of 5′pppRNA against CHIKV, MRC-5 cells were first infected with CHIKV LS3-GFP at 
an MOI of 0.1, followed by transfection with 5′pppRNA (1 ng/ml) or control RNA at several 
time points post-infection. Measurement of EGFP expression by the reporter virus in infected 
MRC-5 cells that were fixed at 24 h p.i. indicated that treatment with 5′pppRNA at 1 or 3 h p.i. 
reduced reporter gene expression to less than 20% of that in untreated infected control cells 
(Fig. 7A). Even when treatment was initiated as late as 5 h p.i., a more than 50% reduction in 
EGFP expression was observed (Fig. 7A). Transfection of control RNA merely led to a ~20% 
reduction in EGFP reporter gene expression, largely independent of the time of addition. 
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Figure 7. Post-infection treatment with 5′pppRNA inhibits CHIKV replication in an addition-dependent 
manner. MRC-5 cells were infected with CHIKV LS3-GFP at an MOI of 0.1, and at the indicated time points 
post-infection they were transfected with 1 ng/ml 5′pppRNA or control RNA. (A) Cells were fixed at 24 h 
p.i., and EGFP reporter gene expression was quantified and normalized to that in untreated cells. *, P < 
0.05. (B) CHIKV progeny titers 24 h p.i. and after 5′pppRNA or control RNA treatment were determined by 
plaque assay. (C) MRC-5 cells were transfected with 0.1, 1, or 10 ng/ml 5′pppRNA or control RNA 1 h prior 
to infection with CHIKV LS3-GFP (MOI, 0.1). At 24 h p.i., cell lysates were prepared and STAT1, RIG-I, and 
IFIT-I protein levels were determined by Western blotting. Actin or the transferrin receptor were used as 
loading controls. Data are representative of at least two independent experiments. 
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Post-infection treatment of CHIKV-infected cells with 5′pppRNA also reduced viral progeny 
titers at 24 h p.i., depending on the time of addition (Fig. 7B). CHIKV titers in the medium of 
untreated infected cells were 6 × 106 PFU/ml at 24 h p.i., while treatment from 1 h p.i. onward 
led to a more than 2-log reduction in infectious progeny, i.e., 5 × 104 PFU/ml. When treatment 
was initiated at 3, 5, or 8 h p.i., CHIKV titers of 2 × 105, 7 × 105, and 1 × 106, respectively, were 
measured at 24 h p.i. Transfection of CHIKV-infected cells with control RNA resulted in a less 
than 1-log reduction in infectious progeny titer (Fig. 7B).
To assess the activation of the RIG-I signaling pathway in MRC-5 cells after 5′pppRNA 
treatment in the presence or absence of CHIKV infection, the expression levels of STAT1, 
RIG-I, and IFIT1 were analyzed by immunoblotting (Fig. 7C). Both in mock-infected and 
CHIKV-infected cells, transfection of 0.1 ng/ml 5′pppRNA induced a strong upregulation of 
STAT1, RIG-I, and IFITI (Fig. 7C), an effect that was more pronounced with treatment of 1 or 
10 ng/ml of 5′pppRNA. In contrast, introduction of control RNA had no effect on expression 
of these proteins. CHIKV infection alone did not lead to increased STAT1, RIG-I, and IFIT1 
expression, and CHIKV infection did not inhibit the 5′pppRNA-induced upregulation of RIG-I 




The absence of directly acting antivirals and registered vaccines for the treatment of important 
human pathogens, such as DENV and CHIKV, has emphasized the need for the development 
of therapeutic strategies. Initiated within minutes of virus binding to target cells, the innate 
immune response is the first natural barrier against viral infection. The innate response 
triggers an array of protective processes, resulting in the production of antiviral effectors and 
the induction of adaptive immune responses (285-288). Mimicking the early steps of the host 
antiviral response through stimulation of innate recognition receptors represents a novel 
therapeutic strategy for the treatment of emerging diseases, such as those caused by DENV 
and CHIKV.
We previously demonstrated that a 5′pppRNA derived from the 5′ and 3′ UTRs of VSV blocked 
the replication of multiple viruses both  in vitro  and  in vivo (319). In the present study, we 
further characterized the antiviral potential of 5′pppRNA and demonstrated that 5′pppRNA 
treatment restricted DENV and CHIKV infection in human myeloid, epithelial, and fibroblastic 
cells. The antiviral effect was observed when 5′pppRNA was administered both pre- and 
post-infection, with demonstrated inhibition of DENV and CHIKV protein expression, RNA 
levels, and production of infectious progeny. The  in vitro  protective antiviral effect was 
dependent on an intact RIG-I/MAVS/TBK1/IRF3 axis but largely independent of IFNAR and 
STAT1. The protective effect was sustained over time, as cells remained free from infection 
even 72 h after infection, and 5′pppRNA also blocked antibody-dependent enhancement of 
DENV infectivity, a phenomenon that is associated with complications and disease severity 
in dengue patients. The present data on the 5′pppRNA immune-stimulating effect on human 
cells, combined with previous observations demonstrating that 5′pppRNA triggered a full 
range of antiviral and inflammatory responses in serum, lungs, and spleens of treated mice 
(319), highlights the importance of evaluating the efficacy of RIG-I agonists as a potential 
immune stimulator in humans.
The type I IFN system represents an important innate antiviral response to DENV and CHIKV. 
Indeed, type I IFN has been shown to restrict the propagation of DENV and CHIKV in both in 
vitro and in vivo models. Treatment with either IFN-α or IFN-β suppressed the replication of 
both DENV (330) and CHIKV (77) in cell culture. Moreover, infection of mice lacking IFNAR led 
to a significantly higher lethality after DENV (331) or CHIKV infection (81, 332). Among the 
viral RNA sensors, RIG-I, MDA5, and TLR3 are activated upon DENV infection and are essential 
for host defense against the virus (333). RIG-I appears to play a major role in the response 
to CHIKV infection, as CHIKV-induced IFN-β expression was more strongly reduced in RIG-I-
deficient MEFs than in those lacking MDA5 (194). The antiviral activity of 5′pppRNA observed 
in previous studies has been attributed to the potent activation of inflammatory and antiviral 
programs driven by transcription factors such as IRF3, IRF7, STAT1, and NF-κB (319). In this 
study, the antiviral protective response was dependent on a functional RIG-I pathway but 
was largely independent of STAT signaling. We also demonstrated that 5′pppRNA treatment 
triggered a robust host antiviral response associated with the expression of several IFN-
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stimulated genes (ISGs), including RSAD2 (Viperin), IFIT, and IFITM proteins MX1 and 
OAS. Although hundreds of ISGs have been identified, only a few of them have been fully 
characterized with respect to their inhibitory function. Recently, Schoggins et al. identified 
a panel of broadly active antiviral molecules that facilitate inhibition of viral infection (308), 
with IFITM proteins and Viperin characterized as important ISGs required for inhibition of 
CHIKV (120, 334, 335). Although most of these essential antiviral genes were upregulated 
following RIG-I stimulation (319), an in-depth analysis is now required to identify which 
IRF3-driven ISGs mediate the 5′pppRNA antiviral effect observed against DENV and CHIKV 
infection in vitro.
Poly(I:C), another dsRNA innate immune stimulator, has been extensively studied in 
vitro and in vivo and has demonstrated a broad range of efficacy against many viral infections, 
including those by DENV and CHIKV (314, 315, 336-339). In vitro studies have shown that the 
poly(I:C)-mediated DENV antiviral response was dependent primarily on IFN-β induction 
and was reversed by IKK inhibitors (315). Poly(I:C), in combination with TLR7/8 agonists, 
not only prevented DENV infection in vitro but also decreased DENV viremia in vivo through 
increased inflammatory and humoral responses (315, 338). The immune response generated 
by poly(I:C) was previously evaluated in a phase 1 clinical trial with healthy volunteers, and 
whole-genome transcriptional analysis of peripheral blood mononuclear cells demonstrated 
upregulation of genes involved in multiple innate pathways, including antiviral and 
inflammasome signaling (340). This observation underscores the fact that synthetic dsRNA 
remains an attractive innate immune stimulator in humans.
Vaccination is the primary approach to prevent viral infection. Increasing the immunogenicity 
of vaccines with molecular immune modulators that elicit immune responses is crucial to 
enhance vaccine efficacy. Poly(I:C) and, more recently, 5′pppRNA have been used as adjuvants 
and were shown in combination with influenza vaccine to improve protection in mice (310, 
341-343). Interestingly, we observed that RIG-I activation using 5′pppRNA not only induced 
antiviral effectors but also mobilized cytokines and chemokines involved in trafficking 
processes of immune cells, including CXCL10, CCL5, and CCL3. The proinflammatory 
cytokine IL-6, which was potentiated by the 5′pppRNA treatment, also is crucial to maintain 
and potentiate CD8+ T cell survival and killing in vivo (344). A significant type III IFN response 
was observed in cells challenged with 5′pppRNA. Recent studies have shown that type I and 
III IFNs activate similar components of the JAK-STAT pathways, although type III IFNs induced 
a delayed and stronger induction of ISGs than type I IFNs (345). We did not find a significant 
antiviral role for type III IFN in DENV-infected A549 cells, although the induction of type III IFN 
may have biological relevance in vivo by bridging the innate and adaptive immune responses. 
Indeed, IL-28A stimulation presented antiviral immunostimulatory effects by increasing the 
total number of lymphocytes and CD4+ T cells in lung lymphocyte preparations of vaccinia 
virus-infected mice (346). The present study demonstrates the antiviral effect of 5′pppRNA 
but also suggests new perspectives on the use of RIG-I agonists as vaccine adjuvants in the 
context of DENV and CHIKV infection.
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Taken together, our study provides compelling evidence that stimulation of the natural 
host defense with 5′pppRNA represents a valuable alternative strategy to conventional 
antiviral drugs directed against specific viral targets. RIG-I activation mimics and stimulates 
evolutionarily conserved immune responses to infection and induces multiple antiviral 
factors that block viral infection at different steps, reducing the possible development of 
antiviral resistance. These novel approaches to boost host antiviral innate and inflammatory 
immune responses are broad spectrum in nature rather than virus specific. Such a broadly 
acting antiviral molecule may be desirable in tropical areas where the population is exposed 
to multiple pathogens, e.g., where both DENV and CHIKV are endemic and cause co-infections 
and where the facilities for (differential) diagnosis are limited.
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Identifying and understanding host factors involved in CHIKV replication
Over the past decade, the status of CHIKV has shifted from relatively uncommon and poorly 
documented to being a wide-spread emerging virus. At present, it is even considered a global 
public health concern with the potential of high morbidity and a large social impact. CHIKV 
transmission has been reported in all inhabited continents (both Americas, Europe, Africa, 
Asia, and Oceania), illustrating the rapid globalization of the virus. Especially Latin America 
may be facing large epidemics in the near future. Many infected travelers return to non-
endemic areas, providing the opportunity for local transmission and new outbreaks. Despite 
this rapid spread and the increasing social and economic burden that CHIKV poses, no 
registered vaccines or effective antiviral drugs are available. A thorough understanding of the 
viral replicative cycle will provide a better basis for the development of antiviral strategies. 
CHIKV is expected to rely heavily on cellular factors for its replication, but only a handful of 
host factors involved in CHIKV replication have been identified thus far. Research tools can 
aid in identifying these host factors and thus increase our understanding of this pathogen. 
This thesis describes the development and characterization of a novel infectious cDNA clone 
(chapter 2), and its application in a kinome-directed siRNA screen aimed at identifying host 
factors involved in CHIKV replication (chapter 3). A selection of these and other identified 
host factors were described in more detail in this thesis. The involvement of MAPK signaling 
during CHIKV replication was studied in chapter 4, and the role of stress granule components 
G3BP1 and -2 in chapter 5. Chapter 6 describes that both CHIKV and DENV replication can 
be inhibited using a RIG-I agonist (5’pppRNA), which may represent a suitable starting point 
for antiviral treatment in a clinical setting. 
Construction and characterization of a synthetic CHIKV cDNA clone 
An infectious cDNA clone is a plasmid that contains a full-length DNA copy of the viral genomic 
sequence. Infectious RNA is generated by in vitro transcription and can subsequently be 
transfected into cells to launch and recover the (mutant) virus, although in recent years also 
DNA-launched systems have been developed. Full-length cDNA clones are valuable research 
tools that enable reverse genetics and can be tailored to specific requirements. They enable 
the insertion of reporter genes and mutational analyses, for example to assess the function of 
a specific residue or viral protein, or examine mutations related to drug resistance. When we 
set out to create the synthetic infectious cDNA clone CHIKV LS3 (Leiden synthetic 3), already 
several other infectious CHIKV clones existed (e.g. (62, 69, 114-117)). However, some of these 
clones were based on older and/or different genotypes than the genotype that caused 
the major outbreak in 2005. We decided not to use a single isolate and a single sequence 
thereof as a basis for our infectious cDNA clone, but to base it on the consensus sequence 
of all deposited CHIKV genomes that contained the A226V mutation present in GenBank 
at the moment of design. The designed sequence was created by gene synthesis and the 
resulting cDNA clone was termed LS3. There is the risk that a virus based on such a consensus 




are incompatible with each other. If this would have been the case, LS3 could have easily 
been converted to the sequence of a natural isolate by introducing only a few mutations. 
The synthetic virus and its derived GFP-reporter virus were extensively characterized in cell 
culture, and they behaved very similar to natural isolate, ITA07-RA1. Also in a mouse model 
it caused a lethal infection comparable to that caused by a natural isolate (chapter 2) (69). 
The majority of previously developed CHIKV infectious clones are transcribed into genomic 
RNA using an upstream SP6 promoter. This is a strong promoter that yields high amounts 
of RNA in vitro. However, it also generates capped CHIKV RNA with a non-native 5’ terminus, 
as it will contain m7GpppG (instead of m7GpppA) at the 5’end (Figure 1). This additional 5’- 
terminal G residue will eventually be removed during subsequent passages and the virus will 
return to its native sequence, as was shown for Rubella virus (347), but it may take several 
replication cycles to achieve this. It is unclear what the exact implications of the additional 
5’-terminal G are for viral replication. We therefore placed our molecular clone under control 
of a phi2.5 promoter, which generates a genuine 5’ terminus. A disadvantage of using this 
promoter is that it is less efficient and yields lower amounts of RNA. A full-length CHIKV clone 
under control of the routinely used SP6 promoter (named CHIKV LS2) was also generated, 
and it would be interesting to compare virus derived from both constructs side-by-side to 
determine the effect of the extra 5’-terminal G on CHIKV replication. DNA-launched CHIKV 
infectious clones have been constructed that use a CMV early promoter to drive production 
of viral RNAs in the nucleus of infected cells, which results in native 5’ termini (e.g (348)).
As CHIKV spreads globally and infections are becoming increasingly common, the number 
of CHIKV-related studies is growing fast. Unfortunately, this results in a growing diversity of 
CHIKV strains being studied, ranging from the ‘old’ African S27 and Ross isolates to a myriad 
of (often ill-defined) clinical isolates. These different CHIKV variants may have different 
characteristics, potentially leading to contradictory reports. Therefore it would be advisable 
to confirm key findings with at least one other CHIKV isolate. We preferred to work with 
our consensus-based virus instead of a clone based on a single genome derived from a 
quasispecies population. The bulk of the experiments described in this thesis were performed 
with CHIKV LS3(-GFP), but frequently one or more other CHIKV strains were used to confirm 
results. In general these different CHIKV variants behaved the same, although e.g. NL10/152 
showed a delayed onset of CPE compared to other strains. This suggests that the synthetic 
virus is a good representative of the currently circulating CHIKV Indian/Indian Ocean strains 
and constitutes an appropriate tool to study various aspects of the viral replication cycle, 
including the role of host factors. 
RNAi screening to identify host factors involved in CHIKV replication 
Despite the enormous surge in CHIKV-related research efforts and publications since its 
re-emergence in 2005, its replicative cycle is still not completely elucidated. Especially 
our comprehension of the involvement of cellular components remains incomplete. 
The identification of host factors is the first step towards testing their importance for viral 
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replication. A number of host factors involved in CHIKV replication have been described (e.g. 
(118-122)), but till date large-scale RNAi approaches have not been published for CHIKV. 
Functional genomics represent an unbiased approach to identify host factors involved 
in viral replication, including siRNA (short interfering RNA) and shRNA (short hairpin RNA) 
screening, which are based on RNA interference (RNAi). RNAi is a highly conserved cellular 
process characterized by sequence-specific transcript cleavage and degradation. The 
silencing process is controlled by the RNA-induced silencing complex (RISC) and is initiated 
by short (~21-nt) dsRNA molecules, which can be introduced endogenously or exogenously. 
One strand of the dsRNA/siRNA molecule is loaded into RISC (the antisense or guide strand) 
and functions as a template for the sequence-dependent mRNA cleavage. Full sequence 
complementarity triggers enzymatic cleavage opposite of position 10 of the siRNA, and 
cleaved RNAs are degraded rapidly (349) Selective depletion of cellular mRNAs results in 
knockdown of the encoded protein. 
Like every screening approach, also siRNA-mediated knock-down of expression has its 
drawbacks. A major concern are the potential “off-target” effects of the siRNAs (imperfect 
gene targeting), which can result in false positive hits (Figure 2). Off-target effects are caused 
by the fact that siRNAs with an imperfect sequence similarity can still bind to mRNAs they 
are not intended to target (350). Imperfect sequence similarity will not lead to RISC-induced 
cleavage of the mRNA bound by the siRNA, but it will result in translational repression by 
ribosome interference (351). The risk of finding false positive hits due to off-target binding 
increases when a high concentration of siRNA is used. The likelihood of false positives due 
to off-target binding can be reduced by (a) using lower amounts of siRNA, (b) using pooled 
siRNA that target different parts of the mRNA (and thus also lower concentrations of each 
individual siRNA), or (c) separately testing several individual siRNAs that target the same gene. 
Strikingly, the reduction in off-target effect that is observed when pooled siRNA are used is 
	
Figure 1. Comparison of the 5’ termini of in vitro transcribed RNA produced with SP6 and phi2.5 promoters. 
The top line shows the 5’-end of the consensus genome sequence, based on the selected CHIKV strains 
described in the text. Minimal promoter sequences are underlined. The +1 nucleotide (transcription start) 
is indicated in bold. The CHIKV genome is shaded in grey. The products resulting from SP6 transcription 
(using a m7GpppG cap analog) and T7 transcription (using a m7GpppA cap analog) are shown. The extra 
G at the 5’-end of the genome resulting from SP6 polymerase transcription on LS2 constructs is indicated 




not only due to lower amounts of the individual siRNAs. The effect could not be reproduced 
to the same extent by using low concentrations of a single siRNA, thus indicating that it is 
rather the competition between the different siRNAs than the concentration (352). Off-target 
binding can further be reduced by chemical modifications of the siRNA, for example by 
2’-O-methylation of the guide (antisense) strand (353). The passenger (sense) strand can be 
modified to prevent interaction with RISC, and thus favor guide strand uptake (and reduce 
passenger strand-induced off-target effects). In addition, the seed region of the guide strand 
is often modified to destabilize off-target binding, hence increasing target specificity (353). 
Some siRNA can cause off-target effects by behaving as microRNA (miRNA). The latter are 
encoded by mammalian cells and resemble siRNAs in the sense that they are also short RNA 
sequences that can affect mRNA levels, using the same cellular machinery. They are involved 
in many cellular processes, but mostly play a regulatory role, as they can induce only modest 
Figure 2. Schematic overview of sequence-specific transcript depletion by RNAi. One strand of the siRNA duplex 
(guide strand) is loaded into the RISC and functions as a template for sequence-dependent transcript 
cleavage. A siRNA with perfect sequence similarity ideally targets only one transcript, and siRNA/RISC 
binding results in mRNA cleavage and degradation (left). Off-target effects are caused by siRNA that bind 
with imperfect sequence similarity, often to the 3’ UTR of mRNAs. As only limited sequence similarity is 




(~2-fold) changes in mRNA levels (354). It is striking that a single miRNA can regulate dozens 
of transcripts, thus having a widespread effect on cellular processes. siRNA can behave as 
miRNA by sequence-specific imperfect pairing with motifs that are located mostly in the 
3’UTR of an mRNA. As only short regions of sequence complementarity are required, many 
different transcripts can be affected, thus resulting in sequence-dependent miRNA-like off-
target effects (Figure 2). As with genuine miRNA binding, this interaction results in modest 
(less than 2-fold) changes of transcript levels (355). 
Another concern when utilizing siRNAs is the possible activation of the cellular innate 
immune response, which can be stimulated by either the oligonucleotides or the delivery 
method. Activation can occur through Toll-like receptors or cytoplasmic RNA sensors, such 
as RIG-I (reviewed in (356)). The degree of innate immune activation depends on the siRNA 
structure, sequence, delivery method, and cell type. It can result in the production of high 
levels of inflammatory cytokines and interferons, especially in animal models and primary 
human blood cells (357-359). Presently, siRNAs are often modified by introducing chemically 
modified nucleotides in order to avoid recognition by Toll-like receptors and other nucleic 
acid sensors (360, 361).
Taken together, off-target binding and activation of the innate immune response can result in 
false-positive hits in siRNA screens. RNAi screening can also yield the opposite: false-negative 
results. False negatives may occur when the degree of target gene knockdown is insufficient. 
This can be due to suboptimal siRNA sequences, or when the mRNA half-life is very short or 
the protein turn-over time very long. Optimization for these factors (assay timing) is often 
not possible in a large(r)-scale screen, as the optimal time frame to achieve depletion for 
the majority of the targets needs to be taken into consideration. Biological redundancy is 
another potential source of false-negative results. Parallel pathways or homologous genes 
with (partially) overlapping functions may mask the effect of target depletion. In addition, 
false negatives can occur when the targeted gene is not expressed in the cell type/line chosen 
for the experiments. The number of expressed genes in a given cell type can vary greatly, 
between ~500 genes in ovary tissue to over 6,000 in B lymphoblasts (362). The CHIKV siRNA 
screen described in chapter 3 was performed using MRC5 cells, which are lung fibroblasts. 
Assuming these cells express the same number of genes as adult lung tissue (362), about 
~3,000 genes are expressed, approximately ~15% of all genes in the human genome. This 
suggests there is some potential for false-negative results in our screen. 
Proper controls and quality control can reduce false discoveries, but can never completely 
prevent them. Therefore, it is crucial to confirm the hits (potential host factors) identified in a 
screen to exclude false discoveries. 
Whole-genome RNAi screens are feasible nowadays, but are expensive and need special 
robotic equipment. In addition, they yield enormous amounts of data, which often requires 
collaborating with data analysis experts. Many groups choose to screen a subset of the 
genome, for example the druggable genome (subset of the ~30.000 genes in the human 




describes a siRNA library screen targeting the human kinome for its potential involvement in 
CHIKV replication. Obviously, the choice to use a siRNA library targeting the human kinome is 
associated with its own merits and potential problems. The kinome is more often selected to 
identify host factors involved in viral replication (190, 191, 363, 364), because kinases play key 
roles in many, if not all, cellular processes and are therefore undoubtedly also involved in viral 
replication. However, the fact that kinases perform key functions in many cellular pathways 
also presents a problem. Depletion of a key protein may disturb a range of downstream 
signaling pathways. Therefore it can be troublesome to determine which downstream effect 
was responsible for the abrogation of viral replication. 
In recent years, quite a number of siRNA screens have been performed that aimed at 
identifying viral co-factors. However, when comparing independent RNAi screens done 
using the same virus, there is often only very limited overlap between identified targets. For 
example, between the hits of four genome-wide siRNA screens aiming to identify host factors 
in influenza A virus replication, only ~6.7% overlap was found when comparing the screens 
pairwise (193, 194, 365-367). However, there was a larger overlap when comparing the screens 
at the level of enriched categories, rather than individual genes. The same observation was 
also made for CHIKV proteomic screens (142). It is therefore speculated that the limited 
overlap is mostly due to false-negative hits, rather than false-positives (i.e. each screen 
identified a (different) fraction of truly involved proteins) (368). This is further supported by 
the observation that hits from different screens are highly connected in interaction networks 
(e.g. protein-protein interactions), at a significantly higher frequency than they would be by 
chance. This observation underscores the notion that RNAi screening is a powerful tool to 
identify host factors involved in viral replication, but that it is by no means perfect, and often 
provides only a partial answer. Confirmed hits do provide valuable starting points for further, 
in-depth studies. 
To summarize, RNAi is a powerful forward genetics tool to dissect CHIKV-host interactions, 
but needs to be used with caution. It is a relatively young technique that can be employed 
for unprecedented large-scale loss-of function studies, but also contains various potential 
drawbacks, including aspecificity of siRNA targeting, variability and incomplete knockdown, 
and a restriction to use cell lines that can be efficiently transfected and are subsequently still 
permissive to viral infection. The above-mentioned potential drawbacks of RNAi may paint 
a dark picture of the benefits of using RNAi screening; however, it is a tremendously versatile 
tool, if used with caution. RNAi enables loss-of-function studies at a scale and with an ease 
that cannot be achieved using mouse embryonic fibroblasts (MEFs) or other loss-of-function 
techniques. In addition, it allows the identification of host proteins that are either directly 
or indirectly involved in CHIKV replication, in contrast to other techniques used to identify 
host factors (Y2H, pull-down experiments, etc.). RNAi screening has the potential to provide 
valuable information about genes and especially pathways involved in viral replication and 




MAPK signaling during CHIKV replication
Chapter 4 describes the role of MAPK signaling during CHIKV replication. MAPK signaling 
pathways mediate key responses when triggered by a range of stimuli, including viral infection. 
MAPK signaling can roughly be divided into three major pathways: Ras-Raf-MEK-ERK, p38 
MAPK and SAPK/JNK signaling (reviewed in (208)). SAPK/JNK and p38 MAPK are induced by 
various stresses, whereas the Ras-Raf-MEK-ERK signaling cascade regulates growth factor 
responsive targets and is thus linked with cell proliferation and differentiation. Disturbances 
in Ras-Raf-MEK-ERK signaling are associated with cancer, as an increased signaling activity 
is often found in tumors (369, 370). Ras and Raf are both oncogenes, and are thought to 
transform cells by prolonging the activated state of MAPKK and downstream components. 
Overexpression of constitutively active MAPKK promotes cell transformation (371). ERK1 and 
ERK2 are the central effectors of the Ras-Raf-MEK-ERK pathway. They are related protein-
serine/threonine kinases whose cascade regulates a wide range of processes related to 
survival (cell adhesion, migration, metabolism, differentiation, cell cycle progression, and 
transcription) (210). ERK can inhibit Raf by phosphorylation, thus creating a negative feedback 
loop (Figure 3). Beside the negative feedback loop, several phosphatases are involved in the 
inactivation of ERK. These include MKP3 (also known as DUSP6), MKP4 (DUSP9), and PAC1 
(DUSP2) (210, 372). Raf and MEK have narrow substrate specificities, but ERK can catalyze the 
phosphorylation of hundreds of nuclear and cytoplasmic substrates, including regulatory 
molecules and transcription factors. Several viruses have been described to induce the 
Ras-Raf-MEK-ERK pathway (213, 221, 232-238, 243, 244) and many of them benefit from an 
activated Ras-Raf-MEK-ERK axis, through a mechanism that is not yet fully understood. Little 
is known about the activation of the Ras-Raf-MEK-ERK pathway by alphaviruses, with the 
exception of VEEV, which activates MEK/ERK signaling, and depends on this activation (239). 
Chapter 4 shows that CHIKV does not activate MEK/ERK signaling, and is not affected by 
its pharmacological modulation. Also inhibition of the upstream kinase b-Raf did not affect 
CHIKV replication. This was rather surprising, as many other +RNA viruses, including the 
distantly related VEEV, depend on an activated MEK/ERK signaling pathway (233, 238, 239, 
243, 244). It is hypothesized that a (virally) activated MEK/ERK pathway eventually results 
in a downregulation of the innate immune (IFN) response, which obviously is beneficial for 
the invading virus (247, 248). Another potential proviral aspect of activated Ras-Raf-MEK-ERK 
signaling is its positive effect on cellular transcription and translation, which may also extend 
to viral transcription and translation. ERK can positively regulate transcription, either directly 
or indirectly by phosphorylation of ribosomal protein S6 kinases, mitogen- and stress-
activated protein kinases and ternary complex factors (reviewed in (210)).
Clearly, further experiments are needed to elucidate the exact involvement of MAPK signaling 
in CHIKV replication, and how MEK/ERK activation can be beneficial for the replication of 
some viruses (e.g. VEEV, CVB3, Influenza A and Junin) (233, 238, 239, 243, 244). It would be 
interesting to examine the apparent differences between CHIKV and VEEV, two viruses from 




Figure 3. Ras-Raf-MEK-ERK signaling. The Ras-Raf-MEK-ERK signaling cascade is activated when growth-
stimulating ligands bind to the receptor tyrosine kinases, eventually resulting in phosphorylation and 
activation of the downstream components. The Ras-Raf-MEK-ERK cascade contains a negative feedback 
loop, the level of ERK activity regulates SPRY and DUSP family proteins, which in turn negatively regulate 
Ras or ERK. ERK can also phosphorylate the upstream Rafs, thus inducing an inhibitory feedback loop. 
Reproduced from (373). 
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Finally, CHIKV-induced activation of p38 MAPK occurs only very late in infection, and therefore 
this response is most likely associated with the onset of apoptosis, rather than a specific 
antiviral response. Nevertheless, it would be interesting to further pursue the mechanisms 
behind this activation of the p38 MAPK cascade. 
Stress granules and CHIKV replication – an unexpected proviral role for G3BPs
The G3BPs (G3BP1 and G3BP2) are a good example of the aforementioned risk of overlooking 
host factors during RNAi screens due to redundancy in protein function or pathways. Chapter 
4 describes that depletion of a single G3BP did not have a major effect on CHIKV replication, 
while the simultaneous depletion of both G3BPs strongly affected CHIKV replication. The 
G3BPs are multi-functional, multi-domain proteins that share a conserved acidic domain, 
a Nuclear Transport Factor 2-like domain, an arginine/glycine-rich box, and an RNA 
recognition motif (282, 374). The latter two elements are associated with RNA binding. G3BP 
was originally identified as a binding partner of the Ras-GTPase-activating protein, but that 
property was later disputed (44, 45). G3BP1 has two SH3 domain-binding motifs, whereas 
G3BP2 possesses - depending on the splice variant - 5 or 6 of such motifs. The G3BP1 and 
G3BP2 proteins share several domains and may thus be (partly) functionally redundant, as is 
illustrated by our observation that simultaneous depletion exerts a stronger effect on CHIKV 
replication. G3BP1 and G3BP2 are encoded by genes located on different chromosomes 
(5 and 4) and, despite their similarities, are thought to have different functions despite 
their many shared characteristics. Indeed, G3BP1 is a negative regulator of wnt/β-catenin 
signaling (375) whereas G3BP2 is a positive regulator (376). 
The G3BPs have been studied most extensively in relation to their role in stress granule 
formation. Stress granules (SGs) are formed in response to cellular stress and result in 
translational inhibition (253, 377). The G3BPs have been previously implicated in the 
replication of alphaviruses, including CHIKV. For example, nsP3 of SINV, SFV, and CHIKV was 
shown to bind to G3BP (62, 63, 138, 274). Generally, this nsP3-G3BP interaction is thought 
to partially block the cellular antiviral response, as nsP3 prevents the formation of genuine 
stress granules by sequestering G3BP, thus preventing translational inhibition. Translational 
inhibition can be considered both an antiviral response by the cell to limit the production 
of viral proteins and thus viral replication, as well as a proviral manipulation of the host cell 
machinery by the virus, to reduce competition of host transcripts with viral mRNAs. CHIKV 
structural proteins are still produced when host translation is blocked, possibly due to a 
translational enhancer sequence in the subgenomic mRNA, similar to those described for 
other alphaviruses (68). The data presented in chapter 4 does not dispute the antiviral role 
described for G3BPs during alphavirus replication, but demonstrates that the G3BPs have 
an additional, proviral role early in CHIKV infection. G3BP depletion did not affect entry, 
translation or polyprotein processing, but seriously affected +RNA accumulation. Infections 
performed with a replication-deficient virus indicated that the G3BPs were likely needed for 




genome is used as a template by both the viral polymerase and cellular ribosomes. However, 
they operate in opposite directions, thus requiring some form of regulation. Chapter 4 
proposes a role for G3BPs in clearing ribosomes and/or other proteins from the template 
during the switch to genome amplification (Figure 4). In recent years our understanding of 
the complexity of SGs has grown significantly, and they are more and more seen as complex 
signaling hubs instead of the static RNA-protein aggregates they were once thought to be. 
Diverse signaling molecules, including scaffolding proteins, are recruited to stress granules 
(378-381). The recruitment of scaffolding proteins (e.g. RACK1, TRAF2) inhibits the signaling 
pathways they are involved in. For example, RACK1 is an adaptor molecule that integrates 
input from several signaling pathways and plays a key role in cellular processes including cell 
proliferation, transcription and protein synthesis (382). Its recruitment to SGs inhibits stress-
activated p38/JNK signaling, which would otherwise trigger apoptosis (383). Alternatively, 
recruitment of specific proteins can also induce downstream signaling. For example, there 
is a clear link between SG formation and the activation of the innate immune response. 
RIG-I and PKR were found to be sequestered to SG structures, and this RIG-I sequestering is 
needed for IFN-stimulated gene (ISG) activation (378). G3BP1 directly interacts with inactive 
PKR and recruits it to SGs, resulting in phosphorylation of eIF2α which leads to translational 
inhibition (379). These examples illustrate the central role SG formation plays during many 
cellular processes, including antiviral responses. Blocking stress granule assembly, for 
example during viral infection, can affect these signaling cascades. 
As mentioned earlier, also functions (thus far) not linked to stress granule formation 
and regulation are attributed to G3BPs. For example, G3BP2 was described to bind the 
N-terminal domain of IκBα, thus enforcing cytoplasmic anchoring of IκBα/NF-κB complexes 
(265). Nuclear translocation of NF-κB results in the induction of numerous genes involved 
in immune and inflammatory responses (384, 385). Therefore, depletion of G3BP2 may 
enhance the antiviral response to CHIKV infection, although we could not observe changes in 
NF-κB protein expression or cellular localization. Furthermore, G3BP2 modulates the activity 
of GSK3β (376), which in turn modulates pro-inflammatory gene expression, and inhibition 
of GSK-3β reduced VEEV replication (386). It is therefore possible that GSK-3β activity is also 
needed for CHIKV replication, which is disturbed upon G3BP knockdown. Another aspect 
of G3BPs and their function is related to its methylation. The C-terminus of G3BP contains 
prominent target motifs for protein arginine methyl transferases (PRMTs). Methylation can 
affect protein-protein interaction, but also RNA binding activity and intracellular localization 
of the targeted protein (387). The exact role and function of G3BP methylation is not 
completely understood yet. Clearly, we have only just begun to unravel the complexity of 
functions associated with SGs in general, and G3BPs in particular. Future experiments should 




Innate immune stimulation inhibits CHIKV and DENV replication
Both CHIKV and DENV are important human pathogens for which no therapeutic options 
are available. In contrast to CHIKV, DENV is associated with hemorrhagic symptoms and 
mortality. Both viruses have overlapping geographic distributions and initially present with 
similar symptoms. This makes it challenging to distinguish the viruses clinically, especially 
considering the fact that both viruses are mostly endemic in areas where diagnostic capacity 
is limited. An antiviral therapy that would target both viruses would be ideal. 
Infection with either virus elicits a strong, protective innate immune response and 
treatment with IFN-α or IFN-β reduces the replication of these viruses in cell culture (77, 
330). Unfortunately, treating patients with IFN is only effective when started early in disease. 
However, harnessing the host’s own IFN response might be an interesting alternative strategy 
to IFN therapy to treat infections with DENV, CHIKV and other viruses. Chapter 6 describes 
the effect of the exogenous stimulation of the innate immune response on DENV and CHIKV 
infection. A small 5’ triphosphorylated RNA molecule (5’pppRNA) was used as a RIG-I agonist, 
which induced an antiviral state that blocked both DENV and CHIKV replication in cell culture 
(Figure 5). The innate immune response triggered by the RIG-I agonist was characterized by 
increased levels of RIG-I, IFIT-1, STAT1 and phospho-STAT1, resulting in increased levels of 
IFN-α, IFN-β, IL-6, and IL-1α. This activation is dependent on intact RIGI-MAVS-TBK1 signaling, 
but largely independent of the IFN receptor and STAT1. Treatment with 5’pppRNA was still 
protective in cell culture when started after infection, and the activated IFN response could 
prevent viral spread to neighboring cells and tissues. In addition, the protective effect induced 
by the 5’pppRNA is long-lasting, as cells were still protected from DENV infection 72 h post 
treatment (in vitro) (192). The protective effect of 5’pppRNA treatment is at least partially IFN 
independent, as 5’pppRNA was still able to induce an innate immune response in cell culture 
when the IFN receptor (IFNAR) was depleted using siRNA (192). In addition, IFNAR knockout 
mice could still be protected against a lethal influenza challenge by treating them with 
Figure 4. Model depicting the proposed proviral function of G3BP during CHIKV replication. Genomic 
CHIKV RNA is initially translated by ribosomes into non-structural proteins, which assemble into a 
replication complex that synthesizes a complementary negative strand CHIKV RNA. However, ribosomes 
and the replication complex use the same genomic RNA as a template, which could lead to collisions 
as they move in opposite directions (towards each other), stressing the importance of regulation. The 
G3BPs may be involved in regulation the switch from translation to negative strand synthesis, possibly by 




5’pppRNA (319). This latter experiment illustrates that the RIG-I agonist is not only suitable for 
in vitro experiments (as described in chapter 6), but also has potential for clinical application. 
In recent years in vivo transfection reagents have been developed that enable delivery of 
nucleic acids in various animal models. Indeed, as mentioned above, also the 5’pppRNA 
could be effectively delivered to mice using intravenous administration, protecting them from 
a lethal influenza virus challenge (319). Prolonged 5’pppRNA administration further reduced 
viral replication, thus indicating that therapeutic use is a realistic scenario for patients already 
infected when seeking medical attention. The application of innate immune stimulation is 
assumed to have a broad-spectrum antiviral effect rather than providing protection against 
a specific virus, and may therefore have broad therapeutic potential in the clinic. The RIG-I 
agonist induces a general immune response that includes multiple antiviral effectors that 
block viral replication at different steps, therefore raising the barrier for development of 
resistant virus mutants. RIG-I agonists are attractive potential therapeutic agents, as they 
mimic the earliest step of virus recognition by the immune system and triggers its subsequent 
response. A previous study showed that 5’pppRNA stimulation could induce a complete IFN 
response, inducing 97% of the genes activated after IFNα-2b treatment (319). Obviously, the 
patient should be closely monitored, to control the strength of the IFN response and reduce 
potential side effects.
Although not the main focus of this thesis, the innate immune response to viral infection is 
currently considered an important focus area by the scientific society. It is one of the first 
hurdles the invading virus needs to pass, and is triggered within minutes of viral attachment 
and entry. Furthermore, the activation of the innate immune system is essential for 
subsequent adaptive immune activation. It is therefore not surprising that many viruses have 
developed strategies to disable or evade the innate immune response, and CHIKV is not an 
exception. Still, our understanding of exactly how viruses achieve such a feat is incomplete. 
Gaining more insight into these immuno-modulatory mechanisms may provide us with tools 
to combat viral infections, as well as potential treatment options for other (uncontrolled) 
infections in the human body, e.g. autoimmune diseases. In conclusion, CHIKV (and DENV) 
induces a strong, protective IFN response, apparently via the RIGI-MAVS-TBK1-IRF3 cascade 
and downstream ISGs, including viperin (81, 88, 120). Although in recent years some light was 
shed on innate immune activation and evasion by CHIKV, more in-depth analyses are still 
needed to completely elucidate the mechanisms by which CHIKV induces and manipulates 
the innate immune response. 
Concluding remarks
CHIKV is serious human pathogen that has exhibited a dramatic spread over the globe in 
the past decade, resulting in severe human suffering and economic damage. The fact that 
no registered vaccine or antiviral drugs are available is very troublesome, considering the 
high numbers of new infections yearly. However, several promising vaccine candidates are 
currently tested in clinical trials, and will hopefully be available to the public soon. Antiviral 
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leads against CHIKV are followed with fervor and will hopefully soon result in the design of 
intervention strategies. A more complete knowledge of all cellular components involved 
in the CHIKV replication cycle is critical for our understanding of this important human 
pathogen, and indispensable to understand the long-term sequelae often observed. In recent 
years the amount of scientific interest in CHIKV has seen a sharp increase, and our knowledge 
about this fascinating pathogen is expanding equally fast. Unfortunately, there are still many 
unknowns, and future work should assess the exact requirements for CHIKV replication, and 




Figure 5. Induction of the innate immune response by the RIG-I agonist 5’pppRNA. (A) Schematic overview 
of the panhandle structure formed by the 5’ and 3’ UTRs of the VSV genome that forms the 5’pppRNA. 
(B) Heatmap of genes affected by 5’pppRNA treatment, sorted by fold-change (red: upregulated, blue: 
downregulated). (C) Genes among the top 30 upregulated genes could be divided based on different 
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-RNA   negative-stranded RNA
+RNA  positive-stranded RNA
aa   amino acid
ACE2   angiotensin-converting enzyme 2
ActD   actinomycin D
Ae.  Aedes
Arbo   arthropod borne
BHK   baby hamster kidney
BSL3  biosafety level 3
CDK   cyclin-dependent protein kinase
CHIKV   chikungunya virus
CHIKF  chikungunya fever
COP   coatomer protein complex
CPE   cytopathic effect
CPV  cytopathic vacuoles
Cy3   indocarbocyanine 3
DENV   dengue virus
DMEM   Dulbecco’s Modified Eagle Medium
DMSO  dimethyl sulfoxide
DNA   deoxyribonucleic acid
ds   double-stranded
DTT   dithiothreitol
eIF   eukaryotic translation initiation factor
ECSA   East-Central-South African
EMEM   Eagle’s Minimal Essential Medium
ER   endoplasmic reticulum
FA   formaldehyde
FACS  fluorescence-activated cell sorting
FCS  fetal calve serum
FDA  Food and Drug Administration
g   genomic
GAPDH   glyceraldehyde 3-phosphate dehydrogenase
GFP   green fluorescent protein
HCV   hepatitis C virus
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
hnRNP   heterogeneous nuclear ribonucleoprotein
hpi   hours post infection
hpt  hours post transfection
IC50   half maximal inhibitory concentration
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IFA   immunofluorescence assay
IFN  interferon
IgG   immunoglobulin G
IgM   immunoglobulin M
IL   interleukin
IRF  IFN-regulatory factor
ISG  interferon-stimulated gene
IVRA   in vitro RNA synthesis assay
kb   kilobase
kDa   kilo Dalton
Mabs  monoclonal antibodies
MCP-1  monocyte chemoattractant protein 1
MOI   multiplicity of infection
MRC5  Medical Research Council-5
mRNA   messenger RNA
nsP   non-structural protein
ORF   open reading frame
PABP   poly(A)-binding protein
PAGE   polyacrylamide gel electrophoresis
PBS   phosphate-buffered saline
PBST   phosphate buffered saline with 0.05% Tween
PCBP   poly(C)-binding protein
PERK  PKR-like endoplasmic reticulum kinase
PFA  paraformaldehyde
p.i.   post infection
PKR   double-stranded RNA-activated protein kinase
PNS   post-nuclear supernatant
p.t.   post transfection
RC   replication complex
RdRp   RNA-dependent RNA polymerase
RIG-I   retinoic acid-inducible gene 1
RISC  RNA-induced silencing complex
RNA   ribonucleic acid
RNAi   RNA interference
RNase   ribonuclease
RRV   Ross River virus
rt  room temperature
RTC  replication and transcription complex
RT-PCR   reverse transcriptase- polymerase chain reaction
SD   standard deviation
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SDS   sodium dodecyl sulphate
SDS-PAGE  sodium-dodecyl sulfate polyacrylamide gel electrophoresis
SINV   Sindbis virus
SFV  Semliki Forest virus
sg   subgenomic
shRNA   short-hairpin RNA
siRNA   small interfering RNA
ss   single-stranded
TBS(T)  tris-buffered saline (with 0.05% Tween-20)
TfR   transferrin receptor
UPR  unfolded protein response
USAMRIID U.S. Army Institute of Infectious Diseases
UTR   untranslated region
VEEV   Venezuelan equine encephalitis virus
VLP   virus-like particle
WB   Western Blot
WNV   West Nile virus
wt   wild-type





Infectieziekten veroorzaken jaarlijks wereldwijd aanzienlijke morbiditeit en mortaliteit. Ze 
kunnen worden veroorzaakt door bacteriën, schimmels, parasieten, prionen en virussen. Een 
belangrijk deel van deze infectieziekten wordt veroorzaakt door virussen, bijvoorbeeld griep 
en verkoudheid, maar ook AIDS en ebola. Virussen bevolken onze planeet vermoedelijk al 
miljarden jaren, en kunnen praktisch elke levensvorm infecteren, van bacteriën en planten 
tot vissen en mensen. Deze kleine, maar flexibele micro-organismen blinken uit op het 
gebied van adaptatie. Met slechts een klein wapenarsenaal (de kleine genomen van RNA 
virussen, bijvoorbeeld, coderen meestal voor slechts een handjevol eiwitten), zijn virussen 
toch in staat om een gastheercel compleet over te nemen. Ook het tegenovergestelde is 
mogelijk: een virus kan erin slagen om onopgemerkt te blijven in een gastheer, ondanks de 
aanwezigheid van een functioneel immuunsysteem. 
Om zich te kunnen vermenigvuldigen moeten virussen hun erfelijk materiaal (RNA of DNA) 
kopiëren. Veel RNA virussen bezitten geen mechanisme om fouten te corrigeren, waardoor 
er mutaties ontstaan in het virale genoom. In het algemeen levert elke replicatieronde unieke 
veranderingen per virusgenoom op. ‘Een virus’ bestaat dus eigenlijk uit een hele zwerm 
van varianten. Meestal hebben mutaties geen effect, soms zijn ze nadelig voor het virus, 
bijvoorbeeld als het daardoor minder efficiënt repliceert, maar mutaties kunnen er ook toe 
leiden dat virussen nieuwe eigenschappen ontwikkelen. Door deze genomische plasticiteit 
kan een virus zich snel aanpassen aan een veranderende omgeving. 
Grote virusuitbraken leiden met enige regelmaat tot aanzienlijke maatschappelijke onrust 
en economische schade, zoals bijvoorbeeld is gebleken bij de jongste uitbraak van het 
Ebolavirus (2013-heden (2015)), maar ook van MERS-CoV (2012-heden), en SARS-CoV (2002-
2004). Ook het chikungunya virus (CHIKV) is een voorbeeld van een virus dat de afgelopen 
10 jaar een behoorlijke impact heeft gehad op het leven van miljoenen mensen in tientallen 
landen. CHIKV wordt door muggen overgedragen en veroorzaakt koorts, huiduitslag en 
ernstige spier- en gewrichtspijn. De spier- en gewrichtsklachten kunnen weken tot maanden 
aanhouden. CHIKV werd voor het eerst geïsoleerd en beschreven in 1952 tijdens een 
uitbraak in het huidige Tanzania. Tussen 1952 en 2005 werden er af en toe uitbraken van 
relatief beperkte omvang gerapporteerd in Afrika en Azië. In 2005 startte echter een uitbraak 
van ongekende omvang. Deze begon relatief ongemerkt in Afrika, maar kwam wereldwijd 
in het nieuws nadat 30-50% van de bevolking van het Franse La Réunion en omliggende 
eilanden in de Indische oceaan geïnfecteerd raakte binnen een periode van slechts enkele 
maanden. De uitbraak verspreidde zich vervolgens snel naar het Indische subcontinent en 
andere delen van Azië waarbij miljoenen mensen geïnfecteerd raakten. Eind 2013 werden de 
eerste CHIKV infecties gerapporteerd in het Caribbisch gebied, alwaar het zich ook snel over 
omliggende (ei)landen verspreidde. In een tijdspanne van een jaar werden bijna 1 miljoen 
infecties gemeld in het Caribbisch gebied en omliggende landen. Recentelijk is ook in Noord- 
en Zuid-Amerika lokale overdracht van het virus gemeld, en met name in Zuid-Amerika is 
de kans op aanzienlijke uitbraken groot, onder andere doordat Zuid-Amerikaanse landen 
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over minder diagnostische capaciteit beschikken, waardoor een beginnende uitbraak langer 
onopgemerkt kan blijven. Ondanks uitgebreide onderzoeksinspanningen in de afgelopen 
jaren is men er tot op heden niet in geslaagd om een commercieel verkrijgbaar vaccin of 
antiviraal middel te ontwikkelen. Het feit dat CHIKV onverminderd nieuwe infecties blijft 
veroorzaken en de langdurig aanhoudende gewrichtsklachten waar veel patiënten mee 
kampen, onderstrepen het belang van de ontwikkeling van effectieve antivirale strategieën 
tegen dit belangrijke humane pathogeen. 
Het werk beschreven in dit proefschrift verschaft meer inzicht in de replicatiecyclus van 
CHIKV. Het virus is (net als andere RNA virussen) vanwege zijn kleine genoom sterk afhankelijk 
van gastheer factoren voor zijn replicatie. Daarom is in dit proefschrift met name aandacht 
besteed aan het identificeren van deze cellulaire eiwitten, en wat hun rol is. Hiervoor dienden 
er eerst diverse reagentia te worden ontwikkeld, waaronder een infectieuze cDNA kloon. Een 
cDNA kloon is een waardevol hulpmiddel omdat het (onder andere) de gerichte genetische 
modificatie van CHIKV mogelijk maakt, bijvoorbeeld het aanbrengen van puntmutaties of 
de introductie van zogenaamde reporter genen in het virale genoom, waarmee de replicatie 
eenvoudig kan worden gemeten. Dit soort reporter virussen zijn erg handig bij het uitvoeren 
van grootschalige screens naar bijvoorbeeld antivirale middelen of gastheerfactoren 
betrokken bij de virusreplicatie. Hoofdstuk 2 beschrijft het ontwerp, de constructie en de 
karakterisatie van een nieuwe CHIKV cDNA kloon (LS3). De LS3 cDNA kloon is gebaseerd op 
de consensus-sequentie van alle destijds bekende CHIKV genomen (met de de E1-A2226V 
mutatie) die in de periode 2006-2008 geïsoleerd zijn. Diverse aspecten van de replicatiecyclus 
van dit virus werden bestudeerd en vergeleken met die van een natuurlijk isolaat uit Italië 
(CHIKV ITA07). Hieruit bleek dat CHIKV LS3 zich net zo gedraagt als het natuurlijke isolaat en 
dus een geschikt modelvirus is voor verder onderzoek aan CHIKV. 
Tijdens een virusinfectie gaan virale eiwitten de interactie aan met cellulaire componenten, 
zowel om de virusreplicatie mogelijk te maken, als om het immuunsysteem van de gastheer 
te manipuleren. Het bestuderen van deze virus-gastheer interacties kan interessante 
fundamentele inzichten verschaffen, maar dit soort gastheerfactoren kunnen ook geschikte 
aangrijpingspunten vormen voor nieuwe antivirale therapieën. Helaas is voor CHIKV nog 
weinig bekend over welke specifieke cellulaire componenten betrokken zijn bij replicatie, en 
wat hun rol precies is. Hoofdstuk 3 beschrijft een zogenaamde siRNA screen die uitgevoerd is 
om gastheereiwitten te identificeren die (direct of indirect) een effect hebben op de replicatie 
van CHIKV. De primaire screen leverde een lijst met potentiële anti- of provirale eiwitten op 
waarvan er een aantal bevestigd zijn in een onafhankelijke secundaire analyse. Zo kon worden 
vastgesteld dat de cellulaire eiwitten COPB2, DUSP1, SHC1 en MARK4 een proviraal effect 
hebben, dus nodig zijn voor efficiënte replicatie. Het onderzoek beschreven in hoofdstuk 
3 heeft waardevolle inzichten verschaft in cellulaire eiwitten en signaaltransductieroutes 




Hoofdstuk 4 beschrijft onderzoek naar de rol van MAPK (mitogen-activated protein kinase) 
signaaltransductie in CHIKV geïnfecteerde cellen. MAPK-signaaltransductie is betrokken bij 
vele processen waaronder de afweerrespons, celdeling en homeostase. Voorgaande studies 
hebben aangetoond dat verscheidene virussen MAPK-signaaltransductie manipuleren, en 
met name de MEK/ERK-cascade. Remming van de MEK/ERK-cascade had een nadelig effect 
op de replicatie van deze virussen, terwijl activatie van deze signaaltransductieroute juist 
een positief effect had op virusreplicatie. In tegenstelling tot wat is gevonden voor andere 
virussen, leek stimulatie of remming van de MEK/ERK signaaltransductie geen meetbaar 
effect te hebben op CHIKV replicatie. Hetzelfde geldt voor manipulatie van p38 MAPK-
signaaltransductie, die wel wordt geactiveerd in CHIKV-geïnfecteerde cellen, maar tamelijk 
laat tijdens de infectie, waardoor het aannemelijk is dat dit een algemene apoptotische 
respons is, en niet zozeer een specifieke reactie op het virus. 
Hoofdstuk 5 beschrijft de interactie tussen CHIKV en stress granule componenten, met name 
G3BP1 en G3BP2. Stress granules zijn aggregaten van eiwitten en RNA die gevormd worden 
in de cel als reactie op diverse vormen van stress, zoals hitte, oxidatieve stress of infectie. Ze 
bevatten onder andere vastgelopen (pre-initiatie) translatiecomplexen, met daarin mRNA en 
RNA-bindende eiwitten. Verscheidene virussen hebben manieren ontwikkeld om de vorming 
van deze stress granules te voorkomen, of reeds gevormde stress granules uiteen te laten 
vallen. De voornaamste reden hiervoor is waarschijnlijk dat de vorming van stress granules 
leidt tot verminderde translatie, wat ongunstig kan zijn voor de productie van virale eiwitten. 
De vorming van stress granules wordt over het algemeen als een antivirale reactie gezien. 
Daarom was het verassend dat G3BP1 en G3BP2, belangrijke stress granule componenten, 
nodig bleken te zijn voor efficiënte replicatie van CHIKV. 
Tenslotte beschrijft hoofdstuk 6 het antivirale effect van een speciaal RNA molecuul 
(5’pppRNA) tegen CHIKV en dengue virus (DENV) infectie. 5’pppRNA is een zogenaamde RIG-I 
agonist en kan de aangeboren immuunrespons stimuleren. Zowel CHIKV als DENV worden 
door muggen overgedragen en de initiële symptomen kunnen erg op elkaar lijken. Aangezien 
de twee virussen circuleren in dezelfde gebieden, waar de mogelijkheden voor (differentiaal) 
diagnostiek meestal beperkt zijn, zou een breedwerkend antiviraal middel dat beide virussen 
remt ideaal zijn. Hoofdstuk 6 laat zien dat behandeling met 5’pppRNA de gastheercel in een 
antivirale staat brengt en CHIKV en DENV infectie effectief remt. Deze respons berust op 
de activatie van de RIG-I/MAVS signaaltransductieroute, maar is grotendeels onafhankelijk 
van de interferon response. Verder onderzoek naar potentiële bijwerkingen zal nodig zijn 
voordat 5’pppRNA getest kan worden in klinische studies om te bepalen of het ook werkelijk 
therapeutisch ingezet kan worden.
Samenvattend, biedt dit proefschrift meer inzicht in de replicatie cyclus van CHIKV en de 
gastheer factoren die hierbij betrokken zijn. Naast het vergroten van onze algemene kennis 
omtrent CHIKV en CHIKV-gastheer interacties, biedt dit proefschrift tevens waardevolle 
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